var title_f4_29_4560="Intraabdominal version of transverse lie at cesarean";
var content_f4_29_4560=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F58320&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F58320&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intraabdominal version of transverse lie at cesarean",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 385px; height: 444px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The assistant performs intra-abdominal version prior to hysterotomy and holds the fetus in its new longitudinal position. The surgeon will then perform the lower-segment uterine incision at the dotted line.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_29_4560=[""].join("\n");
var outline_f4_29_4560=null;
var title_f4_29_4561="Racecadotril: International drug information";
var content_f4_29_4561=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Racecadotril: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4302644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Hidrasec (MX, TH);",
"     </li>",
"     <li>",
"      Tiorfan (ES, FR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F3460320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Enkephalinase Inhibitor",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F3330434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of acute diarrhea",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F3330436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;display:inline\">",
"     Adults: Oral: Initial: 100 mg, may repeat every 8 hours as needed until diarrhea stops for up to 7 days",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F3330437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capsule: 100 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10500 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-5115C1355F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_29_4561=[""].join("\n");
var outline_f4_29_4561=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4302644\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3460320\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3330434\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3330436\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821258\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3330437\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10500\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10500|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_29_4562="Urethral pressure profile";
var content_f4_29_4562=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65452&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65452&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Urethral pressure profile",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 416px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Robinson, D, Norton, PA. Diagnosis and Management of Urinary Incontinence. In: Gynecologic Surgery. William, WM, Stovall, TG (Eds), Churchill Livingstone, New York 1996. p.704.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_29_4562=[""].join("\n");
var outline_f4_29_4562=null;
var title_f4_29_4563="Interstitial sarcoidosis CT";
var content_f4_29_4563=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F51488&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F51488&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 547px\">",
"   <div class=\"ttl\">",
"    Sarcoidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 527px; height: 247px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left: The chest radiograph shows interstitial disease (multiple small nodules in the mid-to-upper zones) with shrinking hilar nodes (Stage III). Right: HRCT shows the beaded or irregular thickening of the bronchovascular bundles, with nodules along bronchi, vessels, and subpleural regions.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Talmadge E King Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_29_4563=[""].join("\n");
var outline_f4_29_4563=null;
var title_f4_29_4564="Pentazocine: Patient drug information";
var content_f4_29_4564=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Pentazocine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/48/29446?source=see_link\">",
"     see \"Pentazocine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/16/5382?source=see_link\">",
"     see \"Pentazocine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F208028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Talwin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F208029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Talwin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10022823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10022822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702707",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to pentazocine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10022827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697210",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a drug or drinking problem, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before you use other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10022828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10022830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699000",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Poor pain control.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10022825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle, vein, or into the fatty part of the skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698543",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a pain diary.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10022832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10961 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-84F2B57B49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_29_4564=[""].join("\n");
var outline_f4_29_4564=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208028\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208029\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022823\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022822\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022827\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022828\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022830\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022825\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022832\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/48/29446?source=related_link\">",
"      Pentazocine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/16/5382?source=related_link\">",
"      Pentazocine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_29_4565="Endosc fundic gland polyp A";
var content_f4_29_4565=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F78092%7EGAST%2F58144&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F78092%7EGAST%2F58144&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gastric fundic gland polyp",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 313px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAE5AWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5Wx+FJg04k9zT41J6AflQAxRzzXpnwl+Hz+Kb4X+pRyR6Jbt+8YcGdh/yzU/zbt06mqPwr8CXPjPVTuDQ6VbMPtVzj8di+rH9ByfQ/U9jYW2m2MFlp8K29pAoSKJeigf17k9zzXHisT7Ncsdz0sBg/bPnn8P5jUMcMaRQxpDFGoSONFwqKBgKB2ApxlHQHn0p7xZ6VWlA3dPxrx2fSRS6Di4By1MluFEfyrkn1qKXB4GelV5SFIGKm5qojDy2S2KgklRfuYORjmmyt3HbpVdpQvPUiixbElkKr97v+dVZrnB7/wCFSysZOc/T2rOu1CK3zn/GnYEQXF8sYbDEk81j3WovKSBwvY9TUtwd79PxFRmOMJ6NVJK5V7FCSZycRgn3PNCQwJ+9upNz9hTLq4SEHawLD0rPV5J2xt3HPetFEiUn1LF7e+YAkf7tF/hHeqcabm3cvgdhirkNjtJeXao+tODxRn5F3EcHAqk7bE3b3IEtiTubnHc0HaBtLcdMVYnud42KhQHuaqKo35yW4HamrhLyHR7BztJI6YqTdIx4AGOMYpyZxnjBpfNx2FIXKMWAn5mOT6VPsVRk4FOS5BwSMd+lRtKWYgdM560tWLRCgLmjy+cr2pzRHbl9wPYCq7o2fvkZ607BzajmVQuCcgnPNVpYUY/Kx5zk1KE6HrzmlKnqOncZp7A3cph5IiQj4+hqzbX6K+LoYX+8tMlUYweueKhcDOMkDGDVWvuCbj1OltvKlQSQOP8AgNXYSykKTnI/KuSgZ423wkoccj1q/banJvCTH2DVlKnqaRnodMYwQOQPpQo4AVhgetVIZzIn7sipQS2cHn3rJqxqmSFzz0p2wsMNz15zTrcAdBz9amAAHGMUh3ZGVCoAo6DGT3qMxMSTlhmrJYBc42/WkZlZeBg0WBFZ4t4GGw3uM1XKkHaANx6CrrnnIOB/OoWZH7ZzRYDB17SYNYsGtrhdp+8jgcxt6gV41rWlTaVfSWtyhEi9CPusOxB7iveXUB8KD161i+JdDh1mzMMgVZ05imxyp9D7V24bEOk+V7HmZjl8cTHmj8S/HyPDDRWhqdjPYXktvPEUkQ4IP9Paqb5HGMfhXr3vqj5GUXFuL3IufWilNFMkdsOeorr/AIb+Cr7xlros4P3NnFh7q6IysKe3qx7Dv9M1R8HeF77xXrcWnacp3n5pJGHyQoOrt7fzPFfV/hbRNO8LaNBpWlLiCP5pJWHzTP3dj6n07dK5sTiFSVlud2CwcsRK/RGpoulWei6VbabpkAt7G3XCoOrHuzHuxPU1ZZwQTwBVOS7C/eYj0A5qvLeBMFgR6AivFlNt3Z9PDD8qSWxemkCKSTVDz92ffoKp3F28rkDnnNRNK2doyX9qhs6YwSLjygD3qhc3IH3e/pUF1KEPJwayLm8RMgEA9RSsaRii/LPgH1qs04LYJFY8t4zZKjA65NUprl8H5zz6VaQmjdub5I0yXHFYV7qqsxIOeOwqnO28nv7moEt3nkURKGUjO7tirUe5Dkok320sWJ+TaON3eqclxdXKlVARe5XmpXtsyrHGxbj5sdqkmxbL5YHOfu1asQ5spJascNJ3/UVZQLEg8oAMfahFMnzsOMfSrCRgbQMetJuwJdSrIkkmS5yD+lSxxbVG0fpVtEUEk4yPSlOEcyYK/WpuN7FOSPA+YZz7dKr+WB97B7Yq5dXPmsMAYHpUSRAhSxAPv1q07EK73I1iZ+I1H48UjKYcZAPvirS4QYB+fHb0qKQrnLrkE9cUky22iuh8xsN8v0p7sEY4HUdcVXk2NwoOevpSASLnoVJ6VZHPcnkldFyTnsM1GWJBEmePeowFb/eHY0x2IbAznvxTREroldwOR17UzeSMcfSmop2gjgd6UoepHWnYXMxC/TnPvSLgZLLkHtS+Vz3A96QRfKccduuaAuyHeYnI7elTSQFYxIgDx+3UVE6NkBxx2NNhkkiJVSTkdCKonm7ly1vWtnXduK57jHFdJaTRXMSyRsCK5HcwA3Ywe9Ot55rWcGFihIztI+VqiUOY1jUs9djsSZVOUBI9R2pgmuMEqnHeq+i65b3GEm/dy9MHpW8yxOcqAc8gCueUXHdG/texmLdMcLNE3PfHFTrPucICqqR3HepzD8wGNp64NQy2w3DeGB9RSuVGfUlVMsdzA8elMECA5LHPtSpE4AO7K9MU/aVIGMYHpipuNu4zyg2Aqg1DLDggY4HvU7twP4ST0x1pZCzJkHI+uKBHH+MvDaazZ5Tal5GP3bkfe/2W9v5V43fWsttcSQTo0csZ2srdQR2r6LdMgnOT3Ncd448Mrq8BntVAv0GBjpKP7p9/Su/CYrk9yWx5GZZf7de0p/F+f/BR43twOvHrRU80ZhdklBVlOGBHINFetfsfLWtofWvgrw5ZeEtFFhYDfI2Gurlhhp3H8lHYf1rYklduFx+VWBaE7cgY9KleBU25B/AV85OTm+aWrPt6ahSShBaGaYWK7mbJ71G6PyGbdn8603RQuNtVZ5AnPAAqDRNspoix5ZuPQVUu75IkJB5qK+vtzsF6VlXCM4Jfkc00Wl1ZTvL+SRj5eAaqgbRlmyevWrLxKgLAdqpytlun5Va7IsjlcsTg8e1V3A+5k59qmbGN2Of50wAdT8tUiGQzIVTAPJrQvbxxFFBEFVFgEZAHXnOazpHy3Y4OKtWcbSsSeg4qr2Ikk7MW1jS1iaV+XI4BFZqo803mOCc9PerGpzEz+UhJA4JzTkcnYq9uBxQnbUi2ogRiASOh7dqsJF61peH9NN/fwwGUJvONzdPXmrlxp4/fSIuYEcp5p7mpbLUlflMOVvLBJHeqMsjSN1PB7Vo30S57n0rMZdpwaasKaEiTAY9QT3qcEEEYHsRSKgLfUVL5eT049KG7lIrSEh/Yd6UDcmSATTnQ7iBUbEouCO9NBJXKqLz8wzzUsiuDgCnOoC9QenSkDMoOfTOM9aoztYqTRZ6ZBHfPSog7DHmDcP7wqd3ycdD79xTUGflPTtir6GV7PQliUEfIfw9KsLHnGetQxwBVEkRIPcetWFdSM8fjU3NYq4gj24z2x0pxUDqBjn/JpQzPnA49RTHBYDGKm5VkiGWMNxn8etUJ7ZgRjjng4rUCfMuSCRT54/MjwSMnpVKViJwTMUOdrI45HOcUkcqlSjDcp5Unsat3NsfKyB84PbvVchHi3KpEo+8vrWt09TFpx3GGMyoGPbv0wc1fsNUu7Jvv+bF3U9cVDbXJthuCh42GGU1fjt7a8iDW0xWQjhGqJ+ZpHyep1NpqEd7brKjAj0HUVajkSTg854+lcEhutMu90O7afvLng10FvetNH5icAcGsJ0+qNoNPTqbrII9xQ5X8aYFLIxyCBWbb34YlWk5q9HIDECCMVnY0tYayEg5INJE3DAr06HsafgHOzj8agZnCnIbGewpblbjWkG7B3ZFQSAZOc55wKdIVZiCCf6Uxs7QAeapIbjc4bxx4YW+DX9kn+kgZkjHWUeo9/wCdFdk/K8dv0orspYucI8r1PLxOV0a8+d3Tfb/hj2fyV3Lk4IHTNNl4XHp3qV8bcd6q3MhCe/0rjZcbtmdeShDwa5rU7t2kCKxAzW7dqWU1y10S1/sGcjsalux3U7WbJokwOcdeainIyd386tSgpHWbcNjqMChE31ILpsg4rOlcAgAHNWJpOfqO1ViBvI/pVJlkYXc1PmTGM/8A6qniAC/N2zUbIZT14qiblWCAzyhVyB34rcaIQWxSMdBk1VsFQSHbtwvemanqKtHJBCS0rnbwOnvQ9WZ9dTEhUNJJKf73WrloOT29qgKGFVRRkDtU0TY6jgc1bFHubmmXJtpElTqpIwfcYq/LtmtjHFNxu3Y6VgwEqD1IPtTzMY1AYMR7Csy+VXuNvQQSFYFge1ZxXMpOKtT3GQQin8arICc9yfWriE3cfH254qwmM+o+lQKcYyR7ZqWPkAg/jSYIeyEDIFU7hd5UrjIGMVfkztyeRnrmoGUAYx83XmlFjexTKADkZqIgE4wBzzVpnUqQQA3oKryKCwXIz9e1WiJOxTmJSRRhSpPBqeJAGzxg8+tVNuLkg8gHGM1NGdhGwZXHatHsZK25poY0UAt17GqxCxykcBW7e9RMwcZ6kdvSqV7eeUhD5DEfKwPeko3ZTqqOrL11craKzSEBQOtZMmv/ADhIYmceucVTnnlugokYFQOnTn3qJBwT+JIFbwpJK8tTgrYuUnaloi8ur3LEgQKCffinLrE6kloAwz2PSqyZJU88gfrVhY1Ck8E/nTcYroZxrVn9o0otQtrlcOdj4zzVaREcFoioYeh5xVUx7gMgEenWongRGBiJz7E1Kgk9DV4iTVpIl3EIc4z6etaGlKLiF4fuyxndGw61mxvhSsncZJ96kgnaGZJIyMDvnFEldWLhUWjZrNeefCbe9QLIOEcVHpExtbzY/Ktxz0NXJ4hdwJNGM7h2qhLbnftUlG6qT6jtWKfQ6ZXWvQ6C6tllAfbgkVVVrm2+6TJHnv1qHStTZgYJwRKvGfWrjTDIDBlweuOKzatodMJJq6LFrfK4UNgH0PUVoEiRfl6kdTWK8Uc+SGw3ZhTreaaLh/nWpaNdzTkRc8ZPrVd8A9ecdMVLHOrDPUnvRKq8kH6GoC1imxzjBHpRSyp8vp60VaYj2dhtwOagmRmOAKvyYYfKMjtTV2hA0owScDNKx5cZ2Vyi1sohyM81xPiGL7Jq0MoHyvxk+teiTZIZmwsfb3rivHcajR5ZlzmNgQfWlKOljtwcnOXI+uhmXkjbTjGPSsqc5U9m9akjkaWFG9RwDSNGZPr7CpQ0UWzzhVz601Yhn5sZzU86gMO341BO4XBBGM/nTKFddz4J4FNaQFtkXU8VEDIx69609JtFklRnyxJ709kS3YguR9h0tmJ+YjtWXp8SiHzDy7ck5610fjKVItL8hV/eSMFAPWsSNdqIoPQdqpOyIabsVpF3Skg1YjTJ4zQww59Sec1PGAuMHBFDl2NEh7RjaD3qeJFKYbIwKiLAgZGf8aeGCgnFQEkVtQg2RF0wR2xVCBgeMDnoc1dkk3kx54HNZ88ZTpxmtE9DOxYOOBmpMlUwOnUc1Wi6fNk47VI798e4oaNETCQ4+b7o9qVgGUcc4qqs6Nwealfp35pWGinOducDApsYOcnk/Wp3kQxESLkZ4yKrAGNCcZHtVoiSK+0eaxI78nFMKmNm2HNDgh/NjJ5657UqvvH3uozk1oY2sSRTjdtkXacZJA4rL1OPecgggHO2r23PsfWs6dQd2QQ3bkVpBa3Rz1pXjZkCjjAwDnrmlUHnPyk+o4pRgDb159jTXxgk/qMVtfQ4WSQcHdkEZ5BNXYxwT/F2qtbop7AY7jvVkJlf5HriokawVhQnmL83TOaY6ZHBwOtSRrgnODz3pXAAAOMdak0a0KjqAvy9+5qISYbYOVY/kankHQcqPTFVpRhiR27irWpjJ8up0GjTkR+WTwOKmvUJhZgPnU7lrM0cebCXUsOc8djWhHKJEw/HY5rmmrSbPTovmgkNvLbzoI7uMdR823savaVqKylbe6C7scNjhhVTSznzbbqFY4+lU7iARyEEFcNwTRvoxpW946maxBXMDY54GKpBZIjiRcHNO0jVMhYJiFkHAOPvVq3UIdN561jK6epupdjJaNmO6HIPt3/Cpba46pJwRweKei7Cygkn0zSmJZchuDjqaTNFK5IWVicD6UVVCvE3Xj0x1opFHucihSB0AHFR7ozGm8EkHFS3H3lc9hjFUBIAGUH+LODVXsePBcyJbljM4XAAFcn8RWEWhyREjc7BRXTK6h2L/X6155481JL7U4rGF1Ii+Z/TPpSud+Djy1VLotTPsVBgT0HTNW2AUdMGlt4vKgjUckjJHpVe4cksAOPas0y46lGZi8pCnnHIqtM26QKOB6YqwsfLseeelV3TD5OfarRTLEKhdpYZ/rWtp4MYDqdmPbJFZtoBKyBuEHqa17mVLKydyOSOMUnvYyk+hzmtSm91kAFiIx/FTmQiMc8ntUVhueWScq3zNx3rU+Vl9qt6Fx3KMH3iW6VJuUjAPHt2qxEg+7jP1qqF/wBIY8AZwO1TuaWJ7RC7jcRSapiNPl4PtVqKEFdw+7WRqUrSTCFDk5wT6CiOrMpb6FWIbJz8xIbmr8aeYcUy3t9oPGTV2E7RwvI4qpS7D6FGWIQuc/XmrHlJNAqDmU8gjtTbmZWcKVOcjkjir2hfZYbqV70kRiJioCkkt2HHSgm9jNfTIYgSjP5ueWPT8qorMzO0UqkMO9b15cRSM0gUQLjITdnA+tYEkpubzci4iTofU04u5UtFdl5dLV7BbqaaMIz+WsRb5zxyQPT3rKkjaO4MTsPL7ZNbIv0TTXgSBBI8m55jy2McKPSs3a19fxQxD52P3j2qo3M3qnzEUrRhSn/6qqPFzxxj1rW1W2towyQTCZBxuwRk1SGCg5yPWqTJauUSRgkNhsdKqsN6MByy5+tXZ02sWJ5zVaZNx8xMlumAeoraLRyVEymvOeAM896Mkuo5CjqaHwpJHJI5B7UJs38nII45rXzORk6JyApz79Kswl+cquR1OeaYoDMCvA7Zpm/aw3gjnr61O5qlYlWTcScnPQ5qNweudw75FCyZbLAAe3WlZhycnA9O9LYbIzyxJOAOMdefeqzgruyTk88VOzADcQuTyarsd4Zm+6frVxMpIsaTO0MzoeY25xW3ZHzZZOcjHQVzkDeU6kJ0HXPWug0qPaxlT+JeorKsup14ObtYLFxFqbbiR7561c1ZUDq6YOetU7uJY5FuVz8rfNk1qBBNbBwcjHAPNYt7M7Et0ZLoJLZnU7XU5Uiuj8P3zT2gaQjePlaueDFVkXpzwPSrllvspVJx5UgyM0SV4ijozcuISjeYucfypkgGzgE5696tmQSQk5HIz171SVypIIyp9KwV2bJ20AR5AIGOPWiplYYUjH0opFXPXro7VyT+NYt+X+8h2j+9itS4TK73ySOgzWJqjs0f3ioHFDZxUI6GR4i8SJa2oS3y9yRt/Gua0yxdm825ILudxJHem3IFxqwUElU7+ta0OA2M556Umzra9nHkiMvMq3fAHHFUUTzDuc4HpVi5bzC+3IGaIxiL0OOnrSDZEDx7ScdPasuddhP8RrVuNy4C9/XvVFojvHB61SETaWqgjcAATTfEswaERjPocd6fCQJOmazb8mXUAh5A5PNUtXchLW5LaIdg2Y6VY5HXinWEZ+YkGnuFErljgehpNm0VYQEseQc1G6Zm+U5x79akYMo+Q4+tPs4yWBOORzikEmSM5WAgZUnrWCrPFPvdflY8NWxfNl1VTtA6461Sv4tqK6ggZ7VUTEminQvtdQARVl1UEbvutyCKy7ceauR97OOlXwxMYQEdalqzNEO1WSD7MFQAMBj6mq0EnlxKWyGPbFOlTD8gY9cVAQTLkrxjoRVIGRXKmWQ5GVPWhI9igKOKuOqeWMDn8qrbt6kEANTv2JWu5AV2/wCFQDMbLIpI/wB2rTndGT09qopKDlTjI5qlqS1YlZfMPINRyRlOmQKPOAOOh+tK0u4cDpxyeaeoKzIZUbaTyR9OlZpwqnD4wfzrUJK87RVOa3Q53qQTWkGZVYNmfNCXxhRuz1HNQDBcrIdrgcZHFW3LwjBHGeuKk2wyRlZFzxxW6lZHBKF3dFaJ3jPOMdsU95g/Azgd6ZFAjybXYL6GmMGgIOQ38IPHBpqzM05IkEnTAJpTKFPoT0AFNUKCjFsnGelSjYzGQkA44HWlpcd29iFmLdeST6VGDiTGDt+lOJ3ZOOeoFBOXAbr6Va8iW31G4PX3wSe9b+iSlUZOSoPftWIylSMDr1wOlaumFQzKVA3DpWNRXR1Yb3ZFjUX3kR9dx596sWhNunksxIIBXPaqSx+ddqrY254FWtQLpPCigbkHzcc4rG2iR2J2lcrzRsVcnjnoK2IUS60+I9wMciqscKyDcMYK8VPocm61ZGwdj4zSk9Cra6ElnO0LeRLz/dPrWiqqCxPOelU7u1DDd0YdCKbbXBJ8uYjIGOO9ZtX1Rqn0ZbJ2tsBGR7UUpQuu4FeaKkppHrVxJ5YwVJyOPaua1iQrBNIzZwDjjAFbV3Pt+UZJPFcl4rmMFiVY/M5xj2qTDDw1SOf0tQ0jyvxk9R9a11VSxVC3A6kdTVLT4tsadj1rQjBzgH6YpM0lLmbZC8WAST1601AdwJXI9qtyqFiIGTznB9agjyQSx69aQrlWdRuO4H8O1Z8gKjOcZ9q0b5tnT5Vx0rPSN532rgirWw/UfZqVjdiOvc1m2o8y+mcfSty8TyrYrWNpagTOBxzmqWwjatIlGSRwaju0xyBxU6sUUhSD6UCJgjEk5rO+paKYBPBGeBxUm8IQMYOKWJcS/MQDTSMSjHIqrkszC7G9bdxWl5AkiKsRyPWqV9GI7kOvJPPJq9asGRdxGPftTltdE7oxYVNldPE2dp5BPetLClg3A9qm1O1SZd4YKQOCBWZGr7cA5IoeuoJl/wCULxkcVWkgZ5CUJ7c0yCch2R1wR61M9x5TFozg4wPeklY03K8UzCRopMBgenrUV1hZlMan370t1m7mR1BVl+839KcCikIxLY9atA0UpFcuTwFPT2qu8Sscg1ozNE0boRl/4TWZc2zpiWNvqKuLM5WQ+OJGByOv+c0xmCPwfYGls3DqQ3U+2auW9mrXCiRgqE8kjIFU9NyE7lePaQd/LdRg9Kr3G6TrnA74rS1WG2Eu21ZmwMBsYz71QaOQKCCMjFC11FJkb+VLbmOVfxNZwjaM7Rkj3rTli3JuyCTVGbcO3Toa0h2OerFPUglJYbXTHOM0yZR5Sqpw2e9OMru5DZwfQcVHKu9go59cA1qtDlkNyoIyPlX+HFOQFzuTkEflU8JgjADKxwOp71BMu0l4MbT1XNVe5DhZXJHZFRB17E02KIvJ8o2jtSIGMasU685A6U+AySTKqg4z3pbFJXJZIyqrgcetaGkqvmGTGUC44plzasEAVyc/nREPLtEVm2ljjb7Vi3dHco8sr2Lem7PNeUjKiQ/lVyDy57m8PcnA9qosogso1243Pk1o2KCNC+SXespdzeN2VbNtjSRYHBzRpfy3rxZC7mprjZe5z16g0R7hqkLoMY4NBR0rFXhYHr646VmTWuV3IOQOoq4JeGLFeD2oXgHOCTzWN7FkWnSCRRuU7hwRRUCDyLzKkjcO9FNj3PUJ7lYk5bcxGfeuJ1yVrzVIkJO0c46V2l3GNpyMfL1riIyZtVnk/unaPeoREHZNlyMKh6nOPSrkA2MGALnrx2qsnQsF79auWyEgZzyeBUtk7IidGKkyEkntVWQ7Rx1rUmK79voMnFYV3JiVuoPYUxx1Kl7L5jBUyWNX9PgKLk9ao28ZlnHXmtxIzHFxxxVPsKTvoZmqOSrLnmsO2BScNk89av6pIfMxzTbWJSuT17Uyrmja/vXB4NWrxMJwDu/SoNPACjPBzVqdwTnuO/pWbWpV7sxXlMLkN17nHSksrmGaX/WANnvxXR2VtEVbBG5hlsjNUNQ0qCRmbaqn+8BgimmPR9TM1lVESMOSDjIHaq1hcRvkAgnPTNSxAi5NvcuHjAyMmrlzZ20kA8pFVx0ZRiqW1ibWdmP2q8W0AFe9YTSmC58t24NX9PutwZJD86HDZ71U1W381/MjGAtOK6C2dmEqiU7l69KVY8sPMPHpVe2l4OMAgdaleVmYYx+VNopaEkihMiIYY+1UDG8cmZGznvitJHBBIH1p11Grw4OOmc0J2B6mfKhZSyDpzxVdrlRkOCMeorRUiIBVIwexps8aykl0AyOoqr2IabMJj5Uu+M5Q88GtC1u3dfkGRjmo5rWJT8o4J7GoZLZoCHjJC1ro0Y2aNUAyRbguWqiAGLq/X8qmtnLoCScj05pVTBZu/WoWjNGroqeW8fysh21XfBcg529OlaUz7Y+QORx70w2iwWzSzjLnkL0pqRDhfQoTLHHCAuNx4xVdLcEfUdAO1WY7aWQeYysM9MntUjARKRnAH41pzW0M3Hmd2Z9xAEjIAOMccdKfp+mMQZJF+U1esIBcv5sn3B0q3qMypAApAHXih1HayJjRi3zSMu4nCRGFEBxUNlFtmR2znOM471ZjTC/aJgCvZafIzHyfs6Bh1NF9LAo3lzMs3kMhAZWAPTFU4Ynkl8yThF4A9a11jLWwbB3EVRijd7n96NqR8n3NRF9DpqxvZjrr95NFGo2heTV+3K/ZkA4HqarW5LeZL6g8HsKn00FomkYfKMgZqW9Co6Fa9GJEJGDn1q9IFCqygYFVZ4Hnckbgg5zU8RDsM8Aik9hw1dhgn2/IenNXbGUfKzoJFXkqTjPtTBaAuNpPvxU/lmP5hgL9aTaL5bEF0TvLKPk3cAdqKdcLmAtznIOKKSDY7zxFefZ7ZgWyxGMD6VyukRkxszdWJrX8YvllUjHTpUOlRKFjQjHfNZ9DNpRgvMkEe0KpXBHPPerETAKXzyD0qxcwqFDhxtVsEd6rOAgCge5PWpaEveGSSKA5H8VYl0Szjoeec1qSDGRxVCWMeaTyeaaNLWLOnwDhsCtOdB5GDVaxGAORirkxHl47dKOpijkdTXNwuSAc/nVyyjBIJ+6Kpaow+2quBWpYFdoPPFU9BsVuJMe/FPdVKtngGnNHvJIPXvUhX5RgbiOp7VG5onYvvqx86EwwRQAW4tiVGd3qx96qXMy7QCykdevWqsm9QQeahEETAsVyxHJp3vuOMVDYrJIv9uRTqiOkRDFWXIPPSunvdYs9QtZjJpFpBeO2RNDlAo7AKOD7mueECoRt4+lPb7ucniqUraEVIKo1J9DBkG/WJjEDtxz7mrzSKkJ8zPpUUwWKXK/KSfzpl8P9CdicHHpVWvoay7mekfmzsUzs7ir8QUAh1AI70aeFEaBujYORVm8iVoi0X5Hmm30M73ZAiKp5PBPWkIBG0nAzn61F5hEOCpL9hmj7FOI0kupfJZuiDtSsUrvYXUFWNEdWGQeneopZt1uSMYI9eajdZRKqTsGU9D61XciSUxRt8vc1SQn2ZDiYgEBivt2p5cvHjJJHUGtazKKm1hkDv7VTurdHlZgm1T2xVKSvYlxI7QKFOMjHap4QSWJC5piLsQ8j8qjdyn3CT7Ck9dhR0QrKGvY1OcKcnHTNJqe64njUPtwRkZpbfepO9Nue571TQmS7mcNlelUlrcUi+CiKRnGOKgkMzoxjiVhnPNRGCaYfuxgDqD1p32m4jAgMOJT0cGhLrclvuiINdEbAAM/3etRz29wq7nUsB3Na0MIRMtlnzk1Wv7gDEaqWJ6KO9NS1E4RS1KczOwBZdq4wF6UWynySTgM5wBjtUn2O9uMt5aqORhzRbqyXUUDEbgctzV30IS11NvyikK4wMD0qhLIFRh0Y8c1eu2ZY2KnpzzWbaxyahcDy8AKeuOlYx6tnTUW0ULHE0zCMcA8Z9KvrB5o+z27eXGvV+9Ol0pIbSV1llWTuQcfjitPR7X93Dg/KvDE9T60nJWuEY2fvGfHC0EJRsPjuetZxzbyIw5BOMV0OpbHmIU/KBjisC6xNdRwo3KcnFEHfcl73RtWhVox/d9qJiSOMbR696qWQMMzRA/KeQTVmZz0YYx+tQ1Zm8feVyCb/AFToeSB1oqKeYP0NFXEiW50WvzfaL+NTggY56Vp6fEqxowLbugGOKx9rT6gOc4rorSMKF3Z9eaybM626XYleL5AGPJ5I71Rli3MzEdDjArWlUBNx5JrOmYqTuzUCp3M5zl8Y5qvIPmYHp2qaZw0+ad5Zds8D+tUjRjrTCDB9KS5nA5HFTBNoKjlqx9Yfyh15/rQRFXZi3bl9UPIwBx3rbsBlgM49cVg3UDwvFOwK5PWt2xYBBk8n8zVyWgN31NiBI9hJzx2pJdqBQBlj2qoLoAAAsMnkEVYeTzRnGAOh71kxxQyRAVJOBVR12YC8CrhG44PHbNVpl5AHPrTTNEtREUN2zUdwPLUk9MdKli44GRz3FVdUjnkXECjcOtNBYyJ2RrgGQ/KOcmpL2RHtikIZgRTNhXal1HtH97ORmtyG3QRhimVPGatuwSjr7xytjIUVcZPoT2rVgccq+TUGoQG3vkcoFilOOBxmkbcjZB4puzJas7MmnVY381V+Yc1u2mr6bpzTyRWY1B3gCIZxhUc9WA9ulc9AzS4Vm4FJq0i2cSHqT0FBDgpq0tinq5eVkclUZmwuB6+1MtUEYxzuHFFpG9w/nzZx/CvpUtztjbA5NXsrFOV2P3kdgeKScTFc7Rj+lCtgZbrSPLzhT07VNrMd0VDcMTsCkHpVywSKNgW+YmoC44bHFOU7zwcgccVTVwVkXNSiFxGUiYow6VhpDPaTgOAdwxkdzW0gKkZxke/WqutyK9ttjOJQQVKnvRF20M52eowpeQDzTDvixztPNQ286spuTnLfdBPStfTJHltEV/vhfmqgsMchkTGFDGhPdMpxvZjrXzr98QkImcFj1/CpY7GGyuGYBpJT/E/Jqj509gwSyXd6rU1jPcTXTNdgK3UL14ptdUQmr2a1LFy0zfKmQx61QeFYbiIJ80znknrWrIeGk4UYNZaIwuIJycFm4B7URCW5sXkDNbERnn+VO8PQpbWYDyZdiWap2iaQFmOD6UtvZKGDHGfrUX0say3J9RKSRFBhgRxVG11Ex2rQgkT52jHpVqROWwOB0FQ29mcF2XaW9aSasK1yC5LRxfOxyal0vTxGPN4LN1J71Bc/fRSc4brWkj4UAEU7uwWKmpFIGjdecnaxz2NO2b13HB44pt6vm/KQcHvUNrI8f7uQEEdD7Ut0VB23IL6Eqd6nnHIoq/Ou+LoBRTUrGrVza0W3+fe3GeTnmukWJQFYjgdqz9NgVIQDkADPStGPAQbx1PWsWcTfNK46Ykjr2rKuGBcjg49avuxB6j61SmUFyQoz60jemktzKc/MTggDpVu0O4+2OM1EY9rsGOQfSrlkgI5b8TTCY6RdqnbgfSuZ8QSZMZHdgD711UqnawOfWuU1uFriRUjyCh3HHNOOoR2sSX6JJpoVBlyv0qHQ5FkRQxwwODS288hAhlABXv61ShY2eoEDgMcjNa7owjePus6G+tSYyyjGB1o0yUtAA2CRVdr5vL6knrTbaTYnU881m1dG6d0aWS7c9euKY+0tk4zTDKDxxUbswUk9OtTsaJChfm4POaBIC2wON5606z8tpYxOdsZYBmz0B71p+fFpjXtlamzvYJsKLl48sMd1zyKpLuTKaTt1MK8iSWJgyDr1zmqlhOY2a33HaDkE+la1y6k7FXIA5Irn4sNqc8oJ2jCj0oWpbV1qJr10J3gtIs5Vw7E9gKa/oR1qxPbLxKF5xy1NjhDk8GqRm9SGIhckAHtmsy833E77j8sQ4GK6FrXYpJGTisCJkbVLmJhgMoAJ9aqOrInpG5YsGUoB049akubYld+B69KS2i8rd6fWr4UNGRihvUmKuY8aFlOe1TxQjrjke1KoKycdKtRAMwzj602yktSD7JuXIGfwrNKvHId2ME4zzXSRxSzXcUMQO0nnA7etWfENnaxSR+T94oA4z1b1/GkpCnJXSOdXzMAZGG71I9tDCgkcb39PSobmLy/njOOelQ3BcLuJyBz9apa7A3yjlumt4ykedxyevSr9hbhbJCxLPJ8zE+9UUVIbGSWTmTaTWvp0sdxpsBAILKCR6UpaIadnZ7ki2cSRF/kAFU4YRJI8mBgcDPpWdfPdG6a3hYhf4iO1bLOkNmE2/dXk+tJppa9QT1ZkXQeW6W3jYleC3sKdqjfv4AFwqMB6VY0uEs7zOBljkE1Fcp5lyWwTs6AetUnrYlo3ijLECPQdqrxXW2R45Cd1MhuvNgXjJI/Wqc6sJAcAe9Zpdza10Xkl8yUk9B7cVPLdJHEQTxWVD8i8Z56A06PMr8fe6Yp2I8iC4kLzA8jnpWpao3l8YPFRQ2ezMkg6d89KtWso3/dyvpQ3oCRGbd92481XvoxHtcHgHmtd2LocAD0xWfcxm5kMYGVA5NJMa1J4VEkXHPviio7SQxAxP94D9KKTNGztIYvkx64p8oKjk57VPFhlAxUdyrYO2oOSDuyk7MU2nAWmknb60kmAMA1Ej4755pG7Gyrz05+lWLQKQQAAenFIVVjmiEEOcd6e4paoknXamTg46VztvF5uvAcbSvIro5T8jE4zjp1rmrAqNekJzlBz604ivaLZPrduYHEqY64PvWDqyM0ayhAHU5rq79RdSqinnHXHb0rKvLY8x7OcHjNWnYhS5rFLT5ROFOeowa1fL24yBnPUVzVjN9lujz8hbBz2NdKLlJQp49BzRIuLsxzRkcqflNPVRjBGTU0qgxKMgcVCik/KWGc1mW3cesIHLLmqNwN6leRzwe4rT5VO5NZ7q3nEkHFCBOxSNs/zfvZCD1py24hjVVHH05NXhwct2qSwt/7Q1OGAzxwA5PmSnCjjpmqTG3ZeRm3lldrCXRwV67TxVaxl8zHG11OCK63U7ZLOTyjcwXI2K2+Fty8jp9RXLW0IGpzHaAvp70/IlNSjdFqV8QMXPQZya5R4HlgabkHeWB74rd1uVhE0Mf8ArJOBg9qbb2o+yKmD0pwfLqKSurGdYXIYhWbPYE9604iSD3HQ1z7LLbO+Y32K33gK2IbtWjBGSD3zVyWl0THR2Y2f92+SPloEiMoZGGPrV7TbKTU5XjtgjyAbtrMFJH41Qu4BbMSQFYHBWkmXpey3LltqFxAGC7cdCehI+tVrm6ae4JY5Y/p7VXaVioCjr2Jq3FbrEmZMFjySTRoiFFXuZl9NtAXacnim2sckx3spMY6Z71OsQvL7C/cB5I9K6bS9Gnvy8FkiL5al3dzhVUdc0N2VkUlG3PLY4/UhcXS/Z4kOG4J9q1reMWNooOAwGMHvXQ20OjpYRtLc7botlyMYRfoepNYMubqZ5GyIhnZu649aOa6Ibi5Nrcghi+dQSS7ncavz2paMhs4xVK2mht5mLuScd6szarb+XtQnIHWh3voO6SEBW3t9iVRsyWlZhuIPeori5adtkecHrW1p9ntgUH75GRntRqlqNdyrYwlLiWMngcgmrFyoVvmP6UR7o7xlxjI796dcRllPdqnqaJ6Ge7NK4RBlvp2rXsoBbwhnA3YzUNlAFkD46dvWr16QkLZ7joKHLoQ9EUL2USPsTOOpzU1vCVQc47022hPl+Y2BnpnrVkKGHUZz3pDjZCSDggEjmltFVAeck96ZKD/AM00Lt5xg0DZHdp+83qOaKe7DkkA/Sinewmdtbh1TqCRip5V3xM386Yi7QOMDA/CpXJEBw1R1Oa/YxbgEKf1qvEpBPPer2PMz6/SoDHjPXJNI3Ur6DwoI7H1pI/v4Y44/Khd2xhjHYH1pIxzgYFCCxNIimNjyPxrk7RtviK8AxuAXpXXOpEZIBJx1rjcFfElwCR8yrzVIN4s6a02kqDj1qlrVsUhLAkYqzbsI5l5GeBU+pHfEyvzkcUr6mEb3OMs7FdQWbJwBkj60llK8Ewt5myynIOOoq7oQaG7uoSCQjZH0NV/Ev7m5guY1xhsN9DWj10NVe7RsmYMqjjGOeantYSSCTkZrGgnzjPP61t2kgZAB0rOSsWnoPuFCn5B0PFVWVc53NnHWnzEvKNrcfyqSGEnPc1GxS21Kjj5Su3I9apjDMQzVsSRHDYGMdqzWtyMtuxzVJgmhru/l7Qwx7UQQ+WOcljyT60gX5uG4q02dmW44qmNGDEDdarNKekZ2jP61pgbSiYBZiAB9e1ZWkkMZ2yctI3Oe1aF1IiImSQwPFD7E2u7Ghq2lXWnulpqNrLbvIu4LIo+YfWuSitGgu54CeByOe1dPqPiS51A+bqc8lxNENqkrjjH5Z96xIc3V4Z2QohGATV7bbCpuTilPfyKEe8Xp2sVZRjg1eJJyGG7HeoolB1OQA5XA5NaFxAuzIYEe9O4SV5FOOIBt7DrVfUrkrtijGXfjitREHk+g7AVh27q9y7uc4faM0R1YS0ibWlxx2duqtjeep96nGqJbSMXkl8jIaSOJtpkx2+lQXFqzpkE8d+lZE8I8wxqxz05qYrmd2VVgnGyLkl3Jq9/LN5YVGbJVRwo7CrWN3yc7e46cUsSR2dntjI3dyO9NjDMCQSM96pu5nFKKsPmhgVMbVFZL26M+UHGa1fs4PL5OKkWKNCDwO3HNCdh77lfTrEBgzDHHStRyVGMD2NMDDr+FKxAQkYzUNtsvdaFWINLesWI44q3sAAAJxWfZzf6Y8bjnt71rzxjyeDyR0oY1oiG3cCU4+YDjpTdSuBmNQepyQKoiXbMyjg9/erEUII8xyckYFFupLWupZEmIQuKj2lsEA4HanRk7flBP1qYHJ+Y4o21FYYnT+vpSdBjNPkC7eD1qFsE5AzSKQjLxweaKbk4x60U9gO88zMSkDJ6EVBO7oCCRtNT7AACp6iqF0zAkHHTjNSznghLcHeTnoeKUptUbxkn0plmxx8wznpUzgs6BgeBmkUr3DHyENgDFVwAjkEAfSrYHyEbc+xqtLuL/ADKAOwoLSJiC0RG7r0NchqCGPxGh4G5MDPqK6yLlSR97rXOeJEEd/Zy8n5sU0NbNGnAhLR9h3NWbtQ8YAJ3etQW7qV4x9a0NhkiXaeAM4pPcxi+5xd6zWmrRyEkBvkY+vpVzWrX7XasNoyRnFTa/aGa3bHBHIJHQin6Ncm5skLDJA2tnnBq79RybTTRzVnIwQo4Ikj4IrXsLw9P5d6i1my8u68xAdrGs0M0Ewyf3bnB56U99S7X2NyWTbKrZP1zV2K5YLuRsgmsdDkgdcdOKnWUKwByD2qWi1Zmx5p8sknk9cdqpTyZAA7frQZiUI45H50yMKxO49O1SlYLDIEG7f/DSapcCGwlbGAF7nvVyNSqZA4NYHiOfz7mOzUcL87n+QppXZS7kenRPDaoCcnGTUtyRIq+1OhYGLbngDio5FI56exqxJj7eMMW8xcrnpS3zpAm7ABPGDVqBEEHUbiOKx5t13esD9yLt6mktWUtFcda252+Zkh3OeKfOZAnUjHarUa7VxzkVTuA1zIIou33j6VRne70LtnG0sC844rmgjrJcIuQd5+ldMWFtbAM3Qd6yYA8ocwR5LEnJopu12OpquVblvSL03dt82d6/Kwz3qpqJMdym3A3HH0p1pZPYB5JZOWOSBVaZpLq681QTt6DH61Sir3Qm2lZ7mluM0yRryF6n1rSSMDqDxWXpaPFJ84+Y8mto4PTg/lUS00FHYiYDI/KkKDjI61KMdiMUjD0A9qVwIQvzcECpgD5ZHr60kUZeTp+lTyAIAD29KGVexmFBHdxk8bj2rZOZFBwM4rHunH2iMjPB5rbtGUxjPpxRIIvQxL+EpKsgUHBp0bmQqoHStS9g+U4+tULOLE/A/GhbFNp6l5FCx8qaiO4ngCruzjk/rUJ6kDtSIRWMfrzSlcHPep249DTDz1A9jSHci2gdRiikZmHXJBHeimB3bjag4wMVQu1ycmtRgOO4IrOu+TgdKDCDKloAGIz1ORV2QY5xntVS3GHyByKvx8g5H51IN6jBEHjG3IPrVW5jKkkEZA61eGQBtA54IqvcqNvQZ7U9zSMtSKH5o+evasPxYqmzifncjZroIEBiVQcMBzWV4niH9nSc5OM5FJFx+Iq2LZhRjnOOlbVv/qwScccVz+ntuijJPOK6CzbKdMCnI5ytqEYdDk9q5jS3NnrE1sx/dyfOOa7G8QkZI+mK4vXF+z6ja3K8DdsJ+tNal/FFo6C+iWe3JyOnGO1cnq0ZiJRjjPTPrXVQkmIY5yBWB4jiP2fzO6EH8M046MVNlSynzGueGxgmrj/OAwwCKoiEMgePPTr2qS2lZSRIMc85qmi0+xbjnxgPlT2xU6vtYGQgmoDHvUMtVrhmAOfr70tCoxbNma7SK1eRzjaM1y6LLIzzAbpJTuOT0pklxLdyfZySEQjcfX0retLSOa5htrPzJJXwvK4Gf8Kajyjuk7GPbXMkDmK4Qoex6itOL98wKlWFQ6rbmJmSXHmRsVyMGoNL3CRlzxnjtxQx8ul0XbmQRQsSRhQayNMyUy7j5juJJqx4gZvsLIg+duAKz7XfhIkT5jgewogtLk1NdEXrm+LARwAM3SpoHW0gwec8sx609NLlgdZPMBb2FLfReZbssnXHUUXWyKULIpRzDVLnykbMcf3jmr80sdlFlQMAYwKzPDEK2vnDOWbGT71fvoHnRgW4HpRKylboFNNxMyeaW6ZS2REOcY5NdBptnGLdNoO5utYlqjY2P95TyfWteOYogGD0py2sjNXVxZ08m7GMfgKm3EjkDPtVON2nuuecDrWqiLjBAyKh+ZcNtSIDIPI56UqxlsAGpAigjH61LEOcEdKBMdEmxCQMn1qtK+ZCBzjvUt1NgFUzk9qZBAchjyaQkrlcW25i55PUVZ0zJYjnjtVh4yI+OpGKhtQEuigGCBTvoVctXS5Xn071VtBh8nArRuMeVWaFxJmkhbotlsrxUDDipkBNRP8AfIPXuDQCImB5GcU0feI9u1SDGCG6Dp7UxuATxQhkcmMEfzoplwwAOPTiimkK56Gf9XjHzVnXYyD6VpqPkyetULpeOT+lI5oPUpQ5yM9KuJ93p1qoMK1WkPy8VJTH7l7dqrz/ADHkVIrc/Wo58bwVPWhFrcSEFVG786z9fUyWMwHTbkVpR/dGRzUWpRrJZSDHJU8UI0i7STZzelHfbR49K6GxIOK5zQW3WoBI+U4rcs3ZWGOlORhLexpXA/dnArkPE1sZbSTaPmHzD8K65yXXj61iasn7t89PQURZVN2ZR0OU3NtHz1HNWr21W4gcFQVK4zWDok3kzPHno2cdq66KRGiXOPpTejI+GRw2n5QzWkr4aPOD7dqsFMyK3G33pPE0aWusQTRjAf5WApYSC3oKvzNrWdzQhj82EoRgY/Kq9xp4RQQ+SB+dXoIyqEgk5GKSVA8eTwah6GtKTOZ0J0k1O+Mm1WWQIFHUADiurh+02CRajb3UcEqS+Wqg4lU4649K5uTU5tF1horWG22XmyRpXj3OHQ5BBPTrg/Srepa3Pe3sl3fSB7mXHKqFB7dBWktdUYuMnOztbzIdUuXiLNOSdzdcdTUulx5HmEcHnHpVCTdc3CeYCcnIU8gVuwIUhyQAPQVMlZeZvdPRbGXfgyXqoc4xnBpyWhEmVwCP1qCRjJqrOxBXbtAz3rVE4VcucYBp3sjOT1HGUmMK3JHoKZIodGJx6fSm2x3uXJ4PSpphgEZFR1KRhWQ8mOR885P51sQxOIMyZ3Hkms/TUW6vHT+CNzn61uzhUTqWJ7VU3qKD90wQga6ZlAwDgjHetGG2LqWkOF6gYqS0tUTc5/i557GiZ3nYqnEanHHehvogS+8gsUQXpCHcoHNazwnBI3Z9KybMfZ74FFyrDBroSOMDOSM0pDTsjH87EhVjg1J9qUDb+FVtXQxN5o4Pfms2G5dyNin6mnFXFNX2NmFS77pDhe1XzNEnAHHHFYai8lj+VlQk+mTUFzDdxKXE+WHtwaT1H7OR0scqMpZsAAcD3rOhkxdFznBNQ2DSSpH5hGSOgFXzDhTgYH0o2FFW3Lo2v9feoJVC+1Ms5iTt6kHmpLkjryPapBbjFcEMD94dDVhvIuY87xFNjBOODWNLKyk7c4ojLu2OQBVCcWWZyImI3BsdwetVZbnJIGfSplty4wxz9amW0VR0PFGgWtuZhDyHJ4HtRWp5QX6+xopomU4o6zRNVstY0q31HTJxPZzruRuhHqrDsR0Iqa72sMDn+lfLXwt8dXHhDVSs2+bSLggXMA5Knp5ij+8P16elfT9tdW95Zw3VpMlxbToJIpUOQ6n/ADjHY5rbE4d0ZabHl4PFquv7y/q5SIxKP6mrEY3LnOc1HPw+fepYOVxjiuY75COVHGe9RSEEjAz9aS4OMgfgKhgkz170i0upbiYk/K350XfzQnA7YPenxwg88rUTB1BGdy+tBSaZyeh8TXMfdZD/ADrdgRgwb3rE0sMNYv1HGHzj2roImAxnJOcYqmRV0qNFoY2Zz7Vkaydlu5XjjpWxHhlJHHpWL4jB+yPwelJBT3OaS3k+zpPH95jmt3TLkvGUbkgUaIqzWFvkA/Lk0TWptpkZBtVuDVPUV+YyfFP/AC7t6vj3GaqwAqAO4q54nG2COQn7kisx9s0txB92SHlWGQc8U1saN7F6wcuFOevBq2yZX9etZNhL82BkHHStRXDLgnFRIcdDkPF8flPa3O0Zikxn2NKpWQ5cZJA7Vs+I7KO6024izyVyv17VzmmzBrSMn7yDacjvWkH7ppU6M3LC3SVZZfMVdmAqnq1T3ErLEVVfmI4qlpki5IPTPU1cumWN94J6c5HSlLczi9LmV/ZzZ3ySESHk4pkqzW4BY74/ftXV3emi00q0lmFwuoT/ALwpImIxCfusD65zxXP3yONqyb/m+7kYyPWrs1uCnGadth9q7AbE+tWJyRC7yHlRkk0ywwBlQMetN1tlSxl+b7ynkVnuy37quR+HgosTKRzK5ckdxWlKN2NpORVDw+oGmW/fjHNa/ljBJweKUn7wLZFcZAI6cVGrbEIXdvzj8KlkjAbAODTPLJPNNCZGuPNhUdS3JrfeXy7cl8cDqRWLHGReRjHy96t6mQlo7KDxx160pCS0Me6lN5dEE/ux2x1qe3tVjbAXmltbYIis45PatBIikO8gKG6VSNn7uxJb2u8kllRffii4t4yQVZXUHB285q5Z281zKUhiaZlj8z5ew7k1XKK4Rx8rHnApO9rkKWu5DaII5TgcDpmrMp+QjgcZGapM7mZ9wUdOOlTfMwHZT1pEy3Ktu4F2659DxV10LJwcfWqJAju1Y8KeK0kO5Bk80MLlTyEPbmlKogBzirTqMDnmqksXzEZouDdwe4iTJ4qJ76PGFOfSo5owRgj61zPi7V7XQrBp5hunbIhiB5c+/sO9VCPM0luRNqMbydkSeM/FsGgafu+WW+mGIYSeP95v9kfrRXg+r6jcaley3d05kmfqT2HYD0FFezRwkIR95XZ8ziM0qym/ZOyKIkKsCDjFej/Cb4gS+Grg6dqLvJotw+WGMm3Y/wDLRfb+8O/XrXmfPrUkeRzkV0ThGceSWx51OrKlNThuj7UR47iJJIpFliZQ6OhyrKRkEHuKlRQMZPevnr4SfEH+xZY9G1eY/wBmSnEUrf8ALux/9kJ6+nX1r6EjkBVQ3zAjgjvXg16EqMuV7dD6jDYpYmN1uV71AoZs98/Sqlo2ZH+laMo3o4KkHtmsiE7Lgj19B0rBnctjbiYbfmJxT5VUoQADnp2qvDuwMnI61KSxjAzzQiPQ5IbofE1yhHyuoPNbYYHJUBRxWJrmYdctpCeWBUmtRJdwAPIA6iqHWXv37mpHjaOmewqjrEJktmQ7cdqvWuGUcVHeRqYj8wz2zSJi7M5Twvc4gNuThkYr1963tQiDMG3dOK5SffZ6m08YwnVh611NneRXVtHs4Pp3qpaahJckr9GZmp2/n6fLEw+YqQDiqWh3IuNJjDZLqNp/DrW/dwkISP4q5XSj5GqX1vnCq29QfcUR1Ll70LroTyo0T7w3IPb0rShZZUHG7ioZIsAkDJbqM0y3Bgwp4Q9MHpQ0Un1J548qCVzjue9ceifZdUurbkRv+9T8etdq4xllfPFcr4jzHqFlcpgfN5be+aIPWxo3zRaZNYkoSmBzV+V1aAh+nes5CUk3bRtalvp2it3dBlgvGatq7Moyte5e0/WjIs6azHcagogNvagzbVhIPB+g9Kim1O4uIIrK4ZZcEAMeSijoPpWXpthIyDzZCO+0HjNXTZm0YOq5H1p7aCjRXxNGvFGkcK7VAHaub1qd5rr7J92M4Yn156V0sTF4QoztHYVha5ZuXinjX5lYKx/2aim/e1NJxcloXvDzhkeAMMxsR9O9bE5BAK/Q5rnrTba3AkTiNlG4jua6BMSwcEVM1rqVpoRCQb+c/WneauW9e2aguI5EyVXFU5W52tkE96EiZLsaFtIr3a45PTpmn6wr/ZWznA9KzIZzbXMZfGM4Ga07mQyQ7CeD1oa1CD2IkYyKpXccds1b3OsQ344PyqKy4o7uOOUWoMhxgCtGwmuFhBuVUOfl9l5607Gstro3vDd62kams4mW3V42jkLIXBBHp9arzRwPcTtaxuI2bILYJrNuVla4ZRIskYHDAYyav6eunf2JezXmq/Z9Qi4itj/H6U99L/ezkny026suun46Fa4RFki2j5s4IxUoCKN7duoqla3G79445x0oa4Y9Py9KllptobfIWQlSPUGqtrqKriKb5XB6k8GrDyEnn0xWfcwrJguMH1FFrlx10ZrNcArgEHFQNOXJJPJ9axjFNCMJISPQ1WvtWh0yykur99kSDnHVj6D1JpqDbshuyTb2LfiLW7TRNMkvLt/lHyoin5pG7KP6ntXgHiLWbvW9RkvLxyWY4VF+6i9gKn8V+I7nxBqDXFwxSJQViiB4RfT3Pqa589TXtYXDeyV5bs+UzDHvES5IfCvxFJ45zRTelFdidjzBM804NjNR0UgJlkwen4V7V8G/iCITBoOvTAw/dtLmQ/6snpGx9D2Pbp06eIr1qynVvo1RUpRrR5JG1GvKjLnj0PtWZwTnjgEGufnKx3KOM5Jq/o//ACArP/rin/oIqjqP3R9P6185y6n2dJXRsWUodVyeankLAHoR61k2PRK0361F9bGd7Sscp4oQZhkJI2vxVy1cssZXJOOaj8V/8eo/3hS2H+qT6VZrV0SZswy5XGenFQ3rnAO3nHJog7fWluf9S/0qVqZwephSKkzvuI9KqaYWtb4oCAh5HtVj/l4/Cqz/APH2n1q91Yty0aOoaQSxEtzxgZrjrjNv4rOeBLF+orq4f+PZPrXI65/yM1r/ALppQ1ZEXo0dBbbGU4Oc9aWSHaQBgjqM1HZdvpViL7h/Gh6FRdyrI5UfcyBXP+JgH05n6FSHA7jBrpm+6/1rnPE3/IOuf92nHc6ILRktnEJ7dWYH5lzkVDdwjyynOO1XdF/487f/AHB/Kor/APi+lVf3jGMrlfT5N0JHG7gEjtirWoC3FmkiyFmAyy46GsfR+k3/AF0P86saj/x5vVtakqbldmtps6mMO4Bz0zVq98uS3IJGxgfSsmw/49YfpVqf/jzes7am8o+7cwV1GA2kkchHmKShHTpWhpOsqiLHcBlcd+xrk5/+Qia2f4Erd000ZK/c7WJxNGGwCPSoLyGMhlAz9O1RaZ/qh9BVuf7jfSuXZj5jm5ofMQo7YKkjp+tXNIuzPEVfPmRnY2efxqO5/wCPh/oKh0j/AI+rv/f/AKVo9gi7s3YemUG0Hv3pJo5cZEhJ/nVi2/49xTn/ANW1Z3satIw55LgHyzI6Z9qjtreNCS2ZGJzubkmrWp/cT61FDWkWTKCWqLittUE/lin5GM4wT04pF++tPl+8v1qWyLgRnjPzdM1G6Aggc1aj+4fwqCT/AFRqQ5jM1C6gsrOS4uZFjgjXczkdB/j7V4V4w8Sza7flhmO0jOIYvQep9zXpPxR/5Fn/ALbr/I14o3Vq9bA0ope0e54Ob4qd/ZLRfmMJyeKSkHelr0TwgooooA//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic view of the body of the stomach looking toward the antrum and pylorus showing numerous polypoid lesions, which on biopsy were proven to be fundic gland polyps.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Akira Horiuchi, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fundic gland polyp",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 354px; height: 373px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Upper endoscopy showing a small polyp in the gastric fundus proven to be a fundic gland polyp after it was removed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David Y Graham, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_29_4565=[""].join("\n");
var outline_f4_29_4565=null;
var title_f4_29_4566="Diphtheria epidemiology US";
var content_f4_29_4566=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F72244%7EPEDS%2F53397%7EPEDS%2F62288&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F72244%7EPEDS%2F53397%7EPEDS%2F62288&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diphtheria cases in the United States",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 406px; height: 670px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Diphtheria. In: Epidemiology and Prevention of Vaccine-Preventable Diseases. The Pink Book, 12th ed, Atkinson W, Wolfe S, Hamborsky J (Eds), Public Health Foundation, Washington, DC 2011. Available at:",
"     <a href=\"file://www.cdc.gov/vaccines/pubs/pinkbook/downloads/dip.pdf\">",
"      www.cdc.gov/vaccines/pubs/pinkbook/downloads/dip.pdf",
"     </a>",
"     (Accessed on September 12, 2012).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tetanus cases in the United States",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 410px; height: 678px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Tetanus. In: Epidemiology and Prevention of Vaccine-Preventable Diseases. The Pink Book, 12th ed, Atkinson W, Wolfe S, Hamborsky J (Eds), Public Health Foundation, Washington, DC 2011. Available at:&nbsp;",
"     <a href=\"file://www.cdc.gov/vaccines/pubs/pinkbook/downloads/tetanus.pdf\">",
"      www.cdc.gov/vaccines/pubs/pinkbook/downloads/tetanus.pdf",
"     </a>",
"     (Accessed on September 12, 2011).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pertussis cases in the United States",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 404px; height: 713px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Centers for Disease Control and Prevention. Pertussis. In: Epidemiology and Prevention of Vaccine-Preventable Diseases. The Pink Book, 12th ed, Atkinson W, Wolfe S, Hamborsky J (Eds), Public Health Foundation, Washington DC 2011. Available at:",
"     <a href=\"file://www.cdc.gov/vaccines/pubs/pinkbook/downloads/pert.pdf\">",
"      www.cdc.gov/vaccines/pubs/pinkbook/downloads/pert.pdf",
"     </a>",
"     (Accessed on September 12, 2012).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_29_4566=[""].join("\n");
var outline_f4_29_4566=null;
var title_f4_29_4567="Physiology of somatostatin and its analogues";
var content_f4_29_4567=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Physiology of somatostatin and its analogues",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/29/4567/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/29/4567/contributors\">",
"     Rodger A Liddle, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/29/4567/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/29/4567/contributors\">",
"     J Thomas LaMont, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/29/4567/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/29/4567/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/29/4567/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Somatostatin holds an interesting place in gastrointestinal endocrinology. Originally discovered as an inhibitor of growth hormone release [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4567/abstract/1\">",
"     1",
"    </a>",
"    ], it is now known to inhibit a variety of gastrointestinal processes (",
"    <a class=\"graphic graphic_table graphicRef67174 \" href=\"UTD.htm?12/18/12587\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4567/abstract/2\">",
"     2",
"    </a>",
"    ]. Somatostatin is produced by paracrine cells that are scattered throughout the gastrointestinal tract and inhibits gastrointestinal endocrine secretion. Somatostatin is also found in various locations in the nervous system and exerts neural control over many physiological functions. Given this vast array of effects, it is not surprising that somatostatin has been the subject of intensive investigation. The development of synthetic analogues has led to treatment of clinical disorders such as acromegaly, hormone-secreting tumors of the gastrointestinal tract, and portal hypertensive bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MOLECULAR FORMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biologically active somatostatin exits in two molecular forms: somatostatin-14 and somatostatin-28. Both are the products of post-translational processing of preprohormone [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4567/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22660?source=see_link\">",
"     \"Synthesis, secretion, and regulation of gastrointestinal peptides\"",
"    </a>",
"    .) Somatostatin is a cyclic peptide (",
"    <a class=\"graphic graphic_figure graphicRef55724 \" href=\"UTD.htm?39/32/40462\">",
"     figure 1",
"    </a>",
"    ) that is remarkably well conserved in evolution. A disulfide bond between cysteine residues maintains the cyclic structure. Somatostatin-14 is identical to the carboxyl terminal 14 amino acids of somatostatin-28. The biological activity of S-14 and S-28 resides in the cyclic region of the mature peptide. The F-W-K-T portion of the ring structure is required for receptor occupancy. This finding made it possible to produce synthetic bioactive peptides such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    acetate (SMS-201-995, Sandostatin&reg;) (",
"    <a class=\"graphic graphic_figure graphicRef55724 \" href=\"UTD.htm?39/32/40462\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Cortistatin is a neuropeptide that is structurally similar to somatostatin and binds to all somatostatin receptor subtypes. It can also bind the growth hormone secretagogue receptor (GHS-R, also known as the ghrelin receptor), but as yet its physiological function is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4567/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TISSUE DISTRIBUTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Somatostatin is distributed throughout the entire body, although it is particularly abundant in nervous tissue of the cortex, hypothalamus, brainstem, and spinal cord. It has also been localized in nerves of the heart, thyroid, skin, eye, and thymus. Somatostatin is abundant in the gastrointestinal tract and pancreas where it is produced by paracrine and endocrine-like D cells and by enteric nerves. Both S-14 and S-28 are expressed throughout regions of the gastrointestinal tract.",
"   </p>",
"   <p>",
"    Somatostatin cells are morphologically diverse. In the gut mucosa, D-cells are flask-shaped and contain long cytoplasmic extensions that end in nerve terminal-like processes poised to participate in endocrine regulation either via release into the systemic circulation or direct secretion onto a neighboring cell. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/33/16917?source=see_link\">",
"     \"Overview of gastrointestinal peptides in health and disease\"",
"    </a>",
"    .) These cells appear uniquely suited to sample the luminal contents and influence local cell responses in a paracrine manner. In the central and peripheral nervous systems, nerves release somatostatin where it functions as a peptidergic neurotransmitter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RECEPTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The somatostatin receptor is a typical G protein-coupled receptor (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/49/22293?source=see_link\">",
"     \"Peptide hormone signal transduction and regulation\"",
"    </a>",
"    ). At present there are five known subtypes of the somatostatin receptor (designated subtypes 1 to 5). These receptors do not differ appreciably in their binding of somatostatin 14 or 28; however, there is significant variation in binding of synthetic somatostatin peptides [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4567/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. All somatostatin receptor subtypes have been found in the brain [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4567/abstract/6\">",
"     6",
"    </a>",
"    ]. In contrast, peripheral tissues vary in the subtype expressed (",
"    <a class=\"graphic graphic_table graphicRef75201 \" href=\"UTD.htm?1/28/1483\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    All subtypes of the somatostatin receptor are coupled to adenylate cyclase through an inhibitory G protein (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/49/22293?source=see_link\">",
"     \"Peptide hormone signal transduction and regulation\"",
"    </a>",
"    ). Receptor activation results in a reduction of cAMP accumulation. In addition, agonist occupancy of some subtypes couples to activation of ion channels (eg, potassium channels) and mobilization of intracellular calcium [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4567/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Certain agonists exhibit functional selectivity at individual somatostatin receptors and activate only a portion of the receptor's potential effects. This property is known as selective agonism, and has been described with other G protein-coupled receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4567/abstract/7\">",
"     7",
"    </a>",
"    ]. This may make it possible to develop agonists with various somatostatin-like activities.",
"   </p>",
"   <p>",
"    Interestingly, somatostatin receptors can interact with each other and form dimers [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4567/abstract/8\">",
"     8",
"    </a>",
"    ]. Agonist-induced receptor dimerization changes ligand binding affinity and receptor internalization [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4567/abstract/8\">",
"     8",
"    </a>",
"    ]. Different receptor types can interact with the somatostatin receptor (receptor heterodimerization), thus, providing a novel pathway for cellular communication. As an example, the dopamine receptor (type 2) and the somatostatin receptor (type 5) can physically associate to diversify receptor signaling [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4567/abstract/9\">",
"     9",
"    </a>",
"    ]. Cross-talk between somatostatin receptors and growth factor receptors of the receptor tyrosine kinase (RTK) family may be important in cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4567/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SOMATOSTATIN RELEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Somatostatin is a key regulatory peptide that functions primarily as a paracrine mediator. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/49/22293?source=see_link\">",
"     \"Peptide hormone signal transduction and regulation\"",
"    </a>",
"    .) It is released from neural, endocrine, and enteroendocrine cells and has a very short half-life in tissue and in blood. Its concentration in the blood is low, generally in sub-picomolar amounts. After intravenous administration, 50 percent of the peptide is removed from the circulation in less than three minutes. Somatostatin secretion occurs in response to a variety of stimuli. Meal ingestion and gastric acid secretion increase somatostatin output from gastric D-cells [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4567/abstract/3\">",
"     3",
"    </a>",
"    ]. Gut somatostatin production is regulated by the autonomic nervous system with catecholamines inhibiting and cholinergic mediators stimulating peptide release [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4567/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SOMATOSTATIN PHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physiological effects of somatostatin are largely inhibitory (",
"    <a class=\"graphic graphic_table graphicRef67174 \" href=\"UTD.htm?12/18/12587\">",
"     table 1",
"    </a>",
"    ). In the peripheral organs, somatostatin decreases endocrine and exocrine secretion and blood flow, reduces gastrointestinal motility and gallbladder contraction, and inhibits secretion of most gastrointestinal hormones (",
"    <a class=\"graphic graphic_table graphicRef67492 \" href=\"UTD.htm?19/10/19627\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef76713 \" href=\"UTD.htm?24/63/25595\">",
"     table 4",
"    </a>",
"    ). Somatostatin also inhibits neurotransmission in the brain, but depending on the neural pathways affected, somatostatin in the central nervous system may stimulate endocrine secretion. For example, somatostatin inhibits ghrelin release from",
"    <span class=\"nowrap\">",
"     X/A-like",
"    </span>",
"    cells of the gastric mucosa, but in the brain, somatostatin receptor activation increases plasma ghrelin levels [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4567/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Excess somatostatin secretion is rare and occurs with somatostatinomas. The clinical syndrome is manifest by the triad of (i) diabetes mellitus, (ii) diarrhea secondary to malabsorption, and (iii) gallstone disease. These pathophysiologic processes are the direct result of the inhibitory effects of somatostatin on insulin secretion, pancreatic exocrine secretion, and gallbladder contraction, respectively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/34/3623?source=see_link\">",
"     \"Somatostatinoma\"",
"    </a>",
"    .) Somatostatin deficiency occurs with persistent",
"    <em>",
"     Helicobacter pylori",
"    </em>",
"    infection in the setting of chronic gastritis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4567/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL IMPLICATIONS OF SOMATOSTATIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical utility of somatostatin is hampered by its short half-life in the circulation (less than three minutes). As a result,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    acetate, a synthetic peptide that maintained the biological activity of somatostatin yet remained active for over 90 minutes was produced (",
"    <a class=\"graphic graphic_figure graphicRef55724 \" href=\"UTD.htm?39/32/40462\">",
"     figure 1",
"    </a>",
"    ). Octreotide is much more stable in the circulation and is more potent in many of the inhibitory actions than native somatostatin [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4567/abstract/13\">",
"     13",
"    </a>",
"    ]. The clinical use of octreotide has been established for a number of indications (",
"    <a class=\"graphic graphic_table graphicRef76713 \" href=\"UTD.htm?24/63/25595\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4567/abstract/2,14\">",
"     2,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Somatostatin analogues, somatostatin LAR (Sandostatin&reg; LAR) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/34/7717?source=see_link\">",
"     lanreotide",
"    </a>",
"    -PR (Somatuline&reg; PR), have also simplified treatment with somatostatin analogues [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4567/abstract/15\">",
"     15",
"    </a>",
"    ]. These agents are slow-release formulations that require only monthly injection and supply high-dose, stable serum levels of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    . These agents provide for improved patient compliance since they are administered on a weekly to monthly schedule depending upon the indication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Secretory diarrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secretory diarrhea is a manifestation of a variety of disorders. Human immunodeficiency virus (HIV) infection, for example, can cause serious volume-depleting diarrhea that may respond to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4567/abstract/16\">",
"     16",
"    </a>",
"    ]. Given the clinical improvement some patients with profound secretory diarrhea have demonstrated with octreotide treatment, it has been tried in a number of other diseases with variable results (",
"    <a class=\"graphic graphic_table graphicRef76713 \" href=\"UTD.htm?24/63/25595\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    One of the approved indications is for patients with vasoactive intestinal polypeptide secreting tumor (VIPoma), also called pancreatic cholera or watery",
"    <span class=\"nowrap\">",
"     diarrhea/hypokalemic/achlorhydria",
"    </span>",
"    (WDHA) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4567/abstract/17\">",
"     17",
"    </a>",
"    ]. These individuals have high serum VIP levels and respond to therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/59/16311?source=see_link&amp;anchor=H3#H3\">",
"     \"The VIPoma syndrome\", section on 'Clinical features'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/59/16311?source=see_link&amp;anchor=H7#H7\">",
"     \"The VIPoma syndrome\", section on 'Octreotide and lanreotide'",
"    </a>",
"    .) Octreotide is also effective in carcinoid syndrome in which it reduces symptoms of flushing and diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4567/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9206?source=see_link\">",
"     \"Clinical features of the carcinoid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Gastrointestinal bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Somatostatin has an important role in regulating intestinal blood flow.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     Octreotide",
"    </a>",
"    reduces splanchnic blood flow and, therefore, has been used to treat gastrointestinal bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4567/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24826?source=see_link\">",
"     \"Overview of the treatment of bleeding peptic ulcers\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23514?source=see_link\">",
"     \"Treatment of active variceal hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pancreatic disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Somatostatin inhibits pancreatic exocrine and endocrine secretion. A possible role in preventing post-ERCP pancreatitis has also been suggested [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4567/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/63/28666?source=see_link\">",
"     \"Post-ERCP pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Somatostatin receptor agonists have been investigated in a number of disorders of the pancreas, including acute pancreatitis and pancreatic fistulae. However, the results of many studies of acute pancreatitis indicate no clear benefit on the clinical utility of either somatostatin or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4567/abstract/22\">",
"     22",
"    </a>",
"    ] in improving pancreatic fistulae drainage [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4567/abstract/23\">",
"     23",
"    </a>",
"    ], or enterocutaneous fistulae [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4567/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/35/7738?source=see_link\">",
"     \"Treatment of acute pancreatitis\"",
"    </a>",
"    .) A meta-analysis suggested that somatostatin analogues may reduce complications following pancreatic surgery but did not reduce overall mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4567/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Diagnostic imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most neuroendocrine tumors express somatostatin receptors on their cell surface, providing a rationale for the use of radiolabeled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    to image these tumors. Conventional imaging techniques, including computed tomography, ultrasound, angiography, and magnetic resonance imaging, are the mainstay of tumor localization. However, because neuroendocrine tumors are frequently small they are often difficult to localize accurately by these methods. Somatostatin receptor scintigraphy appears to be more sensitive for detecting such tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4567/abstract/27\">",
"     27",
"    </a>",
"    ].",
"    <sup>",
"     111",
"    </sup>",
"    In-DTPA-octreotide is most commonly used; however, somatostatin analogues with higher affinity and different specificities for somatostatin receptor subtypes are being developed and may prove useful in imaging neuroendocrine and other solid tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4567/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18330?source=see_link\">",
"     \"Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Inhibition of tumor growth",
"    </span>",
"    &nbsp;&mdash;&nbsp;Somatostatin and analogues can slow the growth of some gastrointestinal cancers, particularly neuroendocrine tumors. This antitumor activity appears to be related to both direct and indirect effects. Directly, activation of somatostatin receptors in tumor cells induces cell cycle arrest or apoptosis primarily through regulation of MAP kinase and phosphotyrosine phosphatase activities. Indirectly, somatostatin reduces tumor growth by inhibiting tumor angiogenesis and secretion of growth factors [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4567/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Non-endocrine solid tumors may express multiple somatostatin receptor subtypes and it has been proposed that other somatostatin analogues with a broader range of binding activity may actually be more effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/34/7717?source=see_link\">",
"     lanreotide",
"    </a>",
"    in inhibiting tumor growth [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4567/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radiolabeled somatostatin analogues can be used to deliver isotopes to tumors that contain somatostatin receptors through somatostatin receptors on tumor cells. As a result, clinical trials in a variety of malignancies are ongoing [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4567/abstract/31-34\">",
"     31-34",
"    </a>",
"    ]. Loss of somatostatin receptors has been described in pancreatic cancer and may lead to lack of somatostatin inhibitory growth responses [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4567/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Other uses",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, somatostatin exerts some anti-angiogenic effects and induces apoptosis in endothelial cells. These actions have stimulated interest in evaluation of somatostatin analogues in the treatment of proliferative diabetic retinopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4567/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neuropathic pain following nerve injury is accompanied by an increase in spinal G protein-coupled receptors and ion channels that reinforce pain pathways. However, there is often a compensatory increase in inhibitory receptors on nerves that include somatostatin receptors. These inhibitory influences are becoming recognized for their ability to restrain allodynia and hyperalgesia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4567/abstract/37\">",
"     37",
"    </a>",
"    ]. For these reasons, somatostatin also has antinociceptive effects and in some circumstances may be useful in treating pain [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4567/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H667400\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Somatostatin is produced by paracrine cells that are scattered throughout the gastrointestinal tract and inhibits gastrointestinal endocrine secretion. In the central and peripheral nervous systems, somatostatin functions as a peptidergic neurotransmitter. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Tissue distribution'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The somatostatin receptor is a typical G protein-coupled receptor. Somatostatin receptors can interact with each other and form dimers. Different receptor types can also interact with the somatostatin receptor (receptor heterodimerization), thereby providing a novel pathway for cellular communication. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Receptors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Meal ingestion and gastric acid secretion increase somatostatin output from gastric D-cells. In the peripheral nervous systems and peripheral organs, somatostatin decreases endocrine and exocrine secretion and blood flow, reduces gastrointestinal motility and gallbladder contraction, and inhibits secretion of most gastrointestinal hormones (",
"      <a class=\"graphic graphic_table graphicRef67492 \" href=\"UTD.htm?19/10/19627\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Somatostatin release'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Somatostatin physiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Somatostatinomas are characterized by somatostatin excess and the triad of diabetes mellitus, diarrhea secondary to malabsorption, and gallstone disease. Somatostatin deficiency occurs with persistent",
"      <em>",
"       Helicobacter pylori",
"      </em>",
"      infection in the setting of chronic gastritis. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Somatostatin physiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"       Octreotide",
"      </a>",
"      and other long acting analogues of somatostatin, have a number of established clinical indications including the treatment of secretory diarrhea, gastrointestinal bleeding, inhibition of tumor growth, and imaging neuroendocrine and other solid tumors (",
"      <a class=\"graphic graphic_table graphicRef76713 \" href=\"UTD.htm?24/63/25595\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical implications of somatostatin'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4567/abstract/1\">",
"      Brazeau P, Vale W, Burgus R, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973; 179:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4567/abstract/2\">",
"      Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996; 334:246.",
"     </a>",
"    </li>",
"    <li>",
"     Chiba T, Yamada T. Gut Somatostatin, 1st ed, Walsh J, Dockray G (Eds), Raven Press, New York 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4567/abstract/4\">",
"      Broglio F, Papotti M, Muccioli G, Ghigo E. Brain-gut communication: cortistatin, somatostatin and ghrelin. Trends Endocrinol Metab 2007; 18:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4567/abstract/5\">",
"      Kidd M, Drozdov I, Joseph R, et al. Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines. Cancer 2008; 113:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4567/abstract/6\">",
"      Raulf F, P&eacute;rez J, Hoyer D, Bruns C. Differential expression of five somatostatin receptor subtypes, SSTR1-5, in the CNS and peripheral tissue. Digestion 1994; 55 Suppl 3:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4567/abstract/7\">",
"      Schonbrunn A. Selective agonism in somatostatin receptor signaling and regulation. Mol Cell Endocrinol 2008; 286:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4567/abstract/8\">",
"      Rocheville M, Lange DC, Kumar U, et al. Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. J Biol Chem 2000; 275:7862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4567/abstract/9\">",
"      Yamada T, Soll AH, Park J, Elashoff J. Autonomic regulation of somatostatin release: studies with primary cultures of canine fundic mucosal cells. Am J Physiol 1984; 247:G567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4567/abstract/10\">",
"      Kumar U. Cross-talk and modulation of signaling between somatostatin and growth factor receptors. Endocrine 2011; 40:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4567/abstract/11\">",
"      Stengel A, Tach&eacute; Y. Activation of somatostatin 2 receptors in the brain and the periphery induces opposite changes in circulating ghrelin levels: functional implications. Front Endocrinol (Lausanne) 2012; 3:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4567/abstract/12\">",
"      Schubert ML. Gastric secretion. Curr Opin Gastroenterol 2005; 21:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4567/abstract/13\">",
"      Arnold R, Frank M, Kajdan U. Management of gastroenteropancreatic endocrine tumors: the place of somatostatin analogues. Digestion 1994; 55 Suppl 3:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4567/abstract/14\">",
"      Mosdell KW, Visconti JA. Emerging indications for octreotide therapy, Part 1. Am J Hosp Pharm 1994; 51:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4567/abstract/15\">",
"      van der Hoek J, Hofland LJ, Lamberts SW. Novel subtype specific and universal somatostatin analogues: clinical potential and pitfalls. Curr Pharm Des 2005; 11:1573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4567/abstract/16\">",
"      Cello JP, Grendell JH, Basuk P, et al. Effect of octreotide on refractory AIDS-associated diarrhea. A prospective, multicenter clinical trial. Ann Intern Med 1991; 115:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4567/abstract/17\">",
"      Harris AG, O'Dorisio TM, Woltering EA, et al. Consensus statement: octreotide dose titration in secretory diarrhea. Diarrhea Management Consensus Development Panel. Dig Dis Sci 1995; 40:1464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4567/abstract/18\">",
"      Kvols LK, Moertel CG, O'Connell MJ, et al. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 1986; 315:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4567/abstract/19\">",
"      Valenzuela JE, Schubert T, Fogel MR, et al. A multicenter, randomized, double-blind trial of somatostatin in the management of acute hemorrhage from esophageal varices. Hepatology 1989; 10:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4567/abstract/20\">",
"      Korula J. Review: somatostatin and its analogues do not reduce mortality in acute bleeding esophageal varices. ACP J Club 2005; 143:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4567/abstract/21\">",
"      Andriulli A, Leandro G, Niro G, et al. Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis. Gastrointest Endosc 2000; 51:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4567/abstract/22\">",
"      Greenberg R, Haddad R, Kashtan H, Kaplan O. The effects of somatostatin and octreotide on experimental and human acute pancreatitis. J Lab Clin Med 2000; 135:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4567/abstract/23\">",
"      Yeo CJ, Cameron JL, Lillemoe KD, et al. Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy? Results of a prospective randomized placebo-controlled trial. Ann Surg 2000; 232:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4567/abstract/24\">",
"      Alvarez C, McFadden DW, Reber HA. Complicated enterocutaneous fistulas: failure of octreotide to improve healing. World J Surg 2000; 24:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4567/abstract/25\">",
"      Stevens P, Foulkes RE, Hartford-Beynon JS, Delicata RJ. Systematic review and meta-analysis of the role of somatostatin and its analogues in the treatment of enterocutaneous fistula. Eur J Gastroenterol Hepatol 2011; 23:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4567/abstract/26\">",
"      Connor S, Alexakis N, Garden OJ, et al. Meta-analysis of the value of somatostatin and its analogues in reducing complications associated with pancreatic surgery. Br J Surg 2005; 92:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4567/abstract/27\">",
"      Gibril F, Reynolds JC, Doppman JL, et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med 1996; 125:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4567/abstract/28\">",
"      Teunissen JJ, Kwekkeboom DJ, Valkema R, Krenning EP. Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours. Endocr Relat Cancer 2011; 18 Suppl 1:S27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4567/abstract/29\">",
"      Florio T. Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors. Front Biosci 2008; 13:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4567/abstract/30\">",
"      Hasskarl J, Kaufmann M, Schmid HA. Somatostatin receptors in non-neuroendocrine malignancies: the potential role of somatostatin analogs in solid tumors. Future Oncol 2011; 7:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4567/abstract/31\">",
"      Tomassetti P, Migliori M, Caletti GC, et al. Treatment of type II gastric carcinoid tumors with somatostatin analogues. N Engl J Med 2000; 343:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4567/abstract/32\">",
"      Kouroumalis E, Skordilis P, Thermos K, et al. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut 1998; 42:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4567/abstract/33\">",
"      Raderer M, Hejna MH, Muller C, et al. Treatment of hepatocellular cancer with the long acting somatostatin analog lanreotide in vitro and in vivo. Int J Oncol 2000; 16:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4567/abstract/34\">",
"      Oberg K. State of the art and future prospects in the management of neuroendocrine tumors. Q J Nucl Med 2000; 44:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4567/abstract/35\">",
"      Fogar P, Greco E, Basso D, et al. Killer genes in pancreatic cancer therapy. Cell Mol Biol (Noisy-le-grand) 2005; 51:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4567/abstract/36\">",
"      Grant MB, Caballero S Jr. The potential role of octreotide in the treatment of diabetic retinopathy. Treat Endocrinol 2005; 4:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4567/abstract/37\">",
"      Taylor BK. Spinal inhibitory neurotransmission in neuropathic pain. Curr Pain Headache Rep 2009; 13:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4567/abstract/38\">",
"      Pan HL, Wu ZZ, Zhou HY, et al. Modulation of pain transmission by G-protein-coupled receptors. Pharmacol Ther 2008; 117:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4567/abstract/39\">",
"      Camilleri M, Andresen V. Current and novel therapeutic options for irritable bowel syndrome management. Dig Liver Dis 2009; 41:854.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2579 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.117.136.88-C2C11C53A9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_29_4567=[""].join("\n");
var outline_f4_29_4567=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H667400\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MOLECULAR FORMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TISSUE DISTRIBUTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RECEPTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SOMATOSTATIN RELEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SOMATOSTATIN PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL IMPLICATIONS OF SOMATOSTATIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Secretory diarrhea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Gastrointestinal bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pancreatic disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Diagnostic imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Inhibition of tumor growth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Other uses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H667400\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2579\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2579|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/32/40462\" title=\"figure 1\">",
"      Somatostatin and octreotide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2579|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/18/12587\" title=\"table 1\">",
"      Hormones inhibited by somatostatin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/28/1483\" title=\"table 2\">",
"      Distribution of somatostatin receptor subtypes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/10/19627\" title=\"table 3\">",
"      Somatostatin physiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/63/25595\" title=\"table 4\">",
"      Clinical uses of somatostatin",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18330?source=related_link\">",
"      Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9206?source=related_link\">",
"      Clinical features of the carcinoid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/33/16917?source=related_link\">",
"      Overview of gastrointestinal peptides in health and disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24826?source=related_link\">",
"      Overview of the treatment of bleeding peptic ulcers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/49/22293?source=related_link\">",
"      Peptide hormone signal transduction and regulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/63/28666?source=related_link\">",
"      Post-ERCP pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/34/3623?source=related_link\">",
"      Somatostatinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22660?source=related_link\">",
"      Synthesis, secretion, and regulation of gastrointestinal peptides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/59/16311?source=related_link\">",
"      The VIPoma syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23514?source=related_link\">",
"      Treatment of active variceal hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/35/7738?source=related_link\">",
"      Treatment of acute pancreatitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_29_4568="Anatomical and physiological changes of pregnancy and exercise";
var content_f4_29_4568=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Anatomical and physiological changes of pregnancy and exercise",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/29/4568/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/29/4568/contributors\">",
"     Raul Artal, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/29/4568/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/29/4568/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/29/4568/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/29/4568/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/29/4568/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of medical or obstetrical complications, pregnant women should be encouraged to continue and maintain an active lifestyle during their pregnancies. Regular aerobic exercise during pregnancy appears to maintain or improve physical fitness [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4568/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Maternal physiological adaptations to pregnancy should be considered, however, and some modification in exercise routines or activity patterns may be necessary because of the normal anatomical changes in pregnancy and fetal requirements.",
"   </p>",
"   <p>",
"    Information on the physiological responses to exercise during pregnancy, including physiological variables that are evaluated during exercise, will be reviewed here. These variables are assessed to determine fitness, ability to engage in various forms of exercise, and corresponding metabolic adjustments. Recommendations for exercise during pregnancy and the puerperium are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/30/7657?source=see_link\">",
"     \"Recommendations for exercise during pregnancy and the postpartum period\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/35/25144?source=see_link\">",
"     \"Exercise physiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMICAL CHANGES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy results in many anatomical changes that could impact a woman's ability to engage in physical activities.",
"   </p>",
"   <p>",
"    The most significant change is increased weight gain, which could increase the forces across the joints during weight bearing exercise. Muscle strengthening prior to and during pregnancy might prevent potential damage to the joints.",
"   </p>",
"   <p>",
"    The uterus expands from a strictly pelvic organ before 12 weeks to become an abdominal organ for the remainder of gestation. The expanding uterus causes an anterior cephalad shift in the center of gravity and progressive lumbar lordosis. Lumbar lordosis leads to low back pain in 40 to 50 percent of all pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4568/abstract/3\">",
"     3",
"    </a>",
"    ]. To compensate for the lumbar lordosis, pregnant women increase the anterior flexion of the cervical spine, resulting in kyphosis. Prominent kyphosis can be associated with paresthesias and motor weakness over the distribution of the ulnar",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    median nerve [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4568/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although prominent lordosis and kyphosis can interfere with the ability to engage in physical activities, physical therapy, weight control, and specific exercise routines can minimize or prevent these problems. Avoiding excessive weight gain is important because a 20 percent weight gain will increase the biomechanical force exerted on a joint by as much as 100 percent, thereby increasing the risk of joint injuries during certain physical activities [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4568/abstract/5\">",
"     5",
"    </a>",
"    ]. Physical therapy and exercises that strengthen muscles at major joints may prevent or minimize this risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19304?source=see_link\">",
"     \"Weight gain and loss in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Laxity of joints varies from one individual to another. Most pregnant women experience a widening of 10 mm of the pubic symphysis beginning at 10 to 12 weeks of gestation, and 1 in 37 women will also experience pubic symphysis regional pain, which is occasionally incapacitating [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4568/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/1/2074?source=see_link\">",
"     \"Musculoskeletal changes and pain during pregnancy and postpartum\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Soft tissue edema of the lower extremities affects as many as 80 percent of pregnant women by term [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4568/abstract/5\">",
"     5",
"    </a>",
"    ]. Edema can cause nerve entrapment with related compression neuropathies, most commonly affecting the median nerve (carpal tunnel syndrome). Compression of the common peroneal nerve may occur at the fibular head. Nerve compression can be exacerbated during",
"    <span class=\"nowrap\">",
"     labor/delivery.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/9/20634?source=see_link&amp;anchor=H8#H8\">",
"     \"Neurologic disorders complicating pregnancy\", section on 'Neuropathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ENERGY NEEDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;For normal weight pregnant women (body mass index [BMI] 20 to 28",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ),",
"    </span>",
"    approximately 300 extra kilocalories (Kcal) per day are required to meet the metabolic needs of pregnancy after the first trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4568/abstract/7\">",
"     7",
"    </a>",
"    ]. The demand is unevenly distributed: approximately 390",
"    <span class=\"nowrap\">",
"     Kcal/day",
"    </span>",
"    at 20 to 30 weeks of gestation versus 250",
"    <span class=\"nowrap\">",
"     Kcal/day",
"    </span>",
"    at 30 to 40 weeks of gestation. Recommendations for weight gain in pregnancy have been published by the Institute of Medicine and are described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19304?source=see_link\">",
"     \"Weight gain and loss in pregnancy\"",
"    </a>",
"    .) The recommendation for a single standard of weight gain for all obesity classes has been challenged because higher BMIs and further weight gain are associated with more severe pregnancy complications, such as preeclampsia and gestational diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4568/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Furthermore, these recommendations do not account for energy intake and energy requirements of active versus sedentary women. The caloric requirement is higher when daily energy expenditure is increased through exercise. Depending on the activity and intensity of exercise, an additional 350 to 500",
"    <span class=\"nowrap\">",
"     cal/hour",
"    </span>",
"    intake may be required.",
"   </p>",
"   <p>",
"    In the laboratory, an estimate of the increased requirement can be made based upon the metabolic equivalent (MET), a unit of resting oxygen uptake. One MET is defined as 3.5 mL O2",
"    <span class=\"nowrap\">",
"     uptake/kg",
"    </span>",
"    per min, which is the resting oxygen uptake in a sitting position; it is roughly equivalent to 1 Kcal per kg body weight per hour. As an example, a 70 kg woman who briskly walks (3 to 4 METs) for one-half hour per day would increase her caloric requirement by 105 to 140 Kcal. During weight-bearing exercise, such as walking, the caloric requirement will progressively increase with the increase in weight during the course of the pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/38/3687?source=see_link&amp;anchor=H6#H6\">",
"     \"Exercise assessment and measurement of exercise capacity in patients with coronary heart disease\", section on 'Peak exercise capacity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Carbohydrate requirements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnant women should consume diets high in complex carbohydrates and avoid intake of large quantities of concentrated carbohydrates over brief periods of time.",
"   </p>",
"   <p>",
"    Carbohydrate metabolism in the later part of pregnancy is directed toward supplying glucose and amino acids to the growing fetus, while providing extra free fatty acids, ketones, and glycerol as sources of maternal fuel. Adequate carbohydrate intake is important. Pregnant women utilize carbohydrates at a greater rate, both at rest and during exercise, than nonpregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4568/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Increased carbohydrate metabolism coupled with lower glycogen reserves could result in lower blood glucose concentrations, which predispose exercising pregnant women to hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4568/abstract/11\">",
"     11",
"    </a>",
"    ]. Indeed it has been demonstrated that borderline hypoglycemic levels can be induced during prolonged exercise of 45 to 60 min at 60 percent of VO(2) max (",
"    <a class=\"graphic graphic_figure graphicRef57446 \" href=\"UTD.htm?19/39/20094\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4568/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/61/13274?source=see_link&amp;anchor=H14#H14\">",
"     \"Maternal endocrine and metabolic adaptation to pregnancy\", section on 'Glucose metabolism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Increased tissue storage of fat occurs at rest; exercise induces higher triglyceride levels, but no change in protein utilization [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4568/abstract/11\">",
"     11",
"    </a>",
"    ]. The amount of carbohydrate metabolized during exercise is commensurate with the level of intensity and there appears to be preferential use of carbohydrates during nonweight-bearing exercise during pregnancy, possibly due to the anaerobic component of this type of activity [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4568/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/35/25144?source=see_link\">",
"     \"Exercise physiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CARDIOVASCULAR ADAPTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy induces profound alterations in maternal hemodynamics, including increases in blood volume, heart rate, and stroke volume, and a decrease in systemic vascular resistance (",
"    <a class=\"graphic graphic_figure graphicRef54685 graphicRef61948 graphicRef55985 \" href=\"UTD.htm?20/30/20963\">",
"     figure 2A-C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4568/abstract/7,13,14\">",
"     7,13,14",
"    </a>",
"    ]. These hemodynamic changes establish the circulatory reserve necessary to provide nutrients and oxygen to both mother and fetus at rest and during exercise. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20105?source=see_link\">",
"     \"Maternal cardiovascular and hemodynamic adaptations to pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pregnancy is characterized by an increase in cardiac output by 30 to 50 percent in singleton gestation; cardiac output is even higher in multiple gestation. Pregnancy is also characterized by a 20 percent increase in heart rate and a decrease of 5 to 10 mmHg in mean arterial pressure followed by a gradual increase to prepregnancy levels. These hemodynamic changes establish the circulatory reserve necessary for oxygen and nutrient supply to the fetus.",
"   </p>",
"   <p>",
"    The immediate physiologic response that an individual at sea level will experience at altitude is hyperventilation and an increased cardiovascular response. The ventilatory response to altitude is central to the preservation of oxygen transport. Exercise and pregnancy can exacerbate these responses. During submaximal exercise, however, no alteration in exercise efficiency or response occurs for most variables when moderate altitude and sea level data are compared [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4568/abstract/15\">",
"     15",
"    </a>",
"    ]. Both cardiac output and stroke volume are elevated at moderate altitude at rest, but not during exercise, suggesting a lower reserve for both variables at moderate altitude.",
"   </p>",
"   <p>",
"    Conflicting evidence exists concerning maternal heart rate response to steady-state submaximal exercise during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4568/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Both blunted and normal responses to weight-bearing and nonweight-bearing exercise have been reported, thus making use of heart rate monitoring to guide exercise intensity during pregnancy difficult. The upper limit in heart rate of 140 bpm during exercise suggested in the past was an arbitrary target set to correspond to a VO2 of 60 percent for women in their reproductive age range, and not based on high quality evidence [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4568/abstract/18\">",
"     18",
"    </a>",
"    ]. It has been suggested that perceptual responses to exercise be used instead. One option is the Borg's 15-point rating of perceived exertion (RPE) Scale. An even simpler and more practical approach is the \"talk test,\" in which moderate exercise intensity is defined as the ability to carry on a normal conversation during exertion or strenuous exercise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Posture and position",
"    </span>",
"    &nbsp;&mdash;&nbsp;Body posture is an important consideration for the pregnant woman, both at rest and during exercise. After the first trimester, the supine position causes relative obstruction of venous return resulting in decreased cardiac output. Therefore, supine positions should be avoided while resting and during exercise. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20105?source=see_link&amp;anchor=H11#H11\">",
"     \"Maternal cardiovascular and hemodynamic adaptations to pregnancy\", section on 'Supine hypotensive syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Motionless standing is also associated with a significant decrease in cardiac output. In one study of 7722 pregnancies, newborns of women who worked in the third trimester weighed 150 to 400 g less than newborns of mothers who remained at home, with the greatest reduction among women who worked in a predominantly standing position, women who were underweight and had a low pregnancy weight gain, and those who were hypertensive [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4568/abstract/19\">",
"     19",
"    </a>",
"    ]. Compared with the left lateral position, cardiac output fell 9 percent in the supine position and 18 percent while standing near term [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4568/abstract/20\">",
"     20",
"    </a>",
"    ]. Motionless standing for prolonged periods of time should be avoided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     RESPIRATORY STATUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal respiratory adaptation to pregnancy is discussed separately (",
"    <a class=\"graphic graphic_figure graphicRef59101 graphicRef80850 \" href=\"UTD.htm?29/52/30528\">",
"     figure 3A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/37/32340?source=see_link\">",
"     \"Respiratory tract changes during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    During treadmill exercise in pregnancy, arteriovenous 02 differences are decreased [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4568/abstract/17\">",
"     17",
"    </a>",
"    ]. Because of increased resting oxygen requirements and increased work of breathing brought about by physical effects of the enlarged uterus on the diaphragm, there is decreased oxygen available for the performance of aerobic exercise during pregnancy. Both subjective workload and maximum exercise performance are decreased [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4568/abstract/21,22\">",
"     21,22",
"    </a>",
"    ], although some experts feel pregnant women do not show changes in maximum aerobic power or acid-base balance during exercise when compared to their nonpregnant state [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4568/abstract/7,23,24\">",
"     7,23,24",
"    </a>",
"    ]. However, it is generally agreed that aerobic training during pregnancy increases exercise capacity compared to sedentary pregnant controls [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4568/abstract/25-28\">",
"     25-28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The anatomical changes that characterize pregnancy also have an effect on the respiratory system during exercise. Pregnant women experience obstructive symptoms secondary to excessive hyperemia, edema and secretions developing during pregnancy. The growing uterus causes a cephalad displacement of the diaphragm that results in an expansion of the chest circumference. These changes lead to an increase in inspiratory capacity of 300 mL (ie, tidal volume minus inspiratory volume) and a reduction in functional residual capacity. During exercise in normal pregnant subjects, there are diminished responses for every respiratory function, reflecting a decrease in pulmonary reserve and inability to exercise anaerobically. During mild exercise, the respiratory frequency of pregnant women is higher than in nonpregnant controls (",
"    <a class=\"graphic graphic_figure graphicRef61573 \" href=\"UTD.htm?37/50/38702\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4568/abstract/21\">",
"     21",
"    </a>",
"    ], and minute ventilation is slightly increased, while oxygen consumption and tidal volume are comparable for the same type of exercise (",
"    <a class=\"graphic graphic_figure graphicRef61573 \" href=\"UTD.htm?37/50/38702\">",
"     figure 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef65817 \" href=\"UTD.htm?16/3/16447\">",
"     figure 5",
"    </a>",
"    ). Pregnant subjects demonstrate a more efficient ventilatory response to moderate exercise (5 to 6 MET) when compared to non-pregnant control subjects, as demonstrated by a trend toward lower ventilatory equivalent (",
"    <a class=\"graphic graphic_figure graphicRef65817 \" href=\"UTD.htm?16/3/16447\">",
"     figure 5",
"    </a>",
"    ). This more efficient response has been attributed to the primary respiratory alkalosis of pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     THERMOREGULATORY CONTROL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Basal metabolic rate and heat production are increased during pregnancy. Maintenance of euhydration is critical to heat balance during prolonged exercise because loss of fluid such as sweat may compromise heat dissipation.",
"   </p>",
"   <p>",
"    The increase in body temperature during exercise is directly related to the intensity of the exercise. During moderate intensity aerobic exercise in thermoneutral conditions, core temperature of nonpregnant women rises an average of 1.5&ordm;C during the first 30 minutes of exercise and then plateaus if exercise is continued [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4568/abstract/10\">",
"     10",
"    </a>",
"    ]. A steady-state of heat production versus heat dissipation is accomplished via increased conductance of heat from core to periphery via the cardiovascular system, as well as through evaporative cooling (ie, perspiration). If heat production exceeds heat dissipation capacity, as with exercise in hot, humid conditions or during very high intensity exercise, the core temperature will continue to rise. Given the increase in body surface during pregnancy, heat dissipation occurs more rapidly; however, the risk of dehydration increases, as well. Studies have reported that, in response to 60 minutes of prolonged exercise at an intensity of 55 percent of VO2 max, the rectal temperature in pregnant women rose by only 0.6&ordm;C [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4568/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Possible teratogenic effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data regarding the effects of exercise on core temperature during pregnancy are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4568/abstract/7,10,29\">",
"     7,10,29",
"    </a>",
"    ]. Fetal temperatures are approximately 1 degree C higher than maternal temperatures (fetal temperature is 0.5 degrees higher than intrauterine temperature which is 0.8 degrees higher than maternal oral temperature). In animal studies, an increase in maternal core temperature greater than 1.5 degree C during embryogenesis is associated with major congenital malformations (eg, neural tube defects, microphthalmia, arthrogryposis, abdominal wall defects, limb deficiencies). These data coupled with human studies suggest that maternal hyperthermia (related to exposure to a hot tub, sauna, or fever) in excess of 39 degrees C during the first 45 to 60 days of gestation may also be teratogenic in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4568/abstract/30\">",
"     30",
"    </a>",
"    ]. Hyperthermia associated with exercise, however, has not been definitively associated with teratogenic consequences in humans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     FETAL RESPONSE TO MATERNAL EXERCISE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is good evidence that the fetus is able to tolerate maternal exercise and that any responses are transient with no lasting adverse effects. Tests of fetal well-being have been generally reassuring after short-duration, strenuous exercise in both active and inactive pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4568/abstract/31\">",
"     31",
"    </a>",
"    ]. Adverse events are unlikely to occur in the uncomplicated gestation. Nevertheless, healthcare providers who prescribe exercise for pregnant women should be cognizant of all potential complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Transient maternal hypoxia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient maternal hypoxia can cause fetal tachycardia and an increase in fetal blood pressure, as demonstrated in animal studies. These fetal responses are protective mechanisms for the fetus to facilitate transfer of oxygen and decrease C02 tension across the placenta. Acute alterations result in transient fetal heart rate changes, whereas chronic hypoxia may result in intrauterine growth restriction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/11/2232?source=see_link&amp;anchor=H6#H6\">",
"     \"Antepartum fetal heart rate assessment\", section on 'Cardiovascular response to hypoxia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Fetal heart rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise induces significant cardiovascular changes. One concern is that selective redistribution of maternal blood flow to the exercising muscles and away from the splanchnic organs could potentially have an adverse effect on the fetus. Although a sustained significant reduction of blood flow to the uterus could lead to hypoxia or asphyxia, no adverse association between maternal exercise and fetal well-being has been demonstrated [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4568/abstract/21,25,32-37\">",
"     21,25,32-37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most commonly analyzed fetal response to maternal exercise is a change in the fetal heart rate (FHR). FHR responses to maternal exercise have been extensively studied prior to, and after, treadmill exercise and cycle ergometry. Maternal exercise is generally associated with an increase of FHR by 10 to 30 beats per minute. This is not deleterious to the fetus, and appears to be independent of gestational age and intensity of exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4568/abstract/38\">",
"     38",
"    </a>",
"    ]. The increase in rate may be accompanied by a reactive pattern; postexercise reactivity is generally achieved within 20 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4568/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fetal bradycardia may also occur [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4568/abstract/32\">",
"     32",
"    </a>",
"    ]. Transient fetal heart rate decelerations and bradycardia have been reported in a small minority of exercising patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4568/abstract/7,31\">",
"     7,31",
"    </a>",
"    ]. The mechanism leading to fetal bradycardia is likely related to vagal reflex, cord compression, or fetal head malposition. No lasting effects on the fetus have been reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Umbilical blood flow and fetal breathing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Doppler velocimetry studies during maternal exercise are technically difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4568/abstract/40\">",
"     40",
"    </a>",
"    ]. Most measurements have been taken before and after exercise, by which time any exercise-induced changes could have returned to normal.",
"   </p>",
"   <p>",
"    A few studies have demonstrated changes in Doppler wave forms [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4568/abstract/31,39-41\">",
"     31,39-41",
"    </a>",
"    ] and fetal breathing patterns [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4568/abstract/42\">",
"     42",
"    </a>",
"    ] in response to maternal aerobic dancing, cycling, or",
"    <span class=\"nowrap\">",
"     walking/jogging",
"    </span>",
"    on a treadmill, but adverse fetal outcomes were not observed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Fetal growth",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiological studies have suggested a link between strenuous physical activities, deficient diets, and lower birth weights, including a decreased risk of giving birth to a large for gestational age infant.",
"   </p>",
"   <p>",
"    A meta-analysis including 30 studies concluded that the differences in birth weights for newborns of mothers that exercised during pregnancy are minimal when compared with controls. However, women who engaged in strenuous exercise during the third trimester were more likely to deliver newborns that weighed 200 to 400 g less than matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4568/abstract/43\">",
"     43",
"    </a>",
"    ]. This discrepancy may be explained, in part, by inadequate caloric intake among exercising women in the former studies, although this mechanism has not been proven. Other uncontrolled studies performed in elite athletes have also yielded conflicting results [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4568/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women who are diet-conscious often do not take in minimum amounts of required nutrients. The combined energy requirements of pregnancy and exercise coupled with caloric restriction may lead to poor weight gain and fetal growth restriction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Premature labor",
"    </span>",
"    &nbsp;&mdash;&nbsp;For most pregnant women, physical",
"    <span class=\"nowrap\">",
"     activity/exercise",
"    </span>",
"    does not increase the risk of preterm delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4568/abstract/2,46-50\">",
"     2,46-50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35898?source=see_link&amp;anchor=H19#H19\">",
"     \"Risk factors for preterm labor and delivery\", section on 'Physical activity and work'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pregnancy results in multiple anatomical changes or conditions which can impact a woman's ability to engage in physical activities. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Anatomical changes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For normal weight pregnant women (body mass index [BMI] 20 to 28",
"      <span class=\"nowrap\">",
"       kg/m(2)),",
"      </span>",
"      approximately 300 extra kilocalories (Kcal) per day are required to meet the metabolic needs of pregnancy after the first trimester. Depending on the activity and intensity of exercise, an additional 350 to 500",
"      <span class=\"nowrap\">",
"       cal/hour",
"      </span>",
"      intake may be required. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Energy needs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Conflicting evidence exists concerning maternal heart rate response to steady-state submaximal exercise during pregnancy. Both blunted and normal responses to weight-bearing and nonweight-bearing exercise have been reported, thus making use of heart rate monitoring to guide exercise intensity during pregnancy difficult. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Cardiovascular adaptation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      During mild exercise, the respiratory frequency of pregnant women is higher than in nonpregnant controls (",
"      <a class=\"graphic graphic_figure graphicRef61573 \" href=\"UTD.htm?37/50/38702\">",
"       figure 4",
"      </a>",
"      ), and minute ventilation is slightly increased, while oxygen consumption and tidal volume are comparable for the same type of exercise (",
"      <a class=\"graphic graphic_figure graphicRef61573 \" href=\"UTD.htm?37/50/38702\">",
"       figure 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef65817 \" href=\"UTD.htm?16/3/16447\">",
"       figure 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Respiratory status'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Basal metabolic rate and heat production are increased during pregnancy so maintenance of euhydration is particularly critical to heat balance during prolonged exercise. Hyperthermia associated with exercise has not been definitively associated with teratogenic consequences in humans, but is a theoretical concern. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Thermoregulatory control'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is good evidence that the fetus is able to tolerate maternal exercise and that any responses are transient with no lasting adverse effects. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'fetal response to maternal exercise'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Maternal exercise is generally associated with an increase of FHR by 10 to 30 beats per minute, but fetal bradycardia may occur. The mechanism leading to fetal bradycardia is likely related to vagal reflex, cord compression, or fetal head malposition. No lasting effects on the fetus have been reported. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Fetal heart rate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women who engage in strenuous exercise during the third trimester are more likely to deliver newborns weighing 200 to 400 g less than matched controls; there are no to minimal effects from mild exercise. Fetal growth delay may be due to inadequate caloric intake among exercising women. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Fetal growth'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most pregnant women who exercise during pregnancy are not at increased risk of preterm delivery. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Premature labor'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4568/abstract/1\">",
"      Artal R, O'Toole M. Guidelines of the American College of Obstetricians and Gynecologists for exercise during pregnancy and the postpartum period. Br J Sports Med 2003; 37:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4568/abstract/2\">",
"      Price BB, Amini SB, Kappeler K. Exercise in pregnancy: effect on fitness and obstetric outcomes-a randomized trial. Med Sci Sports Exerc 2012; 44:2263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4568/abstract/3\">",
"      Carlson HL, Carlson NL, Pasternak BA, Balderston KD. Understanding and managing the back pain of pregnancy. Curr Womens Health Rep 2003; 3:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4568/abstract/4\">",
"      CRISP WE, DEFRANCESCO S. THE HAND SYNDROME OF PREGNANCY. Obstet Gynecol 1964; 23:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4568/abstract/5\">",
"      Ritchie JR. Orthopedic considerations during pregnancy. Clin Obstet Gynecol 2003; 46:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4568/abstract/6\">",
"      Owens K, Pearson A, Mason G. Symphysis pubis dysfunction--a cause of significant obstetric morbidity. Eur J Obstet Gynecol Reprod Biol 2002; 105:143.",
"     </a>",
"    </li>",
"    <li>",
"     Artal, R, Wiswell, RA, Drinkwater, BL. Exercise in Pregnancy, 2nd ed, Artal, R, Wiswell, RA, Drinkwater, BL (Eds), Williams and Wilkins, Baltimore 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4568/abstract/8\">",
"      Artal R, Lockwood CJ, Brown HL. Weight gain recommendations in pregnancy and the obesity epidemic. Obstet Gynecol 2010; 115:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4568/abstract/9\">",
"      Clapp JF 3rd, Seaward BL, Sleamaker RH, Hiser J. Maternal physiologic adaptations to early human pregnancy. Am J Obstet Gynecol 1988; 159:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4568/abstract/10\">",
"      Soultanakis HN, Artal R, Wiswell RA. Prolonged exercise in pregnancy: glucose homeostasis, ventilatory and cardiovascular responses. Semin Perinatol 1996; 20:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4568/abstract/11\">",
"      Bessinger RC, McMurray RG, Hackney AC. Substrate utilization and hormonal responses to moderate intensity exercise during pregnancy and after delivery. Am J Obstet Gynecol 2002; 186:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4568/abstract/12\">",
"      Artal R, Masaki DI, Khodiguian N, et al. Exercise prescription in pregnancy: weight-bearing versus non-weight-bearing exercise. Am J Obstet Gynecol 1989; 161:1464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4568/abstract/13\">",
"      Clark SL, Cotton DB, Lee W, et al. Central hemodynamic assessment of normal term pregnancy. Am J Obstet Gynecol 1989; 161:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4568/abstract/14\">",
"      Wolfe LA, Ohtake PJ, Mottola MF, McGrath MJ. Physiological interactions between pregnancy and aerobic exercise. Exerc Sport Sci Rev 1989; 17:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4568/abstract/15\">",
"      Artal R, Fortunato V, Welton A, et al. A comparison of cardiopulmonary adaptations to exercise in pregnancy at sea level and altitude. Am J Obstet Gynecol 1995; 172:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4568/abstract/16\">",
"      McMurray RG, Hackney AC, Katz VL, et al. Pregnancy-induced changes in the maximal physiological responses during swimming. J Appl Physiol 1991; 71:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4568/abstract/17\">",
"      Pivarnik JM, Lee W, Clark SL, et al. Cardiac output responses of primigravid women during exercise determined by the direct Fick technique. Obstet Gynecol 1990; 75:954.",
"     </a>",
"    </li>",
"    <li>",
"     Artal, R. Personal communication.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4568/abstract/19\">",
"      Naeye RL, Peters EC. Working during pregnancy: effects on the fetus. Pediatrics 1982; 69:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4568/abstract/20\">",
"      Clark SL, Cotton DB, Pivarnik JM, et al. Position change and central hemodynamic profile during normal third-trimester pregnancy and post partum. Am J Obstet Gynecol 1991; 164:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4568/abstract/21\">",
"      Artal R, Wiswell R, Romem Y, Dorey F. Pulmonary responses to exercise in pregnancy. Am J Obstet Gynecol 1986; 154:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4568/abstract/22\">",
"      Clapp, JF 3rd. Exercise in pregnancy: a brief clinical review. Fetal Med Rev 1990; 161:1464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4568/abstract/23\">",
"      Pivarnik JM, Lee W, Spillman T, et al. Maternal respiration and blood gases during aerobic exercise performed at moderate altitude. Med Sci Sports Exerc 1992; 24:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4568/abstract/24\">",
"      Lotgering FK, van Doorn MB, Struijk PC, et al. Maximal aerobic exercise in pregnant women: heart rate, O2 consumption, CO2 production, and ventilation. J Appl Physiol 1991; 70:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4568/abstract/25\">",
"      Collings CA, Curet LB, Mullin JP. Maternal and fetal responses to a maternal aerobic exercise program. Am J Obstet Gynecol 1983; 145:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4568/abstract/26\">",
"      Santos IA, Stein R, Fuchs SC, et al. Aerobic exercise and submaximal functional capacity in overweight pregnant women: a randomized trial. Obstet Gynecol 2005; 106:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4568/abstract/27\">",
"      South-Paul JE, Rajagopal KR, Tenholder MF. The effect of participation in a regular exercise program upon aerobic capacity during pregnancy. Obstet Gynecol 1988; 71:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4568/abstract/28\">",
"      Marquez-Sterling S, Perry AC, Kaplan TA, et al. Physical and psychological changes with vigorous exercise in sedentary primigravidae. Med Sci Sports Exerc 2000; 32:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4568/abstract/29\">",
"      Clapp JF 3rd, Capeless EL. Neonatal morphometrics after endurance exercise during pregnancy. Am J Obstet Gynecol 1990; 163:1805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4568/abstract/30\">",
"      Sasaki J, Yamaguchi A, Nabeshima Y, et al. Exercise at high temperature causes maternal hyperthermia and fetal anomalies in rats. Teratology 1995; 51:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4568/abstract/31\">",
"      Szymanski LM, Satin AJ. Strenuous exercise during pregnancy: is there a limit? Am J Obstet Gynecol 2012; 207:179.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4568/abstract/32\">",
"      Artal R, Romem Y, Paul RH, Wiswell R. Fetal bradycardia induced by maternal exercise. Lancet 1984; 2:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4568/abstract/33\">",
"      Mart&iacute;nez-Fr&iacute;as ML, Garc&iacute;a Mazario MJ, Caldas CF, et al. High maternal fever during gestation and severe congenital limb disruptions. Am J Med Genet 2001; 98:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4568/abstract/34\">",
"      Milunsky A, Ulcickas M, Rothman KJ, et al. Maternal heat exposure and neural tube defects. JAMA 1992; 268:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4568/abstract/35\">",
"      Clapp JF 3rd. Fetal heart rate response to running in midpregnancy and late pregnancy. Am J Obstet Gynecol 1985; 153:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4568/abstract/36\">",
"      Carpenter MW, Sady SP, Hoegsberg B, et al. Fetal heart rate response to maternal exertion. JAMA 1988; 259:3006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4568/abstract/37\">",
"      Wolfe, LA, Lowe-Wyldem, SJ, Tranmer, JE, McGrath, MJ. Fetal heart rate during maternal static exercise. Can J Sport Sci 1988; 13:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4568/abstract/38\">",
"      Artal R, Rutherford S, Romem Y, et al. Fetal heart rate responses to maternal exercise. Am J Obstet Gynecol 1986; 155:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4568/abstract/39\">",
"      Szymanski LM, Satin AJ. Exercise during pregnancy: fetal responses to current public health guidelines. Obstet Gynecol 2012; 119:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4568/abstract/40\">",
"      Veille JC, Bacevice AE, Wilson B, et al. Umbilical artery waveform during bicycle exercise in normal pregnancy. Obstet Gynecol 1989; 73:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4568/abstract/41\">",
"      Rafla NM, Beazely JM. The effect of maternal exercise on fetal umbilical artery waveforms. Eur J Obstet Gynecol Reprod Biol 1991; 40:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4568/abstract/42\">",
"      Hatoum N, Clapp JF 3rd, Newman MR, et al. Effects of maternal exercise on fetal activity in late gestation. J Matern Fetal Med 1997; 6:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4568/abstract/43\">",
"      Sternfeld B, Quesenberry CP Jr, Eskenazi B, Newman LA. Exercise during pregnancy and pregnancy outcome. Med Sci Sports Exerc 1995; 27:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4568/abstract/44\">",
"      Erdelyi, GJ. Gynecological survey of fetal athletes. J Sports Med Phys Fit 1962; 2:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4568/abstract/45\">",
"      Zaharieva E. Olympic participation by women. Effects on pregnancy and childbirth. JAMA 1972; 221:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4568/abstract/46\">",
"      Barakat R, Stirling JR, Lucia A. Does exercise training during pregnancy affect gestational age? A randomised controlled trial. Br J Sports Med 2008; 42:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4568/abstract/47\">",
"      Juhl M, Andersen PK, Olsen J, et al. Physical exercise during pregnancy and the risk of preterm birth: a study within the Danish National Birth Cohort. Am J Epidemiol 2008; 167:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4568/abstract/48\">",
"      Madsen M, J&oslash;rgensen T, Jensen ML, et al. Leisure time physical exercise during pregnancy and the risk of miscarriage: a study within the Danish National Birth Cohort. BJOG 2007; 114:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4568/abstract/49\">",
"      De Ver Dye T, Fernandez ID, Rains A, Fershteyn Z. Recent studies in the epidemiologic assessment of physical activity, fetal growth, and preterm delivery: a narrative review. Clin Obstet Gynecol 2003; 46:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4568/abstract/50\">",
"      Owe KM, Nystad W, Skjaerven R, et al. Exercise during pregnancy and the gestational age distribution: a cohort study. Med Sci Sports Exerc 2012; 44:1067.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 413 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-199.231.185.123-EFBF5593C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_29_4568=[""].join("\n");
var outline_f4_29_4568=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMICAL CHANGES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ENERGY NEEDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Carbohydrate requirements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CARDIOVASCULAR ADAPTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Posture and position",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      RESPIRATORY STATUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      THERMOREGULATORY CONTROL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Possible teratogenic effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      FETAL RESPONSE TO MATERNAL EXERCISE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Transient maternal hypoxia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Fetal heart rate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Umbilical blood flow and fetal breathing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Fetal growth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Premature labor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/413\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/413|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/39/20094\" title=\"figure 1\">",
"      Glucose level during prolonged exercise pregnant vs nonpregnant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/59/37821\" title=\"figure 2A\">",
"      Hemodynamic changes in normal pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/32/9742\" title=\"figure 2B\">",
"      Blood volume in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/50/38703\" title=\"figure 2C\">",
"      Cardiac output in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/24/37261\" title=\"figure 3A\">",
"      Ventilation in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/37/18015\" title=\"figure 3B\">",
"      Pulmonary function in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/50/38702\" title=\"figure 4\">",
"      Oxygen consumption during exercise in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/3/16447\" title=\"figure 5\">",
"      VE VO2 pregnancy exercise",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/11/2232?source=related_link\">",
"      Antepartum fetal heart rate assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/38/3687?source=related_link\">",
"      Exercise assessment and measurement of exercise capacity in patients with coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/35/25144?source=related_link\">",
"      Exercise physiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20105?source=related_link\">",
"      Maternal cardiovascular and hemodynamic adaptations to pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/61/13274?source=related_link\">",
"      Maternal endocrine and metabolic adaptation to pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/1/2074?source=related_link\">",
"      Musculoskeletal changes and pain during pregnancy and postpartum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/9/20634?source=related_link\">",
"      Neurologic disorders complicating pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/30/7657?source=related_link\">",
"      Recommendations for exercise during pregnancy and the postpartum period",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/37/32340?source=related_link\">",
"      Respiratory tract changes during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35898?source=related_link\">",
"      Risk factors for preterm labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19304?source=related_link\">",
"      Weight gain and loss in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_29_4569="Mycophenolate: Drug information";
var content_f4_29_4569=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Mycophenolate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?21/56/22406?source=see_link\">",
"    see \"Mycophenolate: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/50/12072?source=see_link\">",
"    see \"Mycophenolate: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F198686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      CellCept&reg;;",
"     </li>",
"     <li>",
"      Myfortic&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F198687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Mycophenolate;",
"     </li>",
"     <li>",
"      CellCept&reg;;",
"     </li>",
"     <li>",
"      CO Mycophenolate;",
"     </li>",
"     <li>",
"      JAMP-Mycophenolate;",
"     </li>",
"     <li>",
"      Myfortic&reg;;",
"     </li>",
"     <li>",
"      Mylan-Mycophenolate;",
"     </li>",
"     <li>",
"      Novo-Mycophenolate;",
"     </li>",
"     <li>",
"      Sandoz-Mycophenolate;",
"     </li>",
"     <li>",
"      Sandoz-Mycophenolate Mofetil",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F198710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Immunosuppressant Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F198690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     May be used I.V. for up to 14 days; transition to oral therapy as soon as tolerated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Renal transplant:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      CellCept&reg;:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: 1 g twice daily. Doses &gt;2 g daily are not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: 1 g twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Myfortic&reg;:",
"     </i>",
"     Oral: 720 mg twice daily (1440 mg daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cardiac transplantation:",
"     </b>",
"     <i>",
"      CellCept&reg;:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 1.5 g twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 1.5 g twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hepatic transplantation:",
"     </b>",
"     <i>",
"      CellCept&reg;:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 1.5 g twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 1 g twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Autoimmune hepatitis, refractory (unlabeled use):",
"     </b>",
"     <i>",
"      CellCept&reg;:",
"     </i>",
"     Oral: 2 g daily (Manns, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lupus nephritis (unlabeled use):",
"     </b>",
"     CellCept&reg;: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Induction: 1 g twice daily for 6 months in combination with a glucocorticoid (Ong, 2005)",
"     <b>",
"      or",
"     </b>",
"     2-3 g daily for 6 months in combination with glucocorticoids (Hahn, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maintenance: 0.5-3 g daily (Contreras, 2004)",
"     <b>",
"      or",
"     </b>",
"     1 g twice daily (Dooley, 2011)",
"     <b>",
"      or",
"     </b>",
"     1-2 g daily (Hahn, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Myasthenia gravis (unlabeled use):",
"     </b>",
"     <i>",
"      CellCept&reg;:",
"     </i>",
"     Oral: 1 g twice daily (range: 1-3 g daily) (Cahoon, 2006; Ciafaloni, 2001; Merriggioli, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Psoriasis, moderate-to-severe (unlabeled use):",
"     </b>",
"     <i>",
"      CellCept&reg;:",
"     </i>",
"     Oral: 2-3 g daily (Menter, 2009)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F198703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/50/12072?source=see_link\">",
"      see \"Mycophenolate: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Renal transplant:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      CellCept&reg; suspension:",
"     </i>",
"     600 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose twice daily; maximum dose: 1 g twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Alternatively, may use solid dosage forms according to BSA as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     BSA 1.25-1.5 m",
"     <sup>",
"      2",
"     </sup>",
"     : 750 mg capsule twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     BSA &gt;1.5 m",
"     <sup>",
"      2",
"     </sup>",
"     : 1 g capsule or tablet twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Myfortic&reg;",
"     </i>",
"     : 400 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose twice daily; maximum dose: 720 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     BSA &lt;1.19 m",
"     <sup>",
"      2",
"     </sup>",
"     : Use of this formulation is not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     BSA 1.19-1.58 m",
"     <sup>",
"      2",
"     </sup>",
"     : 540 mg twice daily (maximum: 1080 mg daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     BSA &gt;1.58 m",
"     <sup>",
"      2",
"     </sup>",
"     : 720 mg twice daily (maximum: 1440 mg daily)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F198691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage is the same as younger patients, however, dosing should be cautious due to possibility of increased hepatic, renal, or cardiac dysfunction. Elderly patients may be at an increased risk of certain infections, gastrointestinal hemorrhage, and pulmonary edema, as compared to younger patients.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F198692\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal transplant: GFR &lt;25 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     in patients outside the immediate post-transplant period:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CellCept&reg;: Doses of &gt;1 g administered twice daily should be avoided; patients should also be carefully observed; no dose adjustments are needed in renal transplant patients experiencing delayed graft function postoperatively",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Myfortic&reg;: No dose adjustments are needed in renal transplant patients experiencing delayed graft function postoperatively; however, monitor carefully for potential concentration dependent adverse events",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiac or liver transplant: No data available; mycophenolate may be used in cardiac or hepatic transplant patients with severe chronic renal impairment if the potential benefit outweighs the potential risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis: Not removed; supplemental dose is not necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peritoneal dialysis: Supplemental dose is not necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F198693\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment is recommended for renal patients with severe hepatic parenchymal disease; however, it is not currently known whether dosage adjustments are necessary for hepatic disease with other etiologies.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F3022884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Neutropenia (ANC &lt;1.3 x 10",
"     <sup>",
"      3",
"     </sup>",
"     /&mu;L): Dosing should be interrupted or the dose reduced, appropriate diagnostic tests performed and patients managed appropriately",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F198659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as mofetil: 250 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CellCept&reg;: 250 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as mofetil hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CellCept&reg;: 500 mg [contains polysorbate 80]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for suspension, oral, as mofetil:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CellCept&reg;: 200 mg/mL (175 mL) [contains phenylalanine 0.56 mg/mL, soybean lecithin; mixed fruit flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as mofetil: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CellCept&reg;: 500 mg [contains ethanol (may have trace amounts)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as mycophenolic acid: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, delayed release, oral, as mycophenolic acid:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Myfortic&reg;: 180 mg, 360 mg [formulated as a sodium salt]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F198644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Capsule, tablet",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Myfortic&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM172735.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM172735.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     CellCept&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM170919.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM170919.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F198662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral dosage formulations (tablet, capsule, suspension) should be administered on an empty stomach to avoid variability in MPA absorption. The oral solution may be administered via a nasogastric tube (minimum 8 French, 1.7 mm interior diameter); oral suspension should not be mixed with other medications. Delayed release tablets should not be crushed, cut, or chewed. Cellcept&reg; may be administered with food in stable renal transplant patients when necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intravenous solutions should be administered over at least 2 hours (either peripheral or central vein); do",
"     <b>",
"      not",
"     </b>",
"     administer intravenous solution by rapid or bolus injection.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F198717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Anidulafungin, caspofungin, cefepime, dopamine, norepinephrine, tacrolimus, vancomycin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Micafungin.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Cyclosporine.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F198660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prophylaxis of organ rejection concomitantly with cyclosporine and corticosteroids in patients receiving allogeneic renal (CellCept&reg;, Myfortic&reg;), cardiac (CellCept&reg;), or hepatic (CellCept&reg;) transplants",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F198706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of rejection in liver transplant patients unable to tolerate tacrolimus or cyclosporine due to toxicity;  treatment of recurrent or persistent rejection in heart transplant patients; treatment of moderate-severe psoriasis; treatment of lupus nephritis; treatment of myasthenia gravis; prevention of graft-versus-host disease (GVHD); treatment of refractory acute GVHD and chronic GVHD; treatment of refractory autoimmune hepatitis",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F198708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Data for incidence &gt;20% as reported in adults following oral dosing of CellCept&reg; alone in renal, cardiac, and hepatic allograft rejection studies. Profile in 3% to &lt;20% range reflects use in combination with cyclosporine and corticosteroids. In general, lower doses used in renal rejection patients had less adverse effects than higher doses. Rates of adverse effects were similar for each indication, except for those unique to the specific organ involved. The type of adverse effects observed in pediatric patients was similar to those seen in adults, with the exception of abdominal pain, anemia, diarrhea, fever, hypertension, infection, pharyngitis, respiratory tract infection, sepsis, and vomiting; lymphoproliferative disorder was the only type of malignancy observed. Percentages of adverse reactions were similar in studies comparing CellCept&reg; to Myfortic&reg; in patients following renal transplant.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;20%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypertension (28% to 78%), hypotension (33%), peripheral edema (27% to 64%), edema (27% to 28%), chest pain (26%), tachycardia (20% to 22%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Pain (31% to 76%), headache (16% to 54%), insomnia (41% to 52%), fever (21% to 52%), dizziness (29%), anxiety (28%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (22%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperglycemia (44% to 47%), hypercholesterolemia (41%), hypomagnesemia (39%), hypokalemia (32% to 37%), hypocalcemia (30%), hyperkalemia (22%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (25% to 63%), nausea (20% to 55%), diarrhea (31% to 51%), constipation (19% to 41%), vomiting (33% to 34%), anorexia (25%), dyspepsia (22%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (37%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Leukopenia (23% to 46%), anemia (26% to 43%; hypochromic 25%), leukocytosis (22% to 41%), thrombocytopenia (24% to 38%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Liver function tests abnormal (25%), ascites (24%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (35% to 47%), weakness (35% to 43%), tremor (24% to 34%), paresthesia (21%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Creatinine increased (39%), BUN increased (35%), kidney function abnormal (22% to 26%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (31% to 37%), respiratory tract infection (22% to 37%), pleural effusion (34%), cough (31%), lung disorder (22% to 30%), sinusitis (26%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection (18% to 27%), sepsis (27%), lactate dehydrogenase increased (23%),",
"     <i>",
"      Candida",
"     </i>",
"     (17% to 22%), herpes simplex (10% to 21%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     3% to &lt;20%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Angina, arrhythmia, arterial thrombosis, atrial fibrillation, atrial flutter, bradycardia, cardiac arrest, cardiac failure, CHF, extrasystole, facial edema, hyper-/hypovolemia, orthostatic hypotension, pallor, palpitation, pericardial effusion, peripheral vascular disorder, supraventricular extrasystoles, supraventricular tachycardia, syncope, thrombosis, vasodilation, vasospasm, venous pressure increased, ventricular extrasystole, ventricular tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Agitation, chills with fever, confusion, delirium, depression, emotional lability, hallucinations, hypoesthesia, malaise, nervousness, psychosis, seizure, somnolence, thinking abnormal, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Acne, alopecia, bruising, cellulitis, fungal dermatitis, hirsutism, petechia, pruritus, skin carcinoma, skin hypertrophy, skin ulcer, vesiculobullous rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Acidosis, alkalosis, Cushing's syndrome, dehydration, diabetes mellitus, gout, hypercalcemia, hyper-hypophosphatemia, hyperlipemia, hyperuricemia, hypochloremia, hypoglycemia, hyponatremia, hypoproteinemia, hypothyroidism, parathyroid disorder",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdomen enlarged, dysphagia, esophagitis, flatulence, gastritis, gastroenteritis, gastrointestinal hemorrhage, gastrointestinal moniliasis, gingivitis, gum hyperplasia, ileus, melena, mouth ulceration, oral moniliasis, stomach disorder, stomach ulcer, stomatitis, xerostomia, weight gain/loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Impotence, nocturia, pelvic pain, prostatic disorder, scrotal edema, urinary frequency, urinary incontinence, urinary retention, urinary tract disorder",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Coagulation disorder, hemorrhage, neutropenia, pancytopenia, polycythemia, prothrombin time increased, thromboplastin time increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, bilirubinemia, cholangitis, cholestatic jaundice, GGT increased, hepatitis, jaundice, liver damage, transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Abscess",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, hypertonia, joint disorder, leg cramps, myalgia, myasthenia, neck pain, neuropathy, osteoporosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Amblyopia, cataract, conjunctivitis, eye hemorrhage, lacrimation disorder, vision abnormal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Deafness, ear disorder, ear pain, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Albuminuria, creatinine increased, dysuria, hematuria, hydronephrosis, oliguria, pyelonephritis, renal failure, renal tubular necrosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Apnea, asthma, atelectasis, bronchitis, epistaxis, hemoptysis, hiccup, hyperventilation, hypoxia, respiratory acidosis, pharyngitis, pneumonia, pneumothorax, pulmonary edema, pulmonary hypertension, respiratory moniliasis, rhinitis, sputum increased, voice alteration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous:",
"     <i>",
"      Candida",
"     </i>",
"     (mucocutaneous 16% to 18%), CMV viremia/syndrome (12% to 14%), CMV tissue invasive disease (6% to 12%), herpes zoster cutaneous disease (4% to 10%), cyst, diaphoresis, flu-like syndrome, healing abnormal, hernia, ileus infection, neoplasm, peritonitis, thirst",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Atypical mycobacterial infection, BK virus-associated nephropathy, colitis, gastrointestinal perforation, infectious endocarditis, interstitial lung disorder, intestinal villous atrophy, lymphoma, lymphoproliferative disease, malignancy, meningitis, pancreatitis, progressive multifocal leukoencephalopathy (sometimes fatal), pulmonary fibrosis (fatal), pure red cell aplasia, tuberculosis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F198665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to mycophenolate mofetil, mycophenolic acid, mycophenolate sodium, or any component of the formulation",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Cellcept&reg;: Intravenous formulation is also contraindicated in patients who are allergic to polysorbate 80",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F198648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infections:",
"     <b>",
"      [U.S. Boxed Warning]: Risk for infection is increased.",
"     </b>",
"     Immunosuppressive therapy may lead to opportunistic infections, sepsis, and/or fatal infections.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Latent viral infections: Patients receiving immunosuppressive therapy are at an increased risk of activation of latent viral infections, including John Cunningham virus (JCV) and BK virus infection.  Activation of JCV may result in progressive multifocal leukoencephalopathy (PML), a rare and potentially fatal condition affecting the CNS. Symptoms of PML include apathy, ataxia, cognitive deficiencies, confusion, and hemiparesis. Activation of BK virus may result in BK virus-associated nephropathy (BKVAN) which may lead to the deterioration of renal function and/or renal graft loss.  Risk factors for the development of PML and BKVAN include immunosuppression and treatment with immunosuppressant therapy. The onset of PML or BKVAN may warrant a reduction in immunosuppressive therapy; however, in transplant recipients, the risk of reduced immunosuppression and graft rejection should be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lymphoproliferative disorders:",
"     <b>",
"      [U.S. Boxed Warning]: Risk of development of lymphoma and skin malignancy is increased.",
"     </b>",
"     Patients should be monitored appropriately, instructed to limit exposure to sunlight/UV light to decrease the risk of skin cancer, and given supportive treatment should these conditions occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neutropenia: Neutropenia (including severe neutropenia) may occur, requiring dose reduction or interruption of treatment (risk greater from day 31-180 post-transplant).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pure red cell aplasia (PRCA): PRCA, a type of anemia which can range from subclinical to severe, has been reported in patients receiving mycophenolate concomitantly with other immunosuppressive agents (eg, tacrolimus, cyclosporine, corticosteroids). Symptoms may include fatigue, lethargy, or pallor. Although not precisely known, risk factors for the development of PRCA may include immunosuppression and treatment with immunosuppressant therapy. Dose reduction or discontinuation of immunosuppressive therapy may reverse PRCA; however, in transplant recipients, the risk of reduced immunosuppression and graft rejection should be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal disorders: Use may rarely be associated with gastric or duodenal ulcers, GI bleeding and/or perforation. Use caution in patients with active serious digestive system disease; patients with active peptic ulcers were not included in clinical studies.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypoxanthine-guanine phosphoribosyltransferase deficiency: Theoretically, use should be avoided in patients with the rare hereditary deficiency of hypoxanthine-guanine phosphoribosyltransferase (such as Lesch-Nyhan or Kelley-Seegmiller syndrome).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment as toxicity may be increased; may require dosage adjustment in severe impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Non-interchangeability of forms:",
"     <b>",
"      Note: CellCept&reg; and Myfortic&reg; dosage forms should not be used interchangeably due to differences in absorption.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Phenylalanine: Some dosage forms may contain phenylalanine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Polysorbate 80: The intravenous formulation contains polysorbate 80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Mycophenolate is associated with an increased risk of congenital malformations and first trimester pregnancy loss when used by pregnant women. Females of reproductive potential must be counseled about pregnancy prevention and planning.",
"     </b>",
"     Alternative agents should be considered for women planning a pregnancy. Females of reproductive potential should have a negative pregnancy test with a sensitivity of &ge;25 mIU/mL immediately before therapy and the test should be repeated 8-10 days later. Pregnancy tests should be repeated during routine follow-up visits. Acceptable forms of contraception should be used during treatment and for 6 weeks after therapy is discontinued.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . Because mycophenolate mofetil has demonstrated teratogenic effects in rats and rabbits, tablets should not be crushed or cut, and capsules should not be opened or crushed. Avoid inhalation or direct contact with skin or mucous membranes of the powder contained in the capsules and the powder for oral suspension. Caution should be exercised in the handling and preparation of solutions of intravenous mycophenolate. Avoid skin contact with the intravenous solution and reconstituted suspension. If such contact occurs, wash thoroughly with soap and water, rinse eyes with plain water.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician:",
"     <b>",
"      [U.S. Boxed Warning]: Should be administered under the supervision of a physician experienced in immunosuppressive therapy.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; I.V. administration: Intravenous solutions should be given over at least 2 hours;",
"     <b>",
"      never",
"     </b>",
"     administer intravenous solution by rapid or bolus injection.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F198653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acyclovir-Valacyclovir: Mycophenolate may increase the serum concentration of Acyclovir-Valacyclovir. Acyclovir-Valacyclovir may increase the serum concentration of Mycophenolate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Mycophenolate. Management: Separate doses of mycophenolate and antacids by at least 2 hours. Monitor for reduced effects of mycophenolate if taken concomitant with antacids.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Sodium Bicarbonate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belatacept: May increase serum concentrations of the active metabolite(s) of Mycophenolate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholestyramine Resin: May decrease the serum concentration of Mycophenolate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Mycophenolate may decrease the serum concentration of Contraceptives (Estrogens). Average AUC values were unchanged, but there was evidence of substantial patient-to-patient variability in response to this combination.  Management: Women of childbearing potential who are receiving mycophenolate mofetil should consider using an alternative and/or additional form of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Mycophenolate may decrease the serum concentration of Contraceptives (Progestins).  Management: Use of an additional or alternative (nonhormonal) method of contraception should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May decrease the serum concentration of Mycophenolate. Specifically, cyclosporine may decrease concentrations of the active metabolite mycophenolic acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ganciclovir-Valganciclovir: Mycophenolate may increase the serum concentration of Ganciclovir-Valganciclovir. Ganciclovir-Valganciclovir may increase the serum concentration of Mycophenolate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: May decrease the serum concentration of Mycophenolate. Management: Separate doses of mycophenolate and oral magnesium salts. Monitor for reduced effects of mycophenolate if taken concomitant with oral magnesium salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetroNIDAZOLE (Systemic): May decrease the serum concentration of Mycophenolate. Specifically, metronidazole may decrease concentrations of the active metabolite of mycophenolate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Penicillins: May decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Mycophenolate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May decrease the serum concentration of Mycophenolate. Specifically, concentrations of the active mycophenolic acid may be reduced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: May decrease the serum concentration of Mycophenolate. Specifically, quinolones may decrease concentrations of the active metabolite of mycophenolate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Mycophenolate. Specifically, rifamycin derivatives may decrease the concentration of the active metabolite mycophenolic acid.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sevelamer: May decrease the serum concentration of Mycophenolate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F198682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Food decreases C",
"     <sub>",
"      max",
"     </sub>",
"     of MPA by 40% following CellCept&reg; administration and 33% following Myfortic&reg; use; the extent of absorption is not changed. Management: Take CellCept&reg; or Myfortic&reg; on an empty stomach to decrease variability; however, Cellcept&reg; may be taken with food if necessary in stable renal transplant patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Cat's claw and echinacea have immunostimulant properties. Management: Avoid cat's claw and echinacea.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F198655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F198668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Mycophenolate is associated with an increased risk of congenital malformations and first trimester pregnancy loss when used by pregnant women. Females of reproductive potential must be counseled about pregnancy prevention and planning.",
"     </b>",
"     Alternative agents should be considered for women planning a pregnancy. Adverse events have been reported in animal studies at doses less than the equivalent recommended human dose. In humans, the following congenital malformations have been reported: external ear abnormalities, cleft lip and palate, anomalies of the distal limbs, heart, esophagus and kidney. Spontaneous abortions have also been noted. Females of reproductive potential (girls who have entered puberty, women with a uterus who have not passed through clinically confirmed menopause) should have a negative pregnancy test with a sensitivity of &ge;25 mIU/mL immediately before therapy and the test should be repeated 8-10 days later.  Pregnancy tests should be repeated during routine follow-up visits. Acceptable forms of contraception should be used during treatment and for 6 weeks after therapy is discontinued. The effectiveness of hormonal contraceptive agents may be affected by mycophenolate.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Healthcare providers should report female exposures to mycophenolate during pregnancy or within 6 weeks of discontinuing therapy to the Mycophenolate Pregnancy Registry (800-617-8191). The National Transplantation Pregnancy Registry (NTPR, Temple University) is a registry for pregnant women taking immunosuppressants following any solid organ transplant. The NTPR encourages reporting of all immunosuppressant exposures during pregnancy in transplant recipients at 877-955-6877.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F198698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F198669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is unknown if mycophenolate is excreted in human milk. Due to potentially serious adverse reactions, the decision to discontinue the drug or discontinue breast-feeding should be considered. Breast-feeding is not recommended during therapy or for 6 weeks after treatment is complete.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F198670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral dosage formulations should be taken on an empty stomach to avoid variability in MPA absorption. However, in stable renal transplant patients, Cellcept&reg;  may be administered with food if necessary. Some products may contain phenylalanine.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F198667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (CellCept Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (120): $865.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Mycophenolate Mofetil Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (100): $396.29",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (CellCept Intravenous Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (1): $91.79",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension (reconstituted)",
"     </b>",
"     (CellCept Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg/mL (160 mL): $1188.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, EC",
"     </b>",
"     (Myfortic Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     180 mg (120): $560.02",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     360 mg (120): $1120.01",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (CellCept Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $1442.93",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Mycophenolate Mofetil Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $792.59",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F198657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Complete blood count (weekly for first month, twice monthly during months 2 and 3, then monthly thereafter through the first year); renal and liver function; signs and symptoms of infection; pregnancy test (immediately prior to initiation and 8-10 days later in females of childbearing potential, followed by repeat tests during therapy); monitor skin (for lesions suspicious of skin cancer); monitor for signs of lymphoma",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F198671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      CellCept (BB, BF, BJ, BM, BS, BZ, CI, ET, GH, GM, GN, GY, HK, JM, KE, LR, MA, ML, MR, MT, MU, MW, NE, NG, NZ, PY, SC, SD, SK, SL, SN, SR, TN, TR, TT, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Cellmune (IN);",
"     </li>",
"     <li>",
"      Micocept (HK);",
"     </li>",
"     <li>",
"      Myfortic (AR, AT, AU, BE, BG, BR, CH, CL, CN, CO, CZ, DE, DK, EC, EE, ES, FI, FR, GB, GR, HN, ID, IE, IL, IT, KP, MX, MY, NL, NO, PE, PH, PK, PL, PT, RU, SE, SG, TH, TW, UY, VE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F198647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     MPA exhibits a cytostatic effect on T and B lymphocytes. It is an inhibitor of inosine monophosphate dehydrogenase (IMPDH) which inhibits",
"     <i>",
"      de novo",
"     </i>",
"     guanosine nucleotide synthesis. T and B lymphocytes are dependent on this pathway for proliferation.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F198664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Peak effect: Correlation of toxicity or efficacy is still being developed, however, one study indicated that 12-hour AUCs &gt;40 mcg/mL/hour were correlated with efficacy and decreased episodes of rejection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: AUC values for MPA are lower in the early post-transplant period versus later (&gt;3 months) post-transplant period. The extent of absorption in pediatrics is similar to that seen in adults, although there was wide variability reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Myfortic&reg;: 93%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CellCept&reg;: MPA: Oral: 4 L/kg; I.V.: 3.6 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Myfortic&reg;: MPA: Oral: 54 L (at steady state); 112 L (elimination phase)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: MPA: &gt;97%, MPAG 82%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic and via GI tract; CellCept&reg; is completely hydrolyzed in the liver to mycophenolic acid (MPA; active metabolite); enterohepatic recirculation of MPA may occur; MPA is glucuronidated to MPAG (inactive metabolite)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: CellCept&reg;: 94%; Myfortic&reg;: 72%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CellCept&reg;: MPA: Oral: 18 hours; I.V.: 17 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Myfortic&reg;: MPA: Oral: 8-16 hours; MPAG: 13-17 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: Oral: MPA:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CellCept&reg;: 1-1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Myfortic&reg;: 1.5-2.75 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CellCept&reg;: MPA: Urine (&lt;1%), feces (6%); MPAG: Urine (87%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Myfortic&reg;: MPA: Urine (3%), feces; MPAG: Urine (&gt;60%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Alousi AM, Weisdorf DJ, Logan BR, et al, &ldquo;Etanercept, Mycophenolate, Denileukin, or Pentostatin Plus Corticosteroids for Acute Graft-Versus-Host Disease: A Randomized Phase 2 Trial from the Blood and Marrow Transplant Clinical Trials Network,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2009, 114(3):511-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/29/4569/abstract-text/19443659/pubmed\" id=\"19443659\" target=\"_blank\">",
"        19443659",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bertsias G, Ioannidis JP, Boletis J, et al, &ldquo;EULAR Recommendations for the Management of Systemic Lupus Erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics,&rdquo;",
"      <i>",
"       Ann Rheum Dis",
"      </i>",
"      , 2008, 67(2):195-205.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/29/4569/abstract-text/17504841/pubmed\" id=\"17504841\" target=\"_blank\">",
"        17504841",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cahoon WD Jr and Kockler DR, &ldquo;Mycophenolate Mofetil Treatment of Myasthenia Gravis,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2006, 40(2):295-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/29/4569/abstract-text/16403848/pubmed\" id=\"16403848\" target=\"_blank\">",
"        16403848",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chaudhry V, Cornblath DR, Griffin JW, et al, &ldquo;Mycophenolate Mofetil: A Safe and Promising Immunosuppressant in Neuromuscular Diseases,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      ,  2001, 56(1):94-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/29/4569/abstract-text/11148242/pubmed\" id=\"11148242\" target=\"_blank\">",
"        11148242",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ciafaloni E, Massey JM, Tucker-Lipscomb B, et al, &ldquo;Mycophenolate Mofetil for Myasthenia Gravis: An Open-Label Pilot Study,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 2001, 56(1):97-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/29/4569/abstract-text/11148243/pubmed\" id=\"11148243\" target=\"_blank\">",
"        11148243",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Contreras G, Pardo V, Leclercq B, et al, &ldquo;Sequential Therapies for Proliferative Lupus Nephritis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2004, 350(10):971-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/29/4569/abstract-text/14999109/pubmed\" id=\"14999109\" target=\"_blank\">",
"        14999109",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dooley MA, Jayne D, Ginzler EM, et al, &ldquo;Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2011, 365(20):1886-95.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ettenger R, Warshaw B, Menster M, et al, &ldquo;Mycophenolate Mofetil (MMF) in Pediatric (Ped) Renal Transplantation (Tx): A Report of the Ped MMF Study Group (PMMSG),&rdquo; 1996:97 [abstract 97 from ASTP Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Furlong T, Martin P, Flowers ME, et al, &ldquo;Therapy With Mycophenolate Mofetil for Refractory Acute and Chronic GVHD,&rdquo;",
"      <i>",
"       Bone Marrow Transplant",
"      </i>",
"      , 2009, 44(11):739-48.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/29/4569/abstract-text/19377515/pubmed\" id=\"19377515\" target=\"_blank\">",
"        19377515",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gabardi S, Tran JL, and Clarkson MR, &ldquo;Enteric-Coated Mycophenolate Sodium,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2003, 37(11):1685-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/29/4569/abstract-text/14565799/pubmed\" id=\"14565799\" target=\"_blank\">",
"        14565799",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gipson DS, Massengill SF, Yao L, et al, \"Management of Childhood Onset Nephrotic Syndrome,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2009, 124(2):747-57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/29/4569/abstract-text/19651590/pubmed\" id=\"19651590\" target=\"_blank\">",
"        19651590",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hahn BH, McMahon MA, Wilkinson A, et al, \"American College of Rheumatology Guidelines for Screening, Treatment, and Management of Lupus Nephritis,\"",
"      <i>",
"       Arthritis Care Res (Hoboken)",
"      </i>",
"      , 2012, 64(6):797-808.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/29/4569/abstract-text/22556106/pubmed\" id=\"22556106\" target=\"_blank\">",
"        22556106",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lipsky JJ, &ldquo;Mycophenolate Mofetil,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1996, 348(9038):1357-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/29/4569/abstract-text/8918281/pubmed\" id=\"8918281\" target=\"_blank\">",
"        8918281",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Manns MP, Czaja AJ, Gorham JD, et al, &ldquo;Diagnosis and Management of Autoimmune Hepatitis,&rdquo;",
"      <i>",
"       Hepatology",
"      </i>",
"      , 2010, 51(6):2193-213.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/29/4569/abstract-text/20513004/pubmed\" id=\"20513004\" target=\"_blank\">",
"        20513004",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Menter A, Korman NJ, Elmets CA, et al, &ldquo;Guidelines of Care for the Management of Psoriasis and Psoriatic Arthritis: Section 4. Guidelines of Care for the Management and Treatment of Psoriasis With Traditional Systemic Agents,&rdquo;",
"      <i>",
"       J Am Acad Dermatol",
"      </i>",
"      , 2009, 61(3):451-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/29/4569/abstract-text/19493586/pubmed\" id=\"19493586\" target=\"_blank\">",
"        19493586",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Meriggioli MN, Ciafaloni E, Al-Hayk KA, et al, &ldquo;Mycophenolate Mofetil for Myasthenia Gravis: An Analysis of Efficacy, Safety, and Tolerability,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 2003, 61(10):1438-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/29/4569/abstract-text/14638974/pubmed\" id=\"14638974\" target=\"_blank\">",
"        14638974",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ong LM, Hooi LS, Lim TO, et al, &ldquo;Randomized Controlled Trial of Pulse Intravenous Cyclophosphamide versus Mycophenolate Mofetil in the Induction Therapy of Proliferative Lupus Nephritis,&rdquo;",
"      <i>",
"       Nephrology (Carlton)",
"      </i>",
"      , 2005, 10(5):504-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/29/4569/abstract-text/16221103/pubmed\" id=\"16221103\" target=\"_blank\">",
"        16221103",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sabry W, Le Blanc R, Labb&eacute; AC, et al, &ldquo;Graft-Versus-Host Disease Prophylaxis With Tacrolimus and Mycophenolate Mofetil in HLA-Matched Nonmyeloablative Transplant Recipients is Associated With Very Low Incidence of GVHD and Nonrelapse Mortality,&rdquo;",
"      <i>",
"       Biol Blood Marrow Transplant",
"      </i>",
"      , 2009, 15(8):919-29.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/29/4569/abstract-text/19589481/pubmed\" id=\"19589481\" target=\"_blank\">",
"        19589481",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schmeding M, Kiessling A, Neuhaus R, et al, \"Mycophenolate Mofetil Monotherapy in Liver Transplantation: 5-year Follow-up of a Prospective Randomized Trial,\"",
"      <i>",
"       Transplantation",
"      </i>",
"      , 2011, 92(8):923-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/29/4569/abstract-text/21832958/pubmed\" id=\"21832958\" target=\"_blank\">",
"        21832958",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shaw LM, Sollinger HW, Halloran P, et al, &ldquo;Mycophenolate Mofetil: A Report of the Consensus Panel,&rdquo;",
"      <i>",
"       Ther Drug Monit",
"      </i>",
"      , 1995, 17(6):690-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/29/4569/abstract-text/8588243/pubmed\" id=\"8588243\" target=\"_blank\">",
"        8588243",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sifontis NM, Coscia LA, Constantinescu S, et al, &ldquo;Pregnancy Outcomes in Solid Organ Transplant Recipients With Exposure to Mycophenolate Mofetil or Sirolimus,&rdquo;",
"      <i>",
"       Transplantation",
"      </i>",
"      , 2006, 82(12):1698-702.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/29/4569/abstract-text/17198262 /pubmed\" id=\"17198262 \" target=\"_blank\">",
"        17198262",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sollinger HW, &ldquo;Mycophenolate Mofetil for the Prevention of Acute Rejection in Primary Cadaveric Renal Allograft Recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group,&rdquo;",
"      <i>",
"       Transplantation",
"      </i>",
"      , 1995, 60:225-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/29/4569/abstract-text/7645033/pubmed\" id=\"7645033\" target=\"_blank\">",
"        7645033",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vogelsang GB, and Arai S, &ldquo;Mycophenolate Mofetil for the Prevention and Treatment of Graft-Versus-Host Disease Following Stem Cell Transplantation: Preliminary Findings,&rdquo;",
"      <i>",
"       Bone Marrow Transplant",
"      </i>",
"      , 2001, 27(12):1255-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/29/4569/abstract-text/11548843/pubmed\" id=\"11548843\" target=\"_blank\">",
"        11548843",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wolff D, Schleuning M, von Harsdorf S, et al, &ldquo;Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease,&rdquo;",
"      <i>",
"       Biol Blood Marrow Transplant",
"      </i>",
"      , 2010, 17(1):1-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/29/4569/abstract-text/20685255/pubmed\" id=\"20685255\" target=\"_blank\">",
"        20685255",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zhu B, Chen N, Lin Y, et al, &ldquo;Mycophenolate Mofetil in Induction and Maintenance Therapy of Severe Lupus Nephritis: A Meta-Analysis of Randomized Controlled Trials,&rdquo;",
"      <i>",
"       Nephrol Dial Transplant",
"      </i>",
"      , 2007, 22(7):1933-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/29/4569/abstract-text/17405792/pubmed\" id=\"17405792\" target=\"_blank\">",
"        17405792",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9670 Version 50.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-183.166.191.243-65E6C3AFCD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_29_4569=[""].join("\n");
var outline_f4_29_4569=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709159\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198686\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198687\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198710\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198690\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198703\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198691\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198692\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198693\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3022884\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198659\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198644\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874743\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198662\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198717\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198660\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198706\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198708\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198665\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198648\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299731\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198653\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198682\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198655\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198668\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198698\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198669\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198670\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198667\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198657\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198671\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198647\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198664\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9670\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9670|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?21/56/22406?source=related_link\">",
"      Mycophenolate: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/50/12072?source=related_link\">",
"      Mycophenolate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_29_4570="Methadone maintenance therapy during pregnancy";
var content_f4_29_4570=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Methadone maintenance therapy during pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/29/4570/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/29/4570/contributors\">",
"     Neil S Seligman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/29/4570/contributors\">",
"     Susan M Weiner, PhD, MSN, RNC, CNS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/29/4570/contributors\">",
"     Vincenzo Berghella, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/29/4570/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/29/4570/contributors\">",
"     Susan M Ramin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/29/4570/contributors\">",
"     Andrew J Saxon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/29/4570/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/29/4570/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/29/4570/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     Methadone",
"    </a>",
"    has been used for treatment of opioid addiction during pregnancy since the 1960s [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Perinatal methadone substitution therapy provides several potential maternal, obstetrical, and neonatal benefits (",
"    <a class=\"graphic graphic_table graphicRef55718 \" href=\"UTD.htm?32/3/32827\">",
"     table 1",
"    </a>",
"    ). For example, a stable methadone dose reduces stress on the fetus from repeated withdrawal due to inconsistent availability of illicit drugs. Additional benefits include a potential reduction in drug-seeking behaviors, including trading sex for drugs and in engaging in commercial sex to obtain money to buy drugs. Pregnant women enrolled in a substance use disorders treatment program are more likely to receive prenatal care, have infants of higher birth weight and be discharged home with their neonate [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. Nevertheless, there are several barriers to methadone treatment, including lack of insurance, incarceration, transportation and childcare needs, guilt about the effect of drugs on the fetus, and fear of legal consequences, including loss of custody of children.",
"   </p>",
"   <p>",
"    This topic will review management of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    maintenance therapy in pregnant women. Issues relating to detection and consequences of substance use in pregnancy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/12/6346?source=see_link\">",
"     \"Overview of illicit drug use in pregnant women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     METHADONE MAINTENANCE THERAPY VERSUS DETOXIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two main approaches to treatment of opioid addiction during pregnancy are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    maintenance therapy and detoxification (see",
"    <a class=\"local\" href=\"#H30\">",
"     'Detoxification'",
"    </a>",
"    below). Both approaches require substitution of methadone for illicit opioids.",
"   </p>",
"   <p>",
"    The goal of maintenance therapy is administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    in doses sufficient to prevent symptoms of withdrawal and reduce or eliminate drug craving. Detoxification, on the other hand, aims to lower the maternal methadone dose to achieve the lowest possible dose that prevents withdrawal symptoms and ultimately to eliminate methadone use. Proponents of detoxification cite evidence that lower doses of methadone reduce neonatal sequelae of maternal opioid use [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/7-13\">",
"     7-13",
"    </a>",
"    ]. The major disadvantage of detoxification is that a high proportion of women return to illicit opioid use [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/7,14\">",
"     7,14",
"    </a>",
"    ]. These two treatment modalities have never been compared in a randomized trial involving pregnant women. Methadone maintenance therapy is considered the standard of care for pregnant women dependent on opioids [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     Buprenorphine",
"    </a>",
"    substitution therapy is becoming an alternative to methadone maintenance therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/45/5850?source=see_link\">",
"     \"Buprenorphine substitution therapy in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CANDIDATES FOR METHADONE TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regulations regarding",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    use vary by state",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    country [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/17\">",
"     17",
"    </a>",
"    ]. In general, pregnant women who are physiologically dependent on heroin, \"street methadone,\" or other opioids are potential candidates for methadone treatment. Methadone may also be a reasonable option for management of chronic pain, such as low back pain, during pregnancy, but this indication is beyond the scope of this topic [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     INITIAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thorough medical, psychosocial, and physical assessments are important, given the chronic relapsing nature of addiction, the prevalence of concomitant medical disorders, the chaotic lives of substance-abusing women, and their frequent lack of consistent prenatal care [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polysubstance abusers are often vague and poor historians, however, a detailed and accurate medical and obstetrical history can usually be obtained if the questions are asked in a direct and nonjudgmental way. The psychosocial history is also important: 83 percent of women entering",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    treatment programs come from households in which parents used drugs, 67 percent have been victims of sexual assault, and 60 percent had been physically assaulted [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/44/3784?source=see_link&amp;anchor=H11#H11\">",
"     \"Opioid abuse and dependence: Overview and patient evaluation\", section on 'History'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important aspects of the physical examination are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef55487 \" href=\"UTD.htm?33/46/34539\">",
"     table 2",
"    </a>",
"    ) and also discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/44/3784?source=see_link&amp;anchor=H12#H12\">",
"     \"Opioid abuse and dependence: Overview and patient evaluation\", section on 'Physical examination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine prenatal laboratory tests are performed. Women who use heroin are at high risk for infections related to shared needle use and sexually transmitted infections. Counseling regarding HIV testing should be provided, and testing recommended using an opt-out approach. Tests for hepatitis B and C and liver function tests are also suggested. Hepatitis B vaccination is recommended for those whose hepatitis serology is negative. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42010?source=see_link&amp;anchor=H8#H8\">",
"     \"Initial prenatal assessment and patient education\", section on 'Laboratory tests'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32602?source=see_link\">",
"     \"Immunizations during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sonographic confirmation of a viable intrauterine pregnancy is often a prerequisite for acceptance to a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    treatment program tailored specifically to pregnant women. It is also useful for confirmation of gestational age. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34553?source=see_link\">",
"     \"Prenatal assessment of gestational age\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     METHADONE TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     Methadone",
"    </a>",
"    is a synthetic opioid agonist approved for treatment of opioid addiction and moderate to severe pain. Special attention to dosing is needed because of high variability in absorption and metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Physicians, nurses, and other health care personnel that care for pregnant women being treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    should have a thorough understanding of the changes in the pharmacokinetic properties of methadone that occur during pregnancy. With advancing gestational age, plasma levels of methadone progressively decrease and clearance increases [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/22-27\">",
"     22-27",
"    </a>",
"    ]. The half-life of methadone falls from an average of 22 to 24 hours in nonpregnant women to 8.1 hours in pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/28\">",
"     28",
"    </a>",
"    ]. As a result, increased or split methadone doses may be needed as pregnancy progresses to maintain therapeutic effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Continuing and initiating therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conceiving while on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    has been associated with better drug treatment outcomes compared to women who initiate methadone during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/29\">",
"     29",
"    </a>",
"    ]. Pregnant women on methadone maintenance prior to conception and not in withdrawal can be continued on methadone as outpatients.",
"   </p>",
"   <p>",
"    For women desiring",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    treatment, the drug should be initiated as early as possible during pregnancy to get the most benefit. Longer duration of methadone treatment is associated with longer gestation and increased birthweight [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/3,5,30\">",
"     3,5,30",
"    </a>",
"    ]. Teratogenic effects have been observed in some animal studies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/31\">",
"     31",
"    </a>",
"    ]. There is no good evidence of teratogenesis in human pregnancy, but data collected on exposure in human pregnancies are complicated by multiple confounders, including maternal use of illicit drugs, alcohol, and cigarettes; poor maternal nutrition; and an increased prevalence of maternal infection.",
"   </p>",
"   <p>",
"    The optimum setting for initiation of therapy has not been evaluated in the pregnant population. We suggest hospitalization because of the potential for serious adverse events, such as overdose and adverse drug interactions, during initiation of treatment. This is also an ideal time for assessment by a social worker and case manager and for initiation of prenatal care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     First day of treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     Methadone",
"    </a>",
"    is available as an injectable solution, oral solution, and tablet. The starting dose depends on the patient&rsquo;s symptoms. If the diagnosis of opioid dependence is clear, there is no legal requirement that the patient demonstrate withdrawal before initiating methadone.",
"   </p>",
"   <p>",
"    Patients experiencing opioid withdrawal may complain of the following (",
"    <a class=\"graphic graphic_table graphicRef78130 \" href=\"UTD.htm?40/6/41068\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Dysphoria and restlessness",
"     </li>",
"     <li>",
"      Rhinorrhea and lacrimation",
"     </li>",
"     <li>",
"      Myalgias and arthralgias",
"     </li>",
"     <li>",
"      Nausea, vomiting, abdominal cramping, and diarrhea",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some or all of these symptoms may be present, and the severity of each symptom depends on the individual's tolerance to opioids, the continued presence of opioid in the serum and end organs, and the duration of time over which withdrawal has occurred. Physical signs of withdrawal include mydriasis (pupillary dilation), yawning, increased bowel sounds, and piloerection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/5/28758?source=see_link&amp;anchor=H4#H4\">",
"     \"Opioid withdrawal in the emergency setting\", section on 'Clinical features of opioid withdrawal'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Opioid withdrawal typically appears 6 to 12 hours after the last dose of opioids [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/15\">",
"     15",
"    </a>",
"    ]. In symptomatic women, we begin therapy with a single oral dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    20 to 30 mg [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/7,22,32-35\">",
"     7,22,32-35",
"    </a>",
"    ]. After the initial methadone dose, incremental doses of 5 to 10 mg are given every three to six hours as needed to treat withdrawal symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For women with only mild symptoms of withdrawal, an alternative approach is to begin with a low initial dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    (10 mg) and give incremental doses of 5 to 10 mg every four to six hours as needed for withdrawal symptoms on the first day of therapy.",
"   </p>",
"   <p>",
"    Mild symptoms of withdrawal can sometimes be managed adequately with counseling, supportive care,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    0.1 mg orally every four to six hours rather than with incremental doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Subsequent days",
"    </span>",
"    &nbsp;&mdash;&nbsp;On the second day of treatment, the total dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    given in the previous 24 hours is given as the new morning dose. Women who initially presented with only mild symptoms, and were given a low initial dose (10 mg), are given no less than 30 mg on the second day. Incremental doses are administered as needed. Daily adjustments to the morning dose are made until no additional incremental doses are needed to prevent signs and symptoms of withdrawal for 24 hours or longer. This is called the stabilization dose and requires that methadone occupy enough opioid receptors to prevent withdrawal [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/36\">",
"     36",
"    </a>",
"    ]. Stabilization may take a week or more and may require further adjustments over time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Maintenance therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following stabilization,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    maintenance therapy (MMT) is continued at an outpatient treatment center. Continued successful treatment depends upon a comprehensive, multidisciplinary, coordinated approach to care [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/19,37\">",
"     19,37",
"    </a>",
"    ]. Outpatient treatment centers typically offer individual and group counseling, psychiatric services, social services,",
"    <span class=\"nowrap\">",
"     health/parenting",
"    </span>",
"    education, and prenatal care; however, if prenatal care is not available onsite, then these services will need to be arranged separately [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/33,38,39\">",
"     33,38,39",
"    </a>",
"    ]. Ideally, medical stabilization and close supportive clinical follow-up lead to lifestyle stabilization and a reduction in risky behaviors [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once the dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    necessary to block withdrawal symptoms has been achieved, the maintenance dose is not increased for several days even if symptoms occur; we usually wait at least 72 hours before considering an increase in dose [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/38\">",
"     38",
"    </a>",
"    ]. Opioid withdrawal symptoms mimic common discomforts of pregnancy, which should be taken into account before increasing the daily maintenance methadone dose [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A variety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    doses has been used for maintenance. The optimal dose in pregnancy is controversial. Research from the National Institute on Drug Abuse indicates that methadone maintenance doses less than 60 mg are ineffective since they are less likely to prevent drug seeking behavior. Women appear to do better on higher (80 to 120",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    rather than lower methadone doses [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/1\">",
"     1",
"    </a>",
"    ]; doses at these levels are not overly sedating due to the development of tolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/38\">",
"     38",
"    </a>",
"    ]. The rationale for high dose therapy is to reach a level sufficiently high so that additional doses of opioid do not cause euphoria [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/33,38\">",
"     33,38",
"    </a>",
"    ]. Although some studies have reported that daily doses of 80 to 160 mg adversely affected fetal growth, these findings have not been consistent across studies and could have been due to confounders [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/30,42-44\">",
"     30,42-44",
"    </a>",
"    ]. Multiple studies have attempted to evaluate whether there is a correlation between methadone dose and severity of neonatal withdrawal; results have been equally divided for and against a correlation. Comparing the outcomes of these studies is limited by several design factors. In our experience, there is no correlation between methadone dose and severity of neonatal withdrawal [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/57/39833?source=see_link\">",
"     \"Neonatal opioid withdrawal (Neonatal abstinence syndrome)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28746?source=see_link\">",
"     \"Infants of mothers with substance abuse\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After initial stabilization, we increase the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    maintenance dose in 5 to 10 mg increments per week, if indicated, to maintain the lowest dose that controls withdrawal symptoms and minimizes the desire to use additional opioids. In our experience, the average maintenance dose is approximately 120 mg.",
"   </p>",
"   <p>",
"    In pregnant women, the presence or absence of withdrawal symptoms correlates reliably with serum trough levels. In a prospective study that evaluated serum trough levels in a cohort of pregnant women, symptomatic women had mean trough levels of 0.18",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    (&plusmn; 0.11), whereas the mean trough level was 0.30 (&plusmn; 0.16) in asymptomatic women (p&lt;.001), thus for most women a level of &ge;0.24",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    should be adequate to prevent withdrawal symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/45\">",
"     45",
"    </a>",
"    ]. We recommend checking a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    serum trough level in the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women who are excessively sedated and also have a negative urine drug screen.",
"     </li>",
"     <li>",
"      Women who are symptomatic despite an increase in",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      dose. If the trough level is &gt;0.3",
"      <span class=\"nowrap\">",
"       mg/L,",
"      </span>",
"      a urine drug screen should be performed to rule out the possibility of withdrawal from other opioids. If the screen is negative, these women may benefit from \"split\" or \"twice\" daily dosing. Plasma levels are required before switching to split dosing.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Asymptomatic women with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    trough levels below 0.24",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    do not require an increase in dose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Twice daily or split dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, the half-life of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    is about 8 hours during pregnancy, compared with an average half-life of 22 to 24 hours in chronically dosed nonpregnant individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/21,28\">",
"     21,28",
"    </a>",
"    ]. For this reason, twice daily (or rarely three times daily) dosing is sometimes used in pregnant women and results in more sustained plasma levels, fewer withdrawal symptoms, and less illicit drug use [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/28,46\">",
"     28,46",
"    </a>",
"    ]. Split dosing also does not suppress fetal neurobehaviors (eg, fetal movement, fetal breathing) as much as single dosing (see",
"    <a class=\"local\" href=\"#H18\">",
"     'Fetal and neonatal issues'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Twice daily dosing is optimally delivered at 12-hour intervals, but is not possible for all women because it requires take-home doses. Federal and state regulations list criteria for patients who may have doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    to take home.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Drug screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urine drug screens are performed to monitor for continued illicit drug use. Ideally, drug screening is performed at weekly visits; in the US, federal regulations require urine drug screening with a minimum of eight urine tests in the first year of treatment and four urine tests in subsequent years. The urine drug screen-9 tests for opiates,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    , cocaine, benzodiazepines, barbiturates, amphetamines, and phencyclidine (PCP). Experience shows that one- to two-thirds of women enrolled in methadone maintenance programs continue to abuse drugs or alcohol during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Detection of continued polysubstance abuse is important because this practice may lessen some of the benefits of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    maintenance therapy and increases the incidence and severity of neonatal abstinence syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/5,49\">",
"     5,49",
"    </a>",
"    ]. Benzodiazepines particularly have been associated with lower birthweight and increased incidence and severity of neonatal abstinence syndrome when used concomitantly with methadone [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/29,34,50\">",
"     29,34,50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Drug and chemical interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a potential for interactions between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    and other drugs or substances being used by the patient.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Cigarette smoking",
"      </strong>",
"      &mdash; Approximately 77 to 91 percent of opioid-addicted women also smoke cigarettes [",
"      <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/7,38,51,52\">",
"       7,38,51,52",
"      </a>",
"      ]. Smoking has multiple adverse effects on maternal health and pregnancy outcome. In addition, the combination of smoking and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      delays the onset of neonatal abstinence syndrome and increases the severity of neonatal withdrawal [",
"      <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/53-55\">",
"       53-55",
"      </a>",
"      ]. For all of these reasons, and others, smoking cessation should be recommended. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/53/27482?source=see_link\">",
"       \"Smoking and pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Illicit drugs or alcohol",
"      </strong>",
"      &mdash; It is common for individuals with opioid use disorder to use more than one illicit drug or abuse alcohol. Polysubstance abuse increases the risk of preterm birth. In a retrospective cohort study including 258 neonates born to opiate-addicted women treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      , the rates of preterm birth among women using 0, 1, 2, or 3 or more substances (alcohol or illicit drugs) in addition to methadone were approximately 24, 26, 48, and 65 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/56\">",
"       56",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Other effects from using multiple drugs with methadone vary depending on the drug and mixture. Barbiturates induce methadone metabolism, while benzodiazepines like",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"       diazepam",
"      </a>",
"      may act synergistically, causing excessive sedation [",
"      <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/21,35,57,58\">",
"       21,35,57,58",
"      </a>",
"      ]. Chronic alcohol abuse may lower methadone levels through induction of hepatic enzymes, while acute consumption can accentuate its effects.",
"     </li>",
"     <li>",
"      <strong>",
"       Opioid antagonists",
"      </strong>",
"      &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"       Naloxone",
"      </a>",
"      and other narcotic antagonists are only used as a last resort in treating severe maternal narcotic overdose because these agents may precipitate withdrawal in both the mother and fetus [",
"      <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/21,22,59\">",
"       21,22,59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       Rifampin",
"      </a>",
"      &mdash; The antituberculosis drug rifampin induces CYP3A4 and alters P-glycoprotein binding [",
"      <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/59,60\">",
"       59,60",
"      </a>",
"      ], which reduces the plasma concentrations of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      and may lead to opioid withdrawal. Therefore, higher doses of methadone may be required in pregnant women who are taking rifampin [",
"      <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Antiepileptic drugs",
"      </strong>",
"      &mdash; The antiepileptic drugs",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      interfere with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      metabolism. In one study, nonpregnant, methadone maintained individuals experienced withdrawal symptoms within three to four days of starting phenytoin [",
"      <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/61\">",
"       61",
"      </a>",
"      ]; a similar response is likely in pregnant women.",
"     </li>",
"     <li>",
"      <strong>",
"       Antiretrovirals",
"      </strong>",
"      &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       Methadone",
"      </a>",
"      increases blood levels of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"       zidovudine",
"      </a>",
"      (AZT) and may require a reduction of the usual dose by half [",
"      <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/21\">",
"       21",
"      </a>",
"      ]. Methadone can also decrease concentrations of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"       didanosine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"       stavudine",
"      </a>",
"      .",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/10/27816?source=see_link\">",
"       Delavirdine",
"      </a>",
"      may increase methadone concentrations.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"       Darunavir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/62/19433?source=see_link\">",
"       nelfinavir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"       nevirapine",
"      </a>",
"      , and",
"      <span class=\"nowrap\">",
"       Lopinavir/",
"       <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"        ritonavir",
"       </a>",
"      </span>",
"      all have the potential to reduce serum methadone concentrations, which could result in methadone withdrawal symptoms and necessitate a methadone dose increase.",
"     </li>",
"     <li>",
"      <strong>",
"       Other",
"      </strong>",
"      &mdash; The H2 antagonist,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/54/2921?source=see_link\">",
"       cimetidine",
"      </a>",
"      , and the antifungal medication,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"       ketoconazole",
"      </a>",
"      , increase",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      levels [",
"      <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Prolongation of the QT interval",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     Methadone",
"    </a>",
"    can prolong the QT interval and cause torsades de pointes. The confounding influence of other drugs (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    ), a prolonged QT interval at baseline, and hypokalemia can contribute to this risk. This complication of methadone therapy and approaches to identify patients at high arrhythmic risk are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     FETAL AND NEONATAL ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     Methadone",
"    </a>",
"    maintenance treatment has been associated with an increased risk of adverse perinatal outcomes, such as preterm birth &lt;32 weeks gestation, small for gestational age infants, and admission to a neonatal unit, even after attempting to account for adverse sociodemographic factors [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Fetal surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     Methadone",
"    </a>",
"    maintenance therapy affects multiple fetal characteristics used in fetal surveillance. Reductions have been observed in [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/63-65\">",
"     63-65",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fetal baseline heart rate",
"     </li>",
"     <li>",
"      Fetal heart rate variability",
"     </li>",
"     <li>",
"      Number of heart rate accelerations",
"     </li>",
"     <li>",
"      Fetal breathing movements",
"     </li>",
"     <li>",
"      Fetal movement",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is a higher incidence of nonreactive nonstress tests (NST) and longer intervals to achieve reactive NSTs [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/66\">",
"     66",
"    </a>",
"    ]. To reduce the risk of a falsely nonreactive nonstress test, or nonreassuring biophysical profile, we suggest delaying the test until at least four to six hours, after the woman takes her daily maintenance dose. If daily testing is being done, we suggest doing the test just before the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    dose is given.",
"   </p>",
"   <p>",
"    The optimal method of fetal assessment during initial stabilization of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    therapy is unknown. In pregnancies under 28 weeks gestational age, we check the fetal heart rate to document that it is present and in the normal range. We perform a daily nonstress test on fetuses &ge;28 weeks gestational age.",
"   </p>",
"   <p>",
"    There are no studies on which to base recommendations for antepartum fetal surveillance of women on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    maintenance therapy. In our practice, women who consistently demonstrate good compliance by negative urine drug screens do not undergo routine antepartum fetal testing (nonstress test, biophysical profile score), unless there are additional indications for fetal surveillance (eg, preeclampsia, fetal growth restriction).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H120744937\">",
"    <span class=\"h2\">",
"     Growth restriction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    on fetal growth is unclear. In one large study, the relative risk of intrauterine growth restriction was increased two-fold among opiate-addicted women treated with methadone after controlling for known adverse sociodemographic factors [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/62\">",
"     62",
"    </a>",
"    ]. However, others have not observed a significant increase in growth restriction among infants exposed to methadone in utero when adjustments were made for differences in race, body mass index, weight gain during pregnancy, and maternal smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. If there is a clinical suspicion of fetal growth restriction, an ultrasound examination is indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Neonatal abstinence syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Newborn infants who withdraw from opioids present with a well-recognized constellation of symptoms known as the neonatal abstinence syndrome (NAS). Withdrawal from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    usually occurs 48 to 72 hours after birth, but may be delayed by up to a month [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/69\">",
"     69",
"    </a>",
"    ]. The relationship between maternal methadone dose and neonatal withdrawal is controversial. The clinical manifestations and management of neonatal withdrawal are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/57/39833?source=see_link\">",
"     \"Neonatal opioid withdrawal (Neonatal abstinence syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Other effects on the neonate",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is growing concern about the effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    on the developing visual system. A series of 20 infants and children exposed to opiates in utero demonstrated a high rate of ophthalmic abnormalities, including reduced visual acuity (95 percent), nystagmus (70 percent), delayed visual maturation (50 percent), strabismus (30 percent), refractive errors (30 percent), and cerebral visual impairment (25 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/70\">",
"     70",
"    </a>",
"    ]. A cohort study found a higher incidence of abnormal visual evoked potentials among 21 methadone-exposed neonates than in unexposed controls, suggesting an abnormality of the visual pathway from the retina to the occipital cortex [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/71\">",
"     71",
"    </a>",
"    ]. However, neither the long-term effects nor the independent effects of maternal illicit drug abuse, neonatal abstinence syndrome, or pharmacologic treatment of these conditions are clear [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A possible association between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    exposure and major congenital anomalies was reported in a cohort of 618 methadone-exposed neonates (OR 1.94, 95% CI 1.10-3.43) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/62\">",
"     62",
"    </a>",
"    ]. The incidence of Pierre Robin sequence was also increased (1:155 versus 1:7552 in non-exposed neonates). This association warrants further investigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     LABOR, DELIVERY, AND POSTPARTUM ISSUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Methadone",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient's usual oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    dose should be continued intrapartum.",
"   </p>",
"   <p>",
"    After delivery, fluid shifts may result in an increase in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    levels. We continue the antepartum maintenance dose until discharge and have not experienced any cases of oversedation. However, an alternative approach is to reduce the maintenance methadone dose by 20 to 40 percent immediately postpartum [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Analgesia and anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Provision of pain control and anesthesia for the pregnant substance abuser can be complex and challenging [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/74\">",
"     74",
"    </a>",
"    ]. Chronic opioid use leads to cross tolerance of anesthetics and other depressants, a result of chronic receptor stimulation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/75\">",
"     75",
"    </a>",
"    ]. Health care professionals concerned about drug seeking behavior and over medication may make the erroneous assumption that the daily maintenance dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    alone should provide analgesia.",
"   </p>",
"   <p>",
"    During labor and postpartum, pain control in opioid-addicted pregnant women should be similar to that in nonsubstance abusing women. Acute intrapartum and postpartum pain should not be treated with additional doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    . The following recommendations describe selecting, dosing, and administering pain medications for these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/76\">",
"     76",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Higher than usual opioid analgesic doses may be required because of opioid cross tolerance, and the patient's increased pain sensitivity.",
"     </li>",
"     <li>",
"      Mixed agonist and antagonist opioid analgesics, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/48/29446?source=see_link\">",
"       pentazocine",
"      </a>",
"      (Talwin),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/45/14038?source=see_link\">",
"       nalbuphine",
"      </a>",
"      (Nubain), and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9543?source=see_link\">",
"       butorphanol",
"      </a>",
"      (Stadol), should not be administered, as they may displace",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      from the mu receptor and precipitate acute withdrawal. If any of these drugs are accidentally given, withdrawal can also be reversed with any opioid [",
"      <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/74\">",
"       74",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      We have found that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/51/9016?source=see_link\">",
"       oxycodone-acetaminophen",
"      </a>",
"      (eg, Percocet) usually provides adequate postoperative analgesia. If oxycodone-acetaminophen does not control pain adequately,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/48/25353?source=see_link\">",
"       hydromorphone",
"      </a>",
"      (eg, Dilaudid) can be given; however, we have found injectable nonsteroidal anti-inflammatory drugs (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/62/35808?source=see_link\">",
"       Ketorolac",
"      </a>",
"      ) provide good analgesia without the need for additional narcotics in many of these cases. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27546?source=see_link&amp;anchor=H17#H17\">",
"       \"Management of postoperative pain\", section on 'Ketorolac'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Regional anesthesia is safe, however, the incidence of hypotension may be increased because of reduced intravascular fluid volume, malnutrition,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Labor and delivery management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation of opioid-addicted pregnant women presenting to the labor and delivery unit for any reason should include a urine drug screen, ideally with consent.",
"   </p>",
"   <p>",
"    Retesting for HIV in the third trimester is recommended for women at increased risk for acquiring HIV infection, in areas of high HIV prevalence, and for women who declined testing earlier in pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/78\">",
"     78",
"    </a>",
"    ]. The basis of this recommendation is that appropriate intervention peripartum can significantly reduce perinatal transmission. A conventional or rapid test can be used in the third trimester. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=see_link\">",
"     \"Diagnostic assays for HIV infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15433?source=see_link\">",
"     \"Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients on the labor unit have an intravenous line or intravenous access placed early in labor in case of an emergency (eg, hemorrhage, nonreassuring fetal tracing). This is particularly important in this population because peripheral access may be difficult due to sclerosed veins, scars, and cellulitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Breastfeeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rates of breastfeeding are low among",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    maintained women [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/79\">",
"     79",
"    </a>",
"    ]. The American Academy of Pediatrics lists methadone as compatible with breastfeeding at any dose. Methadone is transferred into milk, but at relatively low levels. The milk-plasma ratio is 0.05 to 1.89 for doses of methadone averaging 50 to 70 mg per day [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/2,23,80,81\">",
"     2,23,80,81",
"    </a>",
"    ]. This is equivalent to neonatal methadone intake from breastmilk of &lt;0.2 mg per day, a dose which is unlikely to have any clinical effect [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/81\">",
"     81",
"    </a>",
"    ]. Indeed, infants who are exposed to methadone in utero remain at risk for withdrawal symptoms even while being breastfed by mothers receiving methadone [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/82\">",
"     82",
"    </a>",
"    ]. Neonatal plasma concentrations of methadone are not related to maternal methadone dose [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    should be encouraged to breastfeed; some of the benefits include improved maternal-infant bonding and favorable effects on neonatal abstinence syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/18,81,83,84\">",
"     18,81,83,84",
"    </a>",
"    ]. It is not clear whether the favorable effects of breastfeeding on NAS are related to breastmilk or the act of breastfeeding [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/85\">",
"     85",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32505?source=see_link\">",
"     \"Infant benefits of breastfeeding\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/57/39833?source=see_link&amp;anchor=H9#H9\">",
"     \"Neonatal opioid withdrawal (Neonatal abstinence syndrome)\", section on 'Breastfeeding'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     ALTERNATIVES TO METHADONE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     Methadone",
"    </a>",
"    remains the current standard treatment of pregnant opioid addicted women. Alternative drugs are available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Buprenorphine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     Buprenorphine",
"    </a>",
"    is a partial opioid agonist approved for treatment of opioid addiction. We prefer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    to buprenorphine because more evidence is available regarding its efficacy and short- and long-term safety in pregnancy; however, some providers consider buprenorphine a first-line option for opioid substitution therapy in pregnant women. This issue is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/45/5850?source=see_link&amp;anchor=H1519984#H1519984\">",
"     \"Buprenorphine substitution therapy in pregnancy\", section on 'Buprenorphine or methadone?'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Other drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alternatives to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    are under investigation. One randomized trial including 48 women compared use of oral slow-morphine to methadone during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/86\">",
"     86",
"    </a>",
"    ]. Oral slow-morphine was superior to methadone in helping women to abstain from using heroin, but there were no significant differences between groups in birthweight or duration of neonatal abstinence syndrome.",
"   </p>",
"   <p>",
"    \"Heroin-assisted\" treatment (HAT) combines",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    and injectable heroin. There are only two case reports of HAT during pregnancy, with a total of five women [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/44,87\">",
"     44,87",
"    </a>",
"    ]. The larger series included four women who had a history of addiction for more than two years, failure of at least two alternative treatments, and risk of further physical or social decline [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/44\">",
"     44",
"    </a>",
"    ]. The average methadone dose was 111 mg and infants had higher birthweights compared to women treated with methadone alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Detoxification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indications for detoxification during pregnancy may include refusal or inability to take",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    and patient request [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/15\">",
"     15",
"    </a>",
"    ], but should only be undertaken at a center familiar with opioid detoxification during pregnancy. The safety of detoxification during pregnancy is not well studied. The best evidence suggests that there is no increased risk of harm to the fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/2,32\">",
"     2,32",
"    </a>",
"    ], although miscarriages, preterm births, meconium passage, stillbirths, and elevated amniotic fluid epinephrine and norepinephrine levels have been reported in case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. The major reason detoxification is not recommended is that about 50 percent of women return to illicit opioid use [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/7,14,90\">",
"     7,14,90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Candidates for detoxification should undergo an ultrasound examination to look for preexisting signs of fetuses at risk of adverse outcome, such as oligohydramnios or fetal growth restriction, which would preclude detoxification [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/7,32\">",
"     7,32",
"    </a>",
"    ]. Women not on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    should be admitted for methadone stabilization, after which the methadone dose can be slowly tapered at a rate of up to 20 percent every three days. A more gradual approach of lowering the dose 2 to 5 mg every 6 to 16 days has also been used [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/21,89\">",
"     21,89",
"    </a>",
"    ]. Women already taking methadone can be tapered to 20 mg per day as outpatients, and then admitted for further tapering and discontinuation of drug.",
"   </p>",
"   <p>",
"    Detoxification can take place in any trimester, although most authorities avoid the procedure in the first and late third trimester. If the indication for detoxification is prevention of neonatal withdrawal, the detoxification treatment should be completed two months before delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?4/29/4570/abstract/91\">",
"     91",
"    </a>",
"    ]. Daily nonstress tests are recommended for pregnancies in the late second and the third trimester.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pregnant women are eligible for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      maintenance if they are physiologically dependent on opioids or were dependent on opioids. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Candidates for methadone treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      maintenance therapy rather than detoxification for treatment of pregnant women with opioid dependence (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The major disadvantage of detoxification is that a high proportion of women return to illicit opioid use. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Methadone maintenance therapy versus detoxification'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H30\">",
"       'Detoxification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In an inpatient setting,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      is initiated at a dose of 20 or 30 mg. Incremental doses of 5 to 10 mg are given every three to six hours as needed to treat withdrawal symptoms. After initial stabilization, we increase the methadone maintenance dose in 5 to 10 mg increments per week, if indicated, to maintain the lowest dose that controls withdrawal symptoms and minimizes the desire to use additional opioids. In our experience, the average maintenance dose is approximately 120 mg. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Methadone treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Opioid withdrawal symptoms mimic common discomforts of pregnancy, which should be taken into account before increasing the daily maintenance",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      dose. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Maintenance therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Twice daily dosing is more effective and has fewer side effects than single dosing, but is sometimes not practical since",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      is typically dispensed by licensed providers in a clinic. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Twice daily or split dosing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Weekly urine drug screens are performed to monitor for continued illicit drug use. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Drug screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pharmacokinetics of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      are affected by pregnancy. With advancing gestational age, plasma levels of methadone progressively decrease and clearance increases so that the half-life falls from an average of 22 to 24 hours in nonpregnant women to 8 hours in pregnant women. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Methadone treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The patient's usual",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      dose should be continued intrapartum and postpartum, or can be tapered postpartum. Additional medication for pain control should be administered. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Analgesia and anesthesia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"       Buprenorphine",
"      </a>",
"      is probably the best alternative to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      at this time. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Buprenorphine'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/1\">",
"      DOLE VP, NYSWANDER M. A MEDICAL TREATMENT FOR DIACETYLMORPHINE (HEROIN) ADDICTION. A CLINICAL TRIAL WITH METHADONE HYDROCHLORIDE. JAMA 1965; 193:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/2\">",
"      Blinick G, Wallach RC, Jerez E. Pregnancy in narcotics addicts treated by medical withdrawal. The methadone detoxification program. Am J Obstet Gynecol 1969; 105:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/3\">",
"      Burns L, Mattick RP, Lim K, Wallace C. Methadone in pregnancy: treatment retention and neonatal outcomes. Addiction 2007; 102:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/4\">",
"      Ward J, Hall W, Mattick RP. Role of maintenance treatment in opioid dependence. Lancet 1999; 353:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/5\">",
"      Kandall SR, Albin S, Lowinson J, et al. Differential effects of maternal heroin and methadone use on birthweight. Pediatrics 1976; 58:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/6\">",
"      Hulse GK, Milne E, English DR, Holman CD. The relationship between maternal use of heroin and methadone and infant birth weight. Addiction 1997; 92:1571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/7\">",
"      Dashe JS, Sheffield JS, Olscher DA, et al. Relationship between maternal methadone dosage and neonatal withdrawal. Obstet Gynecol 2002; 100:1244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/8\">",
"      Ostrea EM, Chavez CJ, Strauss ME. A study of factors that influence the severity of neonatal narcotic withdrawal. J Pediatr 1976; 88:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/9\">",
"      Madden JD, Chappel JN, Zuspan F, et al. Observation and treatment of neonatal narcotic withdrawal. Am J Obstet Gynecol 1977; 127:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/10\">",
"      Harper RG, Solish G, Feingold E, et al. Maternal ingested methadone, body fluid methadone, and the neonatal withdrawal syndrome. Am J Obstet Gynecol 1977; 129:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/11\">",
"      Strauss ME, Andresko M, Stryker JC, Wardell JN. Relationship of neonatal withdrawal to maternal methadone dose. Am J Drug Alcohol Abuse 1976; 3:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/12\">",
"      Rosen TS, Pippenger CE. Pharmacologic observations on the neonatal withdrawal syndrome. J Pediatr 1976; 88:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/13\">",
"      Sinha C, Ohadike P, Carrick P, et al. Neonatal outcome following maternal opiate use in late pregnancy. Int J Gynaecol Obstet 2001; 74:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/14\">",
"      Maas U, Kattner E, Weingart-Jesse B, et al. Infrequent neonatal opiate withdrawal following maternal methadone detoxification during pregnancy. J Perinat Med 1990; 18:111.",
"     </a>",
"    </li>",
"    <li>",
"     Medications Development for the Treatment of Pregnant Addicts and Their Infants. National Institutes of Drug Abuse. Monograph 149. Printed 1995. available at www.nida.nih.gov/pdf/monographs/download149.html (accessed March 18, 2009).",
"    </li>",
"    <li>",
"     file://consensus.nih.gov/1997/1998TreatOpiateAddiction108html.htm. (Accessed march 19, 2009).",
"    </li>",
"    <li>",
"     Department of consumer and industry services bureau of health systems administrative rules for substance abuse service programs. Available at file://74.125.47.132/search?q=cache:wCzjLZeHN_kJ:www.michigan.gov/documents/cis_bhs_fhs_sa_part4_37163_7.pdf+PART+4:+METHADONE+TREATMENT+AND+OTHER+CHEMOTHERAPY&amp;cd=1&amp;hl=en&amp;ct=clnk&amp;gl=us&amp;client=firefox-a. (Accessed March 19, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/18\">",
"      Lim S, Prasad MR, Samuels P, et al. High-dose methadone in pregnant women and its effect on duration of neonatal abstinence syndrome. Am J Obstet Gynecol 2009; 200:70.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/19\">",
"      Finnegan LP, Hagan T, Kaltenbach KA. Scientific foundation of clinical practice: opiate use in pregnant women. Bull N Y Acad Med 1991; 67:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/20\">",
"      Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009; 10:113.",
"     </a>",
"    </li>",
"    <li>",
"     New South Whales Methadone Maintenance Treatment: Clinical Practice Guidelines 1999.",
"    </li>",
"    <li>",
"     Alcohol and Other Drug Treatment Guidelines for Pregnant, Substance Using Women. In: Treatment Improvement Protocol Series 2: Pregnant, Substance-Using Women, Mitchell JL (Ed), Center for Substance Abuse Treatment, Rockville, MD 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/23\">",
"      Kreek MJ. Methadone disposition during the perinatal period in humans. Pharmacol Biochem Behav 1979; 11 Suppl:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/24\">",
"      Wolff K, Boys A, Rostami-Hodjegan A, et al. Changes to methadone clearance during pregnancy. Eur J Clin Pharmacol 2005; 61:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/25\">",
"      Nekhayeva IA, Nanovskaya TN, Deshmukh SV, et al. Bidirectional transfer of methadone across human placenta. Biochem Pharmacol 2005; 69:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/26\">",
"      Nanovskaya TN, Deshmukh SV, Nekhayeva IA, et al. Methadone metabolism by human placenta. Biochem Pharmacol 2004; 68:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/27\">",
"      Nanovskaya TN, Nekhayeva IA, Hankins GD, Ahmed MS. Transfer of methadone across the dually perfused preterm human placental lobule. Am J Obstet Gynecol 2008; 198:126.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/28\">",
"      Swift RM, Dudley M, DePetrillo P, et al. Altered methadone pharmacokinetics in pregnancy: implications for dosing. J Subst Abuse 1989; 1:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/29\">",
"      McCarthy JJ, Leamon MH, Stenson G, Biles LA. Outcomes of neonates conceived on methadone maintenance therapy. J Subst Abuse Treat 2008; 35:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/30\">",
"      Doberczak TM, Thornton JC, Bernstein J, Kandall SR. Impact of maternal drug dependency on birth weight and head circumference of offspring. Am J Dis Child 1987; 141:1163.",
"     </a>",
"    </li>",
"    <li>",
"     www.Reprotox.com (accessed March 19, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/32\">",
"      Dashe JS, Jackson GL, Olscher DA, et al. Opioid detoxification in pregnancy. Obstet Gynecol 1998; 92:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/33\">",
"      Berghella V, Lim PJ, Hill MK, et al. Maternal methadone dose and neonatal withdrawal. Am J Obstet Gynecol 2003; 189:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/34\">",
"      Seligman NS, Salva N, Hayes EJ, et al. Predicting length of treatment for neonatal abstinence syndrome in methadone-exposed neonates. Am J Obstet Gynecol 2008; 199:396.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/35\">",
"      Wilbourne P, Wallerstedt C, Dorato V, Curet LB. Clinical management of methadone dependence during pregnancy. J Perinat Neonatal Nurs 2001; 14:26.",
"     </a>",
"    </li>",
"    <li>",
"     Rettig, Richard, et al. Federal Regulation of Methadone: Table of Contents and Executive Summary. Washington: National Academy Press; 1995. available at www.drugpolicy.org/library/fedregi.cfm#p3 (accessed march 18, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/37\">",
"      Miles J, Sugumar K, Macrory F, et al. Methadone-exposed newborn infants: outcome after alterations to a service for mothers and infants. Child Care Health Dev 2007; 33:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/38\">",
"      McCarthy JJ, Leamon MH, Parr MS, Anania B. High-dose methadone maintenance in pregnancy: maternal and neonatal outcomes. Am J Obstet Gynecol 2005; 193:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/39\">",
"      Jansson LM, Svikis D, Lee J, et al. Pregnancy and addiction. A comprehensive care model. J Subst Abuse Treat 1996; 13:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/40\">",
"      Ryan JP, Choi S, Hong JS, et al. Recovery coaches and substance exposed births: an experiment in child welfare. Child Abuse Negl 2008; 32:1072.",
"     </a>",
"    </li>",
"    <li>",
"     Weiner, SM. Perinatal Impact of Substance Abuse. Continuing Education Module, March of Dimes Birth Defects Foundation. White Plains, New York 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/42\">",
"      Rajegowda BK, Glass L, Evans HE, et al. Methadone withdrawal in newborn infants. J Pediatr 1972; 81:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/43\">",
"      Arlettaz R, Kashiwagi M, Das-Kundu S, et al. Methadone maintenance program in pregnancy in a Swiss perinatal center (II): neonatal outcome and social resources. Acta Obstet Gynecol Scand 2005; 84:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/44\">",
"      Kashiwagi M, Arlettaz R, Lauper U, et al. Methadone maintenance program in a Swiss perinatal center: (I): Management and outcome of 89 pregnancies. Acta Obstet Gynecol Scand 2005; 84:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/45\">",
"      Drozdick J 3rd, Berghella V, Hill M, Kaltenbach K. Methadone trough levels in pregnancy. Am J Obstet Gynecol 2002; 187:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/46\">",
"      DePetrillo PB, Rice JM. Methadone dosing and pregnancy: impact on program compliance. Int J Addict 1995; 30:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/47\">",
"      Jansson LM, Dipietro JA, Velez M, et al. Maternal methadone dosing schedule and fetal neurobehaviour. J Matern Fetal Neonatal Med 2009; 22:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/48\">",
"      Wittmann BK, Segal S. A comparison of the effects of single- and split-dose methadone administration on the fetus: ultrasound evaluation. Int J Addict 1991; 26:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/49\">",
"      Fajemirokun-Odudeyi O, Sinha C, Tutty S, et al. Pregnancy outcome in women who use opiates. Eur J Obstet Gynecol Reprod Biol 2006; 126:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/50\">",
"      Johnson K, Greenough A, Gerada C. Maternal drug use and length of neonatal unit stay. Addiction 2003; 98:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/51\">",
"      Brown HL, Britton KA, Mahaffey D, et al. Methadone maintenance in pregnancy: a reappraisal. Am J Obstet Gynecol 1998; 179:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/52\">",
"      Baxter FR, Nerhood R, Chaffin D. Characterization of babies discharged from Cabell Huntington Hospital during the calendar year 2005 with the diagnoses of neonatal abstinence syndrome. W V Med J 2009; 105:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/53\">",
"      Choo RE, Huestis MA, Schroeder JR, et al. Neonatal abstinence syndrome in methadone-exposed infants is altered by level of prenatal tobacco exposure. Drug Alcohol Depend 2004; 75:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/54\">",
"      Winklbaur B, Baewert A, Jagsch R, et al. Association between prenatal tobacco exposure and outcome of neonates born to opioid-maintained mothers. Implications for treatment. Eur Addict Res 2009; 15:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/55\">",
"      Bakstad B, Sarfi M, Welle-Strand GK, Ravndal E. Opioid maintenance treatment during pregnancy: occurrence and severity of neonatal abstinence syndrome. A national prospective study. Eur Addict Res 2009; 15:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/56\">",
"      Almario CV, Seligman NS, Dysart KC, et al. Risk factors for preterm birth among opiate-addicted gravid women in a methadone treatment program. Am J Obstet Gynecol 2009; 201:326.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/57\">",
"      Connaughton JF, Reeser D, Schut J, Finnegan LP. Perinatal addiction: outcome and management. Am J Obstet Gynecol 1977; 129:679.",
"     </a>",
"    </li>",
"    <li>",
"     Kaye M, Chasnoff I. Substance Abuse in Pregnancy. In: High Risk Pregnancy, a Team Approach, Knuppel R, Drukker J.  (Eds), WBS, Philadelphia 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/59\">",
"      Niemi M, Backman JT, Fromm MF, et al. Pharmacokinetic interactions with rifampicin : clinical relevance. Clin Pharmacokinet 2003; 42:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/60\">",
"      Totah RA, Sheffels P, Roberts T, et al. Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology 2008; 108:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/61\">",
"      Tong TG, Pond SM, Kreek MJ, et al. Phenytoin-induced methadone withdrawal. Ann Intern Med 1981; 94:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/62\">",
"      Cleary BJ, Donnelly JM, Strawbridge JD, et al. Methadone and perinatal outcomes: a retrospective cohort study. Am J Obstet Gynecol 2011; 204:139.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/63\">",
"      Jansson LM, Dipietro J, Elko A. Fetal response to maternal methadone administration. Am J Obstet Gynecol 2005; 193:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/64\">",
"      Wouldes TA, Roberts AB, Pryor JE, et al. The effect of methadone treatment on the quantity and quality of human fetal movement. Neurotoxicol Teratol 2004; 26:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/65\">",
"      Ramirez-Cacho WA, Flores S, Schrader RM, et al. Effect of chronic maternal methadone therapy on intrapartum fetal heart rate patterns. J Soc Gynecol Investig 2006; 13:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/66\">",
"      Anyaegbunam A, Tran T, Jadali D, et al. Assessment of fetal well-being in methadone-maintained pregnancies: abnormal nonstress tests. Gynecol Obstet Invest 1997; 43:25.",
"     </a>",
"    </li>",
"    <li>",
"     Liu, AJ, Sithamparanathan, S, Jones, MP. Growth Restriction in Pregnancies of opioid-dependent mothers. Arch Dis Child Fetal Neonatal 2010; :. [Epub ahead of print].",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/68\">",
"      Lifschitz MH, Wilson GS, Smith EO, Desmond MM. Fetal and postnatal growth of children born to narcotic-dependent women. J Pediatr 1983; 102:686.",
"     </a>",
"    </li>",
"    <li>",
"     Weiner, SM, Finnegan, LP. Drug withdrawal in the neonate. In: Handbook of Neonatal Intensive Care, 7th ed, Marenstein, GB, Gardner, SL (Eds), Mosby, Inc, St. Louis 2011; p.201.",
"    </li>",
"    <li>",
"     Hamilton, R, McGlone, L, MacKinnon, JR, Russell, HC, et al. Ophthalmic, clinical, and visual electrophysiological findings in children born to mothers prescribed substitute methadone in pregnancy. Br J Ophthalmology 2010; :. [Epub ahead of print].",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/71\">",
"      McGlone L, Mactier H, Hamilton R, et al. Visual evoked potentials in infants exposed to methadone in utero. Arch Dis Child 2008; 93:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/72\">",
"      McGlone L, Mactier H, Weaver LT. Drug misuse in pregnancy: losing sight of the baby? Arch Dis Child 2009; 94:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/73\">",
"      Helmbrecht GD, Thiagarajah S. Management of addiction disorders in pregnancy. J Addict Med 2008; 2:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/74\">",
"      Meyer M, Wagner K, Benvenuto A, et al. Intrapartum and postpartum analgesia for women maintained on methadone during pregnancy. Obstet Gynecol 2007; 110:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/75\">",
"      Hernandez M, Birnbach DJ, Van Zundert AA. Anesthetic management of the illicit-substance-using patient. Curr Opin Anaesthesiol 2005; 18:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/76\">",
"      Alford DP, Compton P, Samet JH. Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. Ann Intern Med 2006; 144:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/77\">",
"      Kuczkowski KM. Anesthetic implications of drug abuse in pregnancy. J Clin Anesth 2003; 15:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/78\">",
"      American College of Obstetrics and Gynecology Committee on Obstetric Practice. ACOG Committee Opinion No. 418: Prenatal and perinatal human immunodeficiency virus testing: expanded recommendations. Obstet Gynecol 2008; 112:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/79\">",
"      Jansson LM, Velez M, Harrow C. Methadone maintenance and lactation: a review of the literature and current management guidelines. J Hum Lact 2004; 20:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/80\">",
"      Pond SM, Kreek MJ, Tong TG, et al. Altered methadone pharmacokinetics in methadone-maintained pregnant women. J Pharmacol Exp Ther 1985; 233:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/81\">",
"      Jansson LM, Choo R, Velez ML, et al. Methadone maintenance and breastfeeding in the neonatal period. Pediatrics 2008; 121:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/82\">",
"      Wojnar-Horton RE, Kristensen JH, Yapp P, et al. Methadone distribution and excretion into breast milk of clients in a methadone maintenance programme. Br J Clin Pharmacol 1997; 44:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/83\">",
"      Abdel-Latif ME, Pinner J, Clews S, et al. Effects of breast milk on the severity and outcome of neonatal abstinence syndrome among infants of drug-dependent mothers. Pediatrics 2006; 117:e1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/84\">",
"      Ballard JL. Treatment of neonatal abstinence syndrome with breast milk containing methadone. J Perinat Neonatal Nurs 2002; 15:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/85\">",
"      Liu AJ, Nanan R. Methadone maintenance and breastfeeding in the neonatal period. Pediatrics 2008; 121:869; author reply 869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/86\">",
"      Fischer G, Jagsch R, Eder H, et al. Comparison of methadone and slow-release morphine maintenance in pregnant addicts. Addiction 1999; 94:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/87\">",
"      Hartwig C, Haasen C, Reimer J, et al. Pregnancy and birth under maintenance treatment with diamorphine (heroin): a case report. Eur Addict Res 2008; 14:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/88\">",
"      Rementeri&aacute; JL, Nunag NN. Narcotic withdrawal in pregnancy: stillbirth incidence with a case report. Am J Obstet Gynecol 1973; 116:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/89\">",
"      Zuspan FP, Gumpel JA, Mejia-Zelaya A, et al. Fetal stress from methadone withdrawal. Am J Obstet Gynecol 1975; 122:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/29/4570/abstract/90\">",
"      Luty J, Nikolaou V, Bearn J. Is opiate detoxification unsafe in pregnancy? J Subst Abuse Treat 2003; 24:363.",
"     </a>",
"    </li>",
"    <li>",
"     Guidelines for the Treatment of Drug Addiction 2001. Available at www.drstp.drugeducation.com/PDF/EstoniaSummaryEnglish.pdf. (Accessed march 18, 2009).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4790 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-124.240.187.80-F9E9CAA6FC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_29_4570=[""].join("\n");
var outline_f4_29_4570=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      METHADONE MAINTENANCE THERAPY VERSUS DETOXIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CANDIDATES FOR METHADONE TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      INITIAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      METHADONE TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Continuing and initiating therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      First day of treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Subsequent days",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Maintenance therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Twice daily or split dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Drug screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Drug and chemical interactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Prolongation of the QT interval",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      FETAL AND NEONATAL ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Fetal surveillance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H120744937\">",
"      Growth restriction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Neonatal abstinence syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Other effects on the neonate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      LABOR, DELIVERY, AND POSTPARTUM ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Methadone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Analgesia and anesthesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Labor and delivery management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      ALTERNATIVES TO METHADONE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Buprenorphine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Other drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Detoxification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/4790\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4790|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/3/32827\" title=\"table 1\">",
"      Maternal and fetal benefits of methadone treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/46/34539\" title=\"table 2\">",
"      Objective physical signs of substance abuse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/6/41068\" title=\"table 3\">",
"      Maternal opioid withdrawal symptoms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/45/5850?source=related_link\">",
"      Buprenorphine substitution therapy in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=related_link\">",
"      Diagnostic assays for HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32602?source=related_link\">",
"      Immunizations during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32505?source=related_link\">",
"      Infant benefits of breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28746?source=related_link\">",
"      Infants of mothers with substance abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42010?source=related_link\">",
"      Initial prenatal assessment and patient education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27546?source=related_link\">",
"      Management of postoperative pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/57/39833?source=related_link\">",
"      Neonatal opioid withdrawal (Neonatal abstinence syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/44/3784?source=related_link\">",
"      Opioid abuse and dependence: Overview and patient evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/5/28758?source=related_link\">",
"      Opioid withdrawal in the emergency setting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/12/6346?source=related_link\">",
"      Overview of illicit drug use in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34553?source=related_link\">",
"      Prenatal assessment of gestational age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15433?source=related_link\">",
"      Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/53/27482?source=related_link\">",
"      Smoking and pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_29_4571="Chemo neut eccrine hidradenitis";
var content_f4_29_4571=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F50193&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F50193&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Chemotherapy agents associated with neutrophilic eccrine hidradenitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Bleomycin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chlorambucil",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyclophosphamide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cytarabine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Doxorubicin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lomustine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mitoxantrone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Topotecan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vincristine*",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * In combination regimens.",
"    </div>",
"    <div class=\"reference\">",
"     Modified from Susser, WS, et al. Mucocutaneous reactions to chemotherapy. J AM Acad Dermatol 1999; 40:367.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_29_4571=[""].join("\n");
var outline_f4_29_4571=null;
var title_f4_29_4572="Recommended phenylalanine limits in patients with PKU";
var content_f4_29_4572=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F77915&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F77915&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment recommendations for phenylalanine concentrations (micromol/L) in patients with phenylketonuria (PKU) in the United States and selected European countries",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Age",
"       </td>",
"       <td class=\"subtitle1\">",
"        United Kingdom",
"       </td>",
"       <td class=\"subtitle1\">",
"        Germany",
"       </td>",
"       <td class=\"subtitle1\">",
"        France",
"       </td>",
"       <td class=\"subtitle1\">",
"        United States",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Birth*",
"       </td>",
"       <td>",
"        &gt;400",
"       </td>",
"       <td>",
"        &gt;600",
"       </td>",
"       <td>",
"        &gt;600",
"       </td>",
"       <td>",
"        &gt;600",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infant to 10 years",
"       </td>",
"       <td>",
"        120-360",
"       </td>",
"       <td>",
"        40-240",
"       </td>",
"       <td>",
"        120-360",
"       </td>",
"       <td>",
"        120-360",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10-12 years",
"       </td>",
"       <td>",
"        &lt;480",
"       </td>",
"       <td>",
"        &lt;600",
"       </td>",
"       <td>",
"        &lt;900",
"       </td>",
"       <td>",
"        120-360",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12-20 years",
"       </td>",
"       <td>",
"        &lt;480",
"       </td>",
"       <td>",
"        &lt;600",
"       </td>",
"       <td>",
"        &lt;900",
"       </td>",
"       <td>",
"        120-600",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;20 years",
"       </td>",
"       <td>",
"        &lt;700",
"       </td>",
"       <td>",
"        &lt;1200",
"       </td>",
"       <td>",
"        &lt;900",
"       </td>",
"       <td>",
"        120-900",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pregnancy",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        120-360",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Newborn screening phenylalanine concentration at which treatment is initiated.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: MacLeod EL, Ney DM. Nutritional management of phenylketonuria. Ann Nestle 2010; 68:58. Copyright &copy; 2010 S. Karger AG, Basel. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_29_4572=[""].join("\n");
var outline_f4_29_4572=null;
var title_f4_29_4573="Commercially available stents";
var content_f4_29_4573=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F54642&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F54642&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Commercially-available airway stents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Brand",
"       </td>",
"       <td class=\"subtitle1\">",
"        Material",
"       </td>",
"       <td class=\"subtitle1\">",
"        Shapes",
"       </td>",
"       <td class=\"subtitle1\">",
"        Specific problems/complications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dumon",
"       </td>",
"       <td>",
"        Silicone",
"       </td>",
"       <td>",
"        Straight, Y, J",
"       </td>",
"       <td>",
"        Migration in benign disease (straight)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Orlowski",
"       </td>",
"       <td>",
"        Silicone, armored with metal rings",
"       </td>",
"       <td>",
"        Straight",
"       </td>",
"       <td>",
"        Very stiff",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hood",
"       </td>",
"       <td>",
"        Silicone",
"       </td>",
"       <td>",
"        Straight, Y",
"       </td>",
"       <td>",
"        Difficult to insert (Y)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gianturco",
"       </td>",
"       <td>",
"        Stainless steel, self-expandable",
"       </td>",
"       <td>",
"        Straight",
"       </td>",
"       <td>",
"        Stent fracture, airway perforation, fatal hemoptysis,",
"occlusion by tissue growth",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Strecker",
"       </td>",
"       <td>",
"        Tantalum, balloon-expandable",
"       </td>",
"       <td>",
"        Straight",
"       </td>",
"       <td>",
"        Stent collapse, occlusion by tissue growth",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Palmaz",
"       </td>",
"       <td>",
"        Stainless steel, balloon-expandable",
"       </td>",
"       <td>",
"        Straight",
"       </td>",
"       <td>",
"        Stent collapse, occlusion by tissue growth",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wallstent",
"       </td>",
"       <td>",
"        Cobalt-based alloy, uncovered, self-expandable",
"       </td>",
"       <td>",
"        Straight",
"       </td>",
"       <td>",
"        Granuloma, occlusion by tissue growth",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wallstent (Covered)",
"       </td>",
"       <td>",
"        Cobalt-based alloy, polyurethane covering,",
"self-expandable",
"       </td>",
"       <td>",
"        Straight",
"       </td>",
"       <td>",
"        Granuloma at stent ends, airway perforation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ultraflex",
"       </td>",
"       <td>",
"        Nitinol, self-expandable covered and uncovered",
"       </td>",
"       <td>",
"        Straight",
"       </td>",
"       <td>",
"        Granuloma formation, stent fracture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polyflex",
"       </td>",
"       <td>",
"        Polyester wire, silicone covering, self-expandable",
"       </td>",
"       <td>",
"        Straight, Y, J",
"       </td>",
"       <td>",
"        Migration (straight), difficult to insert (Y)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Screw-thread",
"       </td>",
"       <td>",
"        Tygon",
"       </td>",
"       <td>",
"        Straight",
"       </td>",
"       <td>",
"        Only tracheal sizes, mucus retention",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dynamic",
"       </td>",
"       <td>",
"        Silicone, metal hoops",
"       </td>",
"       <td>",
"        Y",
"       </td>",
"       <td>",
"        Difficult to insert",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Montgomery",
"       </td>",
"       <td>",
"        Silicone",
"       </td>",
"       <td>",
"        T-tube",
"       </td>",
"       <td>",
"        Difficult to insert, tracheostomy necessary",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Manufacturer's details for all brands are as follows: Dumon: Endoxane&reg;, Novatech SA, Grasse, France; Orlowski: R&uuml;sch AG, Kernen, Germany; Hood: Hood Laboratories, Pembroke, MA, USA; Gianturco: Cook, Bjaeverskov, Denmark; Strecker: Microvasive-Boston Scientific, Natick, MA, USA; Palmaz: Corning/Johnson and Johnson, Warren, NJ, USA; Wallstent and Covered Wallstent: Microvasive-Boston Scientific; Ultraflex: Microvasive-Boston Scientific; Polyflex: R&uuml;sch AG; Screw-thread: Reynders Medical Supply, Lennik, Belgium; Dynamic: R&uuml;sch AG; Montgomery: Boston Medical Products, Inc., Waltham, MA, USA.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bolliger, CT, Mathur, PN, Beamis, JF, et al. Eur Respir J 2002; 19:365. Copyright &copy; 2002 European Respiratory Society Journals Ltd.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_29_4573=[""].join("\n");
var outline_f4_29_4573=null;
var title_f4_29_4574="Beta agonist effect in EIB";
var content_f4_29_4574=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F81068&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F81068&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Inhaled beta-agonists protect against exercise-induced bronchoconstriction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 397px; height: 337px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The degree of exercise-induced bronchoconstriction (as measured by a fall in peak expiratory flow) with placebo, inhaled salbutamol (albuterol), or the long-acting inhaled beta-2 agonist formoterol. Formoterol produced more prolonged protection than salbutamol.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Henriksen JM, Agertoft L, Pedersen S, J Allergy Clin Immunol 1992; 89:1176.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_29_4574=[""].join("\n");
var outline_f4_29_4574=null;
var title_f4_29_4575="PCP in pediatric AIDS CXR";
var content_f4_29_4575=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80631&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80631&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chest radiograph of an HIV-infected 2-year-old boy with Pneumocystis jiroveci pneumonia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 329px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the presence of bilateral interstitial lung disease, pneumomediastinum, and subcutaneous emphysema.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Meg Ferris, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_29_4575=[""].join("\n");
var outline_f4_29_4575=null;
